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GENERAL INTRODUCTION
Psoriasis is a chronic inflammatory skin disease affecting about 2-3% of the Western 
population. It is characterized clinically by sharply demarcated, elevated red scaly plaques 
(Figure 1) preferentially occuring at specific body sites, such as the elbows, knees and scalp. 
In severe cases the whole body may be involved, this serious condition is called erythroderma. 
Symptoms usually occur first at 20-30 years of age. Twenty to 30% of patients with psoriasis 
suffer from psoriatic arthritis. Psoriasis is a multifactorial disease resulting from polygenic 
predisposition and environmental triggering factors, such as medications, infections or trauma. 
During the last decades there is quickly growing understanding of the cellular processes 
driving inflammation in psoriasis. Importantly, this knowledge might apply for other organ-
specific autoimmune diseases as well, such as for Crohn’s disease, rheumatoid arthritis and 
multiple sclerosis, where the affected organs are less accessible than the skin. 
Several local and systemic therapies are available for psoriasis. Still, treatment of patients 
with psoriasis is often challenging as the long-term use of currently available treatments 
is limited by side-effects. About 40% of patients with psoriasis are not satisfied with the 
available care (1). 
Narrow-band UVB (NB-UVB) therapy is one of the standard systemic treatments, and it 
is highly effective. During NB-UVB therapy patients receive increasing doses of UVB three 
times weekly for about 12 weeks, starting with a low UVB dose to avoid sunburn. For this, 
patients stand or lie for a few minutes in cabins equipped with TL-01 lamps that emit UVB 
radiation with a peak emission at 311 nm.
The mechanism of action of NB-UVB therapy in psoriasis is poorly understood. Much of 
the current knowledge is based on in vitro and mouse experiments. In this thesis molecular 
Figure 1. Clinical appearance of psoriatic plaques. 
See page 149 for a full-color representation of this figure.
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effects of NB-UVB therapy in vivo in patients with psoriasis are analyzed. The aim was to 
identify molecular pathways that are responsible for the beneficial effects of UVB in psoriasis. 
This can help to better understand the pathophysiology of the disease, and to detect potential 
novel therapeutic targets. 
The general introduction will discuss the current understanding of the molecular 
pathophysiology of psoriasis and the molecular targets of available treatments. Subsequently 
the mode of action of UVB phototherapy is summarized as we now understand it. Since a 
major part of the thesis is based on global gene expression profiling, a chapter is included in 
the introduction showing what such microarray studies tought us about psoriasis and about the 
effects of UVB in human cells prior to our own investigations. The general introduction ends 
with a summary of the objectives of our research.
MOLECULAR PATHOPHySIOLOGy OF PSORIASIS
Psoriatic plaques are defined histologically by epidermal hyperplasia, epidermal and 
dermal infiltration by leukocytes and changes in dermal microvasculature (2). In lesional 
psoriatic keratinocytes the differentiation and activation program is disturbed. The pool of 
proliferating keratinocytes is increased, which is accompanied by enhanced production of 
proinflammatory cytokines, adhesion molecules and antimicrobial peptides. In psoriasis 
lesions the number of T cells, myeloid and IFN-α-producing plasmacytoid dendritic cells 
(DC) is markedly increased. Myeloid DC produce IL-23, tumor necrosis factor (TNF)-α and 
inducible nitric oxide synthase (iNOS), which are critical cytokines in the pathogenesis of 
psoriasis. IL-23 stimulates the secretion of IL-22 by T helper (Th)17 cells, and IL-22 induces 
epidermal hyperplasia. The cross-talk between keratinocytes and leukocytes via their pro-
inflammatory cytokines create the vicious circle of chronic skin inflammation in psoriasis. 
Genomwide linkage analysis identified at least nine chromosomal loci with statistically 
significant linkage to psoriasis, called PSORS1 through PSORS9 (3). These are probably 
responsible for the increased incidence of psoriasis among first- and second-degree relatives 
of patients compared to the general population (4). PSORS1 on chromosome 6p might 
account for 35 to 50% of the hereditability of the disease (2). Within this region HLA-C 
(HLA-Cw6) encoding an MHC class I protein, and corneodesmosin, an epidermal protein 
have been extensively studied as possible causative genes, but disease-specific mutations have 
not been identified (5-7). Genetic variations within loci containing epidermal defense genes 
DEFB4 (encoding human β-defensin 2) and LCE3C/3D (encoding late cornified envelope 
proteins 3B and 3C) have been found to be associated with psoriasis (8, 9). Recently, novel 
genetic regions were identified that confirm the involvement of the immune system in the 
pathogenesis of psoriasis: both IL-23 subunits and the IL-23 receptor, TNFAIP3 and TNIP1, 
regulators of TNF-α signaling, and IL4/IL13, genes whose products support development of 
Th2 cells (10-12). 
Below, contribution of epidermal keratinocytes and leukocytes to the pathogenesis and 
pathophysiology of psoriasis is discussed separately.
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The epidermal compartment in psoriasis: the regenerative or wound healing phenotype
The epidermis is a stratified squamous epithelium consisting of keratinocytes. 
Keratinocytes undergo a tightly regulated differentiation program to form a mechanical, 
permeability, as well as antimicrobial barrier to the external environment. Basal epidermal 
cells contain stem cells that retain their proliferative potential but can also differentiate to 
generate multiple suprabasal layers. Cells of the spinous layer synthesize keratin filaments 
interconnected to desmosomes to generate an integrated mechanical structure, while granular 
cells produce lipid-rich lamellar granules. Granular cells also make proteins that become 
irreversibly cross-linked to form the cornified envelope (13). The stratum corneum of 
normal human epidermis is a cross-linked structure of insoluble proteins and lipids and as 
such represents a barrier against invasion by microbial agents. The skin barrier function is 
enhanced by incorporation of proteins with bactericidal or bacteriostatic properties that are 
constitutively or inducibly expressed (14). 
In psoriasis the epidermal balance between proliferation and differentiation is 
disturbed (15) (Figure 2). The large, silvery scales are a consequence of altered differentiation 
(hyper- and parakeratosis: thickening of the stratum corneum with retention of cell nuclei), 
whereas thickening of the epidermis is due to a strongly increased pool of proliferating 
keratinocytes. Altered differentiation of psoriatic keratinocytes is characterized by focal 
absence of the granular layer and hereby a downregulation of late keratinocyte differentiation 
markers (filaggrin, loricrin, caspase 14) and upregulation of early differentiation markers 
(involucrin, small proline-rich proteins) (15). These alterations in keratinocyte differentiation 
lead to impairment of the skin barrier function, which was shown to correlate with the severity 
of the disease (16).
Differentiation of epidermal cells is controlled by several signalling pathways, e.g. by Notch 
and Wnt signalling and the transcription factors peroxisome proliferator-activated receptor 
(PPAR)-α, transcription factor AP2, and CCAAT-enhancer-binding protein (C/EBP)-α/β 
(Figure 2). Proliferation of epidermal stem cells is maintained by p63, c-Myc, β1-integrin and 
transforming growth factor (TGF)-α signalling pathways, and negatively regulated by TGF-β 
signalling (13). Signalling through insulin-like growth factor receptor (IGFR) and epidermal 
growth factor receptor (EGFR) also regulate proliferative behaviour in the epidermis (13). 
Notably, all of these pathways are differentially expressed in lesional psoriatic skin (17-23), 
indicating a complex network of regulatory pathways in which a primary pathogenic switch 
is difficult to pinpoint.
Epidermal keratinocytes release several factors upon microbial invasion or physical 
wounding and also express receptors that alert the immune system to danger signals, as part 
of an innate immune response (24). Psoriasis is often considered a genetically determined 
dysregulation of innate and adaptive immunity (25-27). A dysregulation of the innate detection 
and response system can result in the epidermal phenotype and the abnormal T cell function 
that characterize the disease (27). Examples for abnormalities of the innate response system 
in psoriasis are the increased expression of antimicrobial peptides (8), activation of type I 
interferon (IFN) system (28, 29), and dysregulation of the expression of the IL-1 family of 
cytokines (30). In addition, psoriasis is often compared to the normal skin wounding response, 
or the regenerative epidermal phenotype (31).  As part of this regenerative or “stress” response, 
13
General Introduction
some of the antimicrobial peptide molecules (elafin, psoriasin, LL-37 and β-defensin-2) are 
highly induced. In addition, neutrophils, macrophages, dendritic cells and natural killer cells 
initiate an innate immune response to defend the organism from invading pathogens. 
Several molecular processes have been described driving this epidermal regenerative or 
stress response both during wound healing and in psoriasis, signal transducer and activator of 
transcription (STAT)3 and the mitogen-activated protein kinase (MAPK) cascade being the 
most important. In healing wounds, STAT3 was found to be activated, while epidermis-specific 
disruption of STAT3 in mice led to delayed wound healing (32, 33). In psoriatic patients, 
STAT3 is activated in lesional keratinocytes (34). Transgenic mice with constitutively active 
STAT3 in keratinocytes spontaneously develop skin lesions resembling human psoriasis (34). 
These data indicate that activation of STAT3 plays a role in the development of the regenerative 
epidermal phenotype observed in psoriasis. MAPK-activated protein kinase 2 and mitogen- 
and stress-activated protein kinase (MSK)1 regulate the expression of tumor necrosis factor 
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Figure 2. Epidermal alterations in psoriasis. 
In psoriasis (right panel) signaling pathways that are associated with keratinocyte differentiation, such as Notch and 
PPAR-α signaling, are suppressed, whereas proliferation-associated pathways (e.g. c-Myc, β-integrin EGFR and 
Wnt5a), are induced. STAT3, MEK1 and IL-1 signalling pathways are responsible for the regenerative epidermal 
phenotype, involving an increased expression of antimicrobial peptides, such as β-defensin and LL-37.
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(TNF)-α and other pro-inflammatory mediators in psoriatic lesions (35, 36). Integrin-induced 
activation of MAPK was considered responsible for epidermal hyperproliferation in psoriasis 
and wound healing, either directly or through increased IL-1α production (37). More recently 
expression of IL-20, a cytokine with high expression in psoriasis, was shown to be induced 
by p38 MAPK in keratinocytes (38, 39). IL-20 induces the regenerative epidermal phenotype 
characteristic of psoriais (40).
In summary, psoriasis is characterized by hyperproliferation and disturbed differentiation 
of epidermal keratinocytes. Keratinocytes have an activated phenotype in psoriasis, which is 
similar to their condition during wound healing (Figure 2). Keratinocytes produce mediators 
that activate cells of the immune system and endothelial cells in the dermis. On the other hand, 
leukocyte-derived cytokines may activate keratinocytes, as discussed below.
The contribution of leukocytes in the pathogenesis of psoriasis
The immune system is strongly implicated in the pathogenesis of psoriasis, including both 
acquired immunity (T cells) and innate immunity (antigen-presenting cells (APC), neutrophils, 
mast cells, and keratinocytes). In psoriasis lesions the number of T cells and CD11c+ dendritic 
cells (DC) is markedly increased (41). T cells, especially CD8+ T cells migrate into all 
layers of the epidermis. CD11c+ DC also infiltrate the epidermis, but remain confined to the 
lower cell layers (42). The number of immature Langerhans cells are only slightly reduced, 
however, mobilization of these cells in response to stimuli that normally induce migration 
(chemical allergen, TNF-α, and IL-1β) is largely absent (43). Neutrophils accumulate in 
small aggregates called Munro abscesses beneath the corneal layers (44, 45) (Figure 3). 
As a consequence of the activation of leukocytes, levels of proinflammatory cytokines (IFN-α, 
IFN-γ, TNF-α, IL-1, IL-6, IL-23, IL-22, IL-17) are high in psoriasis lesions (29, 46-49). 
These cytokines drive the activation of leukocytes, as well as contribute to the epidermal 
alterations described above. Chemokines, which are responsible for the chemoattraction of 
leukocytes from the circulation into the skin, form a bridge between the epidermal compartment 
and the immunological components of the psoriatic pathology (Figure 3).
Dendritic cells are a heterogeneous group of antigen-presenting leukocytes that are 
important in activation of both the innate and adaptive arms of the immune system. DC are 
defined by their capacity for antigen uptake and presentation and activation of naive T-cells. 
In non-inflamed human skin there are three main DC populations: epidermal Langerhans 
cells, (mature) dermal myeloid (CD11c+) DC, and sporadically dermal plasmacytoid DC 
(pDC) (50). 
Although pDC have the capacity to present antigen, they are characterized by their ability 
to produce high amounts of type I IFN during viral infection, and in autoimmune diseases. One 
of the earliest events driving the inflammatory eruption in psoriasis is the secretion of IFN-α, 
a type I IFN from pDC (29). pDC are only sporadically seen in normal skin, but are clearly 
increased in psoriasis lesions (51). We have previously shown that the type I IFN pathway 
is activated in psoriatic lesions (28). Treatment of non- or pre-psoriatic patients with IFN-α 
can induce or exacerbate psoriasis (52-55). A functional role of IFN-α/β in the initiation of 
psoriasis has been demonstrated using a xenograft murine model of psoriasis. Blocking of 
IFN-α signalling prevented the T-cell dependent development of psoriatic lesions in non-
15
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lesional skin transplanted onto immunocompromised mice (29). Recently, LL-37 complexed 
to self DNA, was shown to trigger pDC to produce large amounts of IFN-α (56), providing 
the first clear illustration of the autoimmune character of psoriasis.
CD11c+ myeloid DC are dramatically increased in the psoriatic dermis (approximately 
equal to T-cell numbers) (57). This change is not due to an increase in DC that are also present 
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Figure 3. The role of leukocytes in the pathogenesis of psoriasis. 
A chemotactic gradient is formed by chemokines, such as CXCL8/IL-8, CCL20 and CCL27, which aids the 
extravasation of leukocytes into the skin. Myeloid dendritic cells (DC) produce IL-12, IL-23, TNF-α and iNOS, 
activating hereby T helper (Th) cells to produce IL-21, IL-22, IL-12 and IFN-γ. Plasmacytoid DC (pDC) produce 
large amounts of IFN-α, which plays a role in the initiation of psoriatic plaque formation. Neutrophils in the stratum 
corneum are a source of chemokines. Cytotoxic T cells (Tc1, Tc17) infiltrate the epidermis, where they produce 
cytotoxic molecules, as well as proinflammatory cytokines.
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in steady state, but to the occurrence of a novel, immature population of DC (42). Thus, 
psoriatic lesional skin has two populations of dermal DC: (1) CD11c+BDCA-1+ cells, which 
are phenotypically similar to those contained in normal skin and (2) CD11c+BDCA-1- cells, 
which are phenotypically immature and produce inflammatory cytokines. This second group 
may be derived from circulating DC precursors (e.g. monocytes or pre-DC) migrating into the 
skin due to inflammatory and chemotactic signals (50). Importantly, in perilesional, normal-
appearing skin of psoriatic patients an increase in the number of activated DC was observed, 
suggesting a role of these cells in the provocation/initiation of epidermal inflammation (19).
CD11c+BDCA1- myeloid dermal DC in psoriasis are called “inflammatory” DC, or TNF- 
and inducible nitric oxide synthase (iNOS)-producing DC (alias TIP-DC) (58). In addition, 
these inflammatory DC produce IL-20, a cytokine inducing the regenerative epidermal 
phenotype as observed in psoriasis (57, 59), and IL-23 which is important for induction of 
IL-17 and IL-22 in T lymphocytes. Myeloid dermal DC populations induce T-cell proliferation, 
and polarize T cells to become T helper 1 (Th1) and T helper 17 (Th17) cells (42). 
T lymphocytes are the major effector cells of the adaptive immune system. CD8+ cytotoxic 
T cells kill virus-infected cells in a MHC class I restricted manner, whereas MHC class II 
restricted CD4+ T helper (Th) cells activate other cells such as B cells and macrophages. 
T cells are activated by APC via interaction between co-stimulatory molecules on APC 
and their receptors on the surface of T cells (25). Activated T cells secrete proinflammatory 
cytokines, such as IFN-γ, IL-17, IL-22, TNF-α, IL-4 or IL-13, depending on their phenotype. 
In normal skin, a considerable number of T cells are found in the dermis (~2x106 cells/cm2; 
which means that there are about twice as many T cells in the skin than in the circulation), but 
there are almost no T cells located in the epidermis (60). 
In psoriatic skin lesions, both CD4+ and CD8+ T cell subsets are present with CD8+ cells 
predominant in the epidermis (61). Cytotoxic CD8+ T cells in psoriasis produce cytotoxic 
granule components Tia-1, granzyme B and perforin, although their pathogenic action is 
mostly related to cytokine secretion (25). The psoriasis susceptibility gene HLA-C product 
HLA-Cw6 may be involved in the activation of CD8+ T cells by dendritic cells. Activated 
CD8+ T cells may recognize keratinocyte antigens presented in the context of HLA-Cw6 (62). 
The antigen specificity of these cytotoxic T lymphocytes in psoriasis has not been identified (25), 
although they were shown to be stimulated by lesional psoriatic autologous epidermal cells 
and epidermal cell extracts (63). CD4+ Th cells with Th1 and Th17 phenotype accumulate 
in psoriasis lesions (64). When activated, Th1 cells produce IFN-γ, TNF-α, while Th17 cell 
secrete IL-17 or IL-22 (and also some IFN-γ). 
T cells are thought to be critical pathogenic triggers of psoriasis. Therapies that inhibit 
T cell activation and trafficking are effective in treating psoriasis. Immunosuppressive drugs 
with preferential activity towards T cells, such as cyclosporine, have been shown to be highly 
efficacious and are widely used for systemic therapy of psoriasis. In addition, psoriasis can 
be induced in xenograft murine models by the injection of T cells from human skin lesions. 
The genetic association of psoriasis with certain MHC alleles including HLA-Cw6 also 
suggest a pathogenic role of T cells (65). Furthermore, psoriasis may develop for the first time 
after bone marrow transplantation from a donor with psoriasis, or may not recur in patients 
with psoriasis after bone marrow transplantation from healthy donors (66, 67). 
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Infiltrating macrophages in psoriatic plaques are accumulated along the basal membrane 
of the epidermitis (“lining cells”) (68). The importance of these cells in the maintenance 
of psoriatic inflammation has been demonstated in different psoriasis-like dermatitis mouse 
models, where depletion of macrophages led to significant attenuation of psoriasis-like skin 
changes (69, 70).
Leukocytes are recruited to the skin by transmigration through activated endothelial cells. 
In addition, resident skin leukocytes might also expand to create the dense infiltrates seen in 
psoriatic lesions (71). For transmigration of cells, a chemotactic gradient towards the target 
tissue is needed, as well as homing receptors and ligands on the surface of the migrating 
cells and endothelium. Under the influence of T-cell derived proinflammatory cytokines, 
keratinocytes express a broad array of mediators, thereby amplifying the inflammatory 
response. Keratinocyte-derived chemokines play a key role in the recruitment of the 
inflammatory infiltrate. Several chemokines and their corresponding receptors have been shown 
to be associated with the psoriatic phenotype and may support leukocyte recruitment (72). 
CCL27 is exclusively produced by epidermal keratinocytes and binds CCR10. More than 
90% of skin infiltrating lymphocytes in psoriasis and in atopic and contact dermatitis express 
CCR10, suggesting a pivotal role of CCL27-CCR10 interactions during the pathogenesis of 
T cell mediated skin inflammation (73). Chemokines that are highly expressed in psoriasis 
(and not elevated in atopic dermatitis) are CCL4, CCL20, CXCL2, CXCL8/IL-8 (74). 
Neutrophils, a defining feature of psoriasis, are an important source of IL-8, CXCL10 and the 
S100 protein S100A8/9. 
Leukocyte-derived cytokines that can induce the epidermal changes seen in psoriatic 
plaques are IL-21, IL-22 and IFN-γ (46, 75-79). The prototypic Th17 cytokine IL-22 stimulates 
keratinocyte proliferation and of the production of antimicrobial peptides; therefore it is a key 
effector cytokine in the pathogenesis of psoriasis (76-78). Elevated levels of IL-22 are found 
in the blood of patients with psoriasis (80). IL-22 inhibits keratinocyte terminal differentiation, 
induces STAT3 upregulation, and causes psoriasis-like morphological changes in human skin 
equivalents (40). IL-22 secretion is induced by IL-23. IL-23 emerged recently as key cytokine 
in the pathogenesis of psoriasis (81). IL-23 is produced in great quantities in psoriasis lesions 
by dendritic cells and keratinocytes, and it stimulates Th17 cells to produce Th17 cytokines 
(48, 82, 83). The importance of this immunological pathway is underlined by the facts that 
polymorphisms in genes encoding IL23R and IL12/IL23p40 are associated with susceptibility 
to psoriasis (10, 84). In addition, it is noteworthy that monoclonal antibodies targeting 
IL12/IL23p40 are highly effective in treating psoriasis (85). We have shown that a psoriasis-
like dermatitis in mice induced by the TLR7/TLR8 agonist imiquimod is critically dependent 
on the IL-23/IL-17 axis (86). Cyclosporine A, a standard therapy for psoriasis, was shown to 
downregulate the Th17 pathway in psoriatic skin (87). This modulation was observed within 
2 weeks after the start of treatment and correlated well with the clinical improvement of 
the disease (87). Also etanercept (TNF receptor - immunoglobulin fusion protein), another 
effective treatment modality in psoriasis, was shown to inhibit the Th17 pathway (57). 
IFN-γ, a type II IFN, is mainly produced by activated Th1/Tc1 cells and is mainly involved 
in adaptive immune responses. IFN-γ can induce the regenerative psoriatic phenotype in 
epidermal reconstructs (79). Interestingly, the TNF-α-inhibitor infliximab inhibits the synthesis 
of IFN-γ by Th1 cells (88). Thus, IFN-γ secretion might be downstream of TNF-α. TNF-α has 
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been called a sentinel cytokine or “the body's fire alarm”, as it initiates the defense response 
to local injury (89). Many different immune and nonimmune cell types can produce TNF, 
including macrophages, T cells, mast cells, granulocytes, natural killer (NK) cells, fibroblasts, 
neurons, keratinocytes and smooth muscle cells. At low concentrations in tissues, TNF is 
thought to have beneficial effects, such as the augmentation of host defense mechanisms 
against infections. In disease states, TNF mediates a variety of direct pathogenic effects and 
induces the production of other mediators of inflammation and tissue destruction, placing it in 
a key position in the inflammatory cascade within an inflammatory network (89).
In conclusion, components of innate and adaptive immunity are activated in psoriasis 
(Figure 3). Plasmacytoid dendritic cells produce IFN-α, hereby activating other cells of the 
immune system. Dermal dendritic cells acquire an inflammatory phenotype and produce IL-23, 
 TNF-α and iNOS, resulting in the activation of Th1 and Th17 cells. Active Th1 and Th17 
cells synthesize IFN-γ and IL-22, respectively, and these cytokines stimulate the activation 
and proliferation of epidermal keratinocytes, hereby contributing to the vicious circle of 
psoriatic skin inflammation.
Endothelial cell activation in psoriasis
A hallmark of psoriatic skin is the transformation of the local microvascular system, 
characterized by dilation and tortuosity of capillaries, increased permeability, and high 
endothelial venule formation which is usually seen in lymph nodes. Extravasation of leukocytes 
into the dermis is aided by this transformation of the capillaries, as well as by the increased 
expression of adhesion molecules (e.g. intracellular adhesion molecule-1 (ICAM-1), vascular 
cell adhesion molecule-1 (VCAM-1) and E-Selectin) by endothelial cells. 
Accumulating evidence indicates that many of the cells involved in inflammatory processes 
release factors that act directly or indirectly on vascular endothelial cells. The interplay between 
chronic inflammation and angiogenesis is accomplished in the first place by the production 
of nitric oxide (NO), a well-established inflammatory agent produced by the activation of 
iNOS in inflammatory DC. NO stimulates vessel dilation and permeability, a feature required 
for leukocyte extravasation (90). In addition, cyclo-oxygenase-2 (COX-2), an inducible 
enzyme responsible for the increase in prostaglandin biosynthesis during inflammation, also 
contributes to increased angiogenesis by up-regulating the production of vascular endothelial 
growth factor (VEGF) (90). 
VEGF plays a crucial role in neo-angiogenesis as occurs in psoriasis (90), inducing 
migration, survival, and proliferation of endothelial cells. VEGF acts by engaging with its 
tyrosin kinase receptors VEGFR1 and VEGFR2 on endothelial cells. Although VEGF binds 
to both receptors, it appears that most of its biological functions are mediated via VEGFR2.
VEGF is secreted by keratinocytes, and VEGF serum levels are increased in patients with 
psoriasis (90). Distinct single nucleotide polymorphisms of the VEGF gene occur more 
frequently in subsets of psoriasis patients, and these haplotypes may contribute to the elevated 
VEGF levels observed in these patients (91). Furthermore, overexpression of VEGF in mouse 
skin results in a psoriasis skin phenotype, which implies a complex interplay between blood 
vessels, keratinocytes and leukocytes (92). 
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Although vascular remodelling is a hallmark of many chronic inflammatory disorders, 
anti-vascular strategies for treating these conditions have received little attention to date. 
In psoriasis, selective photothermolysis of the dermal microvasculature by use of the 585 nm 
pulsed-dye laser resulted in partial or complete disappearance of psoriasis plaques (93-96). 
The anti-angiogenic agents paclitaxel and AE-941 (Neovastat) demonstrated therapeutic 
activity in patients with severe psoriais (97, 98). Recently, a VEGFR antagonist - 
already in clinical use for the treatment of malignancies and for the inhibition of retinal 
neovascularisation - was shown to inhibit psoriasis-like skin inflammation in mice (99).
MOLECULAR TARGETS OF CURRENT TREATMENTS FOR 
PSORIASIS 
Most established treatments for psoriasis have been developed empirically. Biologics, on 
the other hand, specifically target key mechanisms of psoriasis pathogenesis. Most of these 
compounds are monoclonal antibodies, anti-cytokines or fusion proteins that block T cell 
migration and adhesion, or antagonize/neutralize the effects of cytokines.
Established empirical treatments for psoriasis include topical and systemic therapies. 
In the majority of patients with psoriasis (approximately 60%) the disease is managed by 
topical therapy alone, although many patients are dissatisfied with this type of treatment.
Corticosteroids and Vitamin D3 are the most frequently used topical treatments for psoriasis. 
Topical corticosteroids can be very effective in controlling mild to moderate psoriasis lesions. 
A recent study on the effects of corticosteroids on keratinocytes showed that in addition to 
downregulation of pro-inflammatory genes, corticosteroids regulate keratinocyte motility 
and metabolism, suppress the expression of essentially all IFN-γ-regulated genes, including 
IFN-γ receptor and STAT1, promote terminal epidermal differentiation while simultaneously 
inhibiting early stage differentiation (100). Because of their side effects upon prolonged use, 
corticosteroids are combined with other topical treatments in psoriasis. Vitamin D3 analogues 
(calcipotriol and tacalcitol) and the topical retinoid tazarotene, all of which affect keratinocyte 
functions and the immune response, are nowadays more widely used than either anthralin or 
coal tar (101). Moderate-to-severe psoriasis may be treated with UV phototherapy or systemic 
drugs. The mode of action of traditional systemic therapies is incompletely understood. Some 
of these, such as cyclosporine A and fumarates inhibit immune functions, whereas others 
(retinoids and methotrexate) also target keratinocyte functions (101). 
Novel therapeutic agents are characterized by more specific targeting of defined molecules 
in the pathological pathways. The T-cell targeted alefacept, a lymphocyte function-associated 
antigen (LFA)-3-immunoglobulin fusion protein interferes with LFA-3:CD2 interactions on 
T cells and antigen presenting cells. Alefacept is an effective therapy in selected patients and 
may induce relatively long remissions. In responding patients, alefacept induces a reduction 
in CD11c+ DC as well as T cells (102). A range of inflammatory genes are reduced. T cells 
are the primary target for therapy, but DC and a spectrum of Th1 inflammatory genes are 
coordinately suppressed (103). 
Cytokine-targeted interventions include anti-TNF-α and anti-IL-12/IL-23p40 approaches. 
Infliximab, adalimumab and etanercept target TNF-α; all are indicated for several immune-
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mediated inflammatory diseases. All three TNF antagonists are parenterally administered 
protein therapeutics (biologics); infliximab and adalimumab are monoclonal antibodies 
(mAbs) that specifically bind TNF; and etanercept is a TNF-receptor-fusion protein that 
binds TNF and lymphotoxin (LT) family members. Infliximab not only blocks TNF-α but 
also (indirectly) inhibits IFN-γ synthesis by T cells, blocking hereby Th1 pathway (88), in 
which aspect it differs from etanercept (104). Adalimumab is a fully human recombinant 
anti-TNF antibody, and, theoretically, has similar actions and effects as infliximab. Etanercept 
downregulates Th17 responses and induces apoptosis of dermal dendritic cells in patients 
with psoriasis (57, 105). The response of psoriasis to three distinct TNF inhibitors certainly 
suggests that this cytokine has a key role in disease pathogenesis. New TNF-α blockers are 
golimumab, a fully human anti-TNF-α antibody, and certolizumab pegol. As certolizumab 
does not have an Fc region, unlike infliximab and adalimumab, it should not fix complement 
or cause antibody-dependent cell-mediated cytotoxicity in vitro (106). 
Ustekinumab is a fully human monoclonal antibody against the p40 subunit of IL-12/
IL-23 (107, 108). It binds with high affinity and specificity to the p40 subunit of IL-12 and 
IL-23, preventing these cytokines from binding to IL-12 and IL-23 receptor 1 (IL-12R1) on 
the surface of leukocytes. Ustekinumab appears to be as effective as the anti-TNF antibodies 
during induction therapy and the available long-term data indicate a stable clinical response 
over time, with no rebound after withdrawal of the drug (109). Another monoclonal antibody 
against IL-12/IL-23 p40 is ABT-874 has also been tested in phase II clinical trials and was 
found to be effective and comparable to ustekinumab (110). The clinical efficacy of anti-
p40 antibodies is much longer than its serum half-life, which suggests that this intervention 
collapses a key population of cells. This long-lasting effect makes these drugs highly practical, 
as they require only 4 to 5 injections per year. At present, information on the safety of 
ustekinumab is based on smaller patient numbers and shorter duration of exposure compared 
with the TNF antagonists. 
Meta-analysis of trials with new and established therapies showed that these novel, specific 
treatments are more effective than traditional systemic treatments (111). Infliximab appears 
to be the most effective treatment for moderate-to-severe psoriasis, followed by adalimumab. 
Etanercept induces stable long-term response rates (111).
Several other approaches for the treatment of psoriasis are currently under clinical 
investigation. The PPARγ antagonist pioglitazone is effective in clearing psoriasis (112), 
and in combination therapies it enhanced the efficacy of acitretin (113). Janus kinase (JAK) 
inhibitors lestaurtinib (CEP-701) and INVB18424 aim to block proinflammatory JAK/STAT 
signalling pathways. The pan-selectin antagonist Bimosiamose prevents leukocytes to enter 
the tissues from the circulation. Use of recombinant alfa-fetoprotein (MM-093) is based 
on the observation that psoriasis, as most autoimmune diseases tends to improve during 
pregnancy (114). 
UVB PHOTOTHERAPy FOR THE TREATMENT OF PSORIASIS – 
MECHANISM OF ACTION
The development of UVB phototherapy for psoriasis was based on the observation that 
exposure to sunlight improves the symptoms of psoriasis. Artificial light sources have been 
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used for the treatment of psoriasis since the 1920s. The most frequently applied regimen was 
the combination of topical coal tar and subsequent UVB radiation, introduced by Goeckerman 
in 1925. Broad-band UVB alone is used since the 1970s (115). Also in the 1970s psoralen plus 
UVA therapy (PUVA) was introduced. Psoralens, plant-derived photosensitizers, can be applied 
topically or orally. Subsequent UVA irradiation causes a therapeutically beneficial phototoxic 
reaction in the skin. PUVA therapy has anti-inflammatory and antiproliferative effects, and is 
highly efficacious for the treatment of psoriasis, inducing response rates from 74 to 100% (116). 
UVA effects are different from UVB effects (117). Effects of UVA radiation and PUVA 
therapy are not the subject of this thesis. Further forms of UV phototherapy for psoriasis 
are climatotherapy (also called heliotherapy), and the 308 nm excimer laser. Climatotherapy 
involves intentional gradual daily exposure to natural sunlight to get the therapeutic benefits of 
the included UVB radiation. Climatotherapy at the Dead Sea is combined with daily bathing 
in Dead Sea water. Treatment is usually for 4 weeks and results in decreases in PASI scores by 
75% or more. Most of the benefit of climatotherapy at the Dead Sea has been attributed to the 
sunlight at the Dead Sea (118). Balneophototherapy, which involves salt water baths and artificial 
ultraviolet radiation, can be used as an alternative to climatotherapy at the Dead Sea (118). 
The 308 nm excimer laser is used for the treatment of psoriasis since the late 1990s (119). 
This laser emits monochromatic light adjacent to those of NB-UVB, and probably has similar 
biological and clinical effects (120).
Narrow-band UVB phototherapy using Philips TL-01 fluorescent lamps was introduced in 
1988 for the treatment of psoriasis, following examinations of efficacy of discrete wavelengths 
in clearing psoriasis by Fisher and Parrish (121, 122). Several studies reported a superior 
clinical efficacy of NB-UVB to BB-UVB (123-126). Some other studies found that BB-UVB 
and NB-UVB are equally effective (127, 128).
Minimal erythema dose (MED) is the lowest radiation exposure that is sufficient to 
produce just perceptible erythema on exposed skin after 24 h. MEDs reported for NB-UVB 
and BB-UVB are shown in Table 1. 
Table 1. Minimal erythema dose with narrow-band and broad-band UVB. 
Study       Skin phototype1 MED BB-UVB (mJ/cm2) MED NB-UVB (mJ/cm2)
Van Weelden (114) II 76 410
Johnson (115) II 100 500
Karvonen (116) II 230 970
Storbeck (111) II 114 1034
Srinivas (117) IV 21 300
Tejasvi (118) III-V - 1000
Yuon (119) III-V - 750-1075
Morita (120) IV - 700
1 Types I-IV are determined by sunburn history (I: always burn, never tan; II: always burn, but sometimes tan; III: 
sometimes burn, but always tan; IV: never burn, always tan). Types V and VI by physical examination (V: moderately 
pigmented skin, VI: darkly pigmented skin) (100). 
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Thus, at least 5-times higher doses of NB-UVB are needed for the induction of erythema 
than of BB-UVB. NB-UVB doses required for the induction of hyperplasia, edema, sunburn 
cell formation and Langerhans cell depletion are 5-7 times higher than equally effective 
BB-UVB doses (136). Since in the clinical setting the applied doses are calculated based 
on the induction of erythema, much higher UV doses are given when NB-UVB is used than 
in the case of BB-UVB. Although in mice NB-UVB was more carcinogenic than BB-UVB 
at equally erythemogen doses (137), follow-up of patients receiving NB-UVB for psoriasis 
did not show an increase in skin cancer incidence as compared to controls (138-141). 
In addition, although NB-UVB induced the expression of matrix metalloproteinases and 
reduced the synthesis of collagens by dermal fibroblasts, factors that add to enhanced aging of 
the skin, these effects were weaker than induced by BB-UVB (142).
A further difference between NB-UVB and BB-UVB was that NB-UVB radiation did 
not suppress contact hypersensitivity response in mice, even at 7 times higher doses than 
the effective BB-UVB dose (136), demonstrating that BB-UVB and NB-UVB have different 
biological effects.
In summary, several forms of phototherapy are available for the treatment of psoriasis. 
Wavelengths between 311-313 nm are probably the most effective in clearing psoriasis. 
Studies in mice indicated that BB-UVB and NB-UVB have different biological effects. 
The mode of action of NB-UVB clearing psoriasis is incompletely understood.
UVB effects in healthy human skin
Primary molecular targets of UVB in the skin
The epidermis is the primary target of UVB radiation. UVB radiation is absorbed to the 
greatest extent by chromophores (light absorbing molecules) in the upper layers of the skin, 
mostly in the epidermis (143) (Figure 4). Light absorption in chromophores induces structural 
changes, thereby changing their functionality. Molecules which underwent light-induced 
structural changes are called photoproducts.
DNA damage
DNA absorbs light with wavelengths between 230 and 340 nm, and thereby it is a 
chromophore for UVB radiation (144). When DNA absorbs UVB radiation, different types 
of photoproducts are formed, the most frequent being cyclobutyl pyrimidine dimers (CPD) 
and (6-4)-photoproducts (145). These UVB signature molecules can be observed in both 
keratinocytes and Langerhans cells upon UVB radiation (145) (Figure 4). Involvement of DNA 
photoproduct formation in UV-induced processes can be studied by external or transgenic 
application of DNA repair photolyase enzymes. DNA photoproduct formation is involved in a 
specific biological effect when general or cell-specific repair of the UV signature 
mutations abolishes that biological effect. With this approach CPD formation was 
shown to play a role in UVB-induced apoptosis, inflammation, immunosuppression 
and photocarcinogenesis (146). Interestingly, UV-induced tumor formation, but not 
UV-induced immunosuppression could be prevented by repair of CPD in the basal 
keratinocytes only, demonstrating that different cell types mediate different biological effects of 
UV radiation (146).
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Reactive oxygen species (ROS)
Formation of reactive oxygen species (ROS) such as superoxide anion, hydrogen peroxide 
and singlet oxygen is the result of active cellular metabolism in the presence of oxygen. 
Reactive oxygen species are extremely instable, react with other molecules and hereby cause 
a variety of damages in the cell such as lipid peroxidation, DNA breaks and DNA-protein 
cross-links (147). To counteract oxidative damage, cells have an antioxidative defence 
system, comprising of radical scavengers (e.g. tocopherol, vitamin A) and different enzymes 
(e.g. superoxide dismutase, glutathione peroxidase, and catalase). UVB radiation induces 
enhanced ROS production (Figure 4). Cells respond with upregulation of scavenger enzyme 
activity and synthesis. Hereby UVB radiation drives the cells into a complex stress response.
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Figure 4. Acute effects of UVB in normal human skin. 
The primary molecular effects of UVB are the isomerisation of urocanic acid, the formation of DNA photoproducts 
and reactive oxygen species (ROS), and ligand-independent activation of certain transmembrane receptors. 
These primary changes lead to the secretion of proinflammatory cytokines, to apoptosis of keratinocytes with 
accumulated DNA damage, to the synthesis of vitamin D, enhanced pigmentation, epidermal hyperplasia, and the 
migration of Langerhans cells to the lymph nodes.
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Membrane changes
UVB radiation leads to clustering and internalization of cell membrane receptors for 
epidermal growth factor (EGF), TNF and IL-1, resulting in ligand-independent activation 
of members of the MAPK family (148). Furthermore, CD95 or FAS, another cell surface 
receptor is also activated by UVB radiation on a ligand-independent manner, contributing to 
UVB-induced apoptosis (149). 
Urocanic acid
Urocanic acid (UCA) is generated in the skin from histidin, and accumulates in the 
stratum corneum of the epidermis. The major source of UCA in the epidermis is filaggrin, a 
histidin-rich basic protein. Cleavage of filaggrin by caspase 14 produces UCA that absorbs 
UV radiation, and carboxylic-pyrrolidone acid that support cutaneous hydratation. Upon 
UV radiation the naturally occurring trans-UCA isoform converts to cis-UCA. The action 
spectrum for the production of cis-UCA in human skin is between 280 and 310 nm (150). 
UCA was first identified as a chromophore responsible for UVB-induced suppression of 
contact hypersensitivity (151). Upon UVB radiation in humans, cis-UCA is detectable in the 
skin and in the urine (152). Recently, the 5-HT2A serotonin receptor was identified as receptor 
for cis-UCA (153). In addition, a 5-HT2A receptor antagonist inhibited cis-UCA-induced 
suppression of delayed-type hypersensitivity response in mice (153). Interestingly, although 
cis-UCA stimulates the production of IL-6, TNF-α and PGE2 by keratinocytes, these effects 
were independent of the 5-HT2A receptor, indicating that there has to be another receptor for 
cis-UCA in these cells, and that keratinocytes might not be the effector cells of cis-UCA-
induced immune suppression (154).
Secondary events following UVB irradiation of the skin
Inflammation
Sunburn inflammation (erythema), a well-known acute effect of UV exposure, reaches 
its maximum 6 to 24 h after UV exposure. Wavelengths shorter than 320 nm are the most 
erythemogenic. During the development of sunburn erythema DNA seems to be the most 
important chromophore, based on the similarity of action spectra (144). UVB-exposed 
keratinocytes synthesize a set of cytokines, such as IL-1, IL-6, IL-8, IL-18, TNF-α and PGE2. 
These cytokines are responsible for the onset of inflammation (155). Secretion of IL-1β and IL-
18 upon UVB exposure is dependent on components of the inflammasome (NALP3, NALP1, 
pro-caspase 1), which become activated upon UV-induced elevation of the cytoplasmic Ca2+ 
concentration (156).
Epidermal thickening
UV-induced thickening of the epidermis is an important protecting factor against UV-
induced inflammation. Keratinocyte proliferation increases during the first 2 days after 
UV exposure, accompanied by increased DNA, RNA and protein synthesis. A single UVB 
exposure results in a twofold thickening of the epidermis lasting for about 6 weeks, whereas 
a single UVA exposure does not increase epidermal thickness (143).
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Apoptosis
Shortly after UVB exposure, apoptotic keratinocytes (“sunburn cells”) are formed in the 
epidermis, a process presumably mediated by p53 and dependent on the amount of DNA 
damage accumulated in the cell (157). Sunburn cell formation is thought to protect the 
organism from the accumulation of DNA damage and thereby from the induction of skin 
cancer.
Pigmentation
UV radiation results in increased skin pigmentation, becoming visible ~72 h after UVB 
exposure (earlier after UVA exposure). This increased pigmentation is caused by increased 
activity of melanocytes and of melanocyte tyrosinase. The transfer of melanin to keratinocytes 
also increases. Interestingly, UV-induced pigmentation gives variable protection against 
sunburn inflammation, depending on the skin type and on the wavelength that induced the 
tanning (143). UVA-induced pigmentation is less protective, probably because UVA does not 
induce thickening of the epidermis.
Vitamin D synthesis
The generation of previtamin D3 from provitamin D3 is the result of a photochemical 
reaction with maximum spectral effectiveness from 297 to 302 nm in basal and suprabasal 
layers of the skin (158). UV radiation above 315 nm is unable to produce previtamin D3 
in human skin. Previtamin D3 then undergoes thermal isomerization over a few hours 
generating vitamin D3 (cholecalciferol). Vitamin D3 translocates into the circulation, and its 
sequential activation occurs in the liver and kidney. In addition, several cell species including 
keratinocytes, macrophages, prostate epithelial cells and osteoblasts are able to convert vitamin 
D3 directly to the active 1α,25(OH)2D3 form (158). Skin cells (keratinocytes, epithelial cells 
of the epidermal appendages, melanocytes, Langerhans cells, macrophages, T-lymphocytes 
and dermal fibroblasts) also express vitamin D receptor (VDR), they can respond to active 
1α,25(OH)2D3 (159). VDR activation results in transcription of genes involved in cellular 
growth, differentiation, inflammation and wound healing in keratinocytes. 1α,25(OH)2D3 
protects primary human keratinocytes against the induction of CPD by UVB (144). Moreover, 
calcitriol produced in the skin may enhance UV-induced p53 protein expression and suppress 
nitric oxide (NO) products resulting in increased DNA repair (161). Hereby vitamin D has 
photoprotective effects. In addition, vitamin D mediates immunmodulatory effects of UV 
radiation: UV-induced 1α,25(OH)2D3 produced by DC signals T cells to express the chemokine 
receptor CCR10 on their surface, which enables them to migrate towards CCL27, the skin-
specific chemokine produced by keratinocytes (162).
Induction of antimicrobial peptides
 UVB radiation induces the expression of antimicrobial peptides LL37 (163), β-defensin-2, 
-3, ribonuclease 7 and S100A7 in normal human skin (164). Thus, whereas UVB radiation 
suppresses adaptive immune responses (see below), it induces innate immunity, which might 
partly explain why bacterial infections are not more frequent after UVB exposure.
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In summary, acute effects of UVB in healthy human skin include sunburn inflammation, 
pigmentation, hyperplasia, apoptosis of cells with accumulated DNA damage, synthesis of 
vitamin D and induction of antimicrobial peptides (Figure 4). These effects are the result 
of activation of primary molecular targets of UVB, such as DNA, reactive oxygen species, 
membrane receptors or urocanic acid (Figure 4). 
Immunosuppressive effects of UVB
Effects of UVB on the immune system have been extensively studied in terms of 
suppression of contact hypersensitivity response, mainly in mice. Two models have been 
studied in mice: in the low dose (~100 mJ/cm2) model, contact hypersensitivity response 
(CHS) is suppressed only at the site of irradiation, whereas in the high dose (~5000 mJ/
cm2) model, CHS cannot be induced even at non-irradiated sites, indicating systemic 
immunosuppressive effect of UVB. In both models, mice are first irradiated, about 3 days 
after which a contact sensitizer is applied epicutaneously either at the irradiated site or at a 
distant site (sensitization). Six days later the same contact sensitizer is applied topically to yet 
another body site, usually the ear (challenge). 24 h after this decreased ear swelling can be 
observed in the irradiated mice as compared to non-irradiated control mice (165). 
For a normal CHS to occur, Langerhans cells take up the antigen in the skin and present it 
in the draining lymph node to Th1 and Th17 cells, which are the effector cells of this delayed-
type hypersensitivity reaction (166). Upon UVB radiation, DNA damage occurs in Langerhans 
cells and other skin cells. Langerhans cells carrying DNA damage induce antigen-specific 
regulatory T cells in the draining lymph nodes (167, 168). These cells are responsible for the 
attenuated CHS response, as transfer of these cells into non-irradiated mice prevents the CHS 
response in the recipients. IL-10 is a critical cytokine for the suppression of the CHS response 
by UVB, as neutralizing antibodies against IL-10 prevent the suppressive effect of UVB (169). 
 Next to DNA, cis-UCA is also an important chromophore during UVB-induced 
immunosuppression, as blocking cis-UCA with a monoclonal antibody can reverse delayed-
type hypersensitivity reaction suppression by UVB (170), whereas treatment with cis-UCA 
in the absence of UVB radiation mimics the immunosuppressive effect of UVB in a dose-
dependent manner (171). In addition, cis-UCA inhibits the ability of Langerhans cells to 
present tumor antigens, contributing hereby to the development of UV-induced skin cancer. 
The immunostimulatory cytokine IL-12 prevents this effect of cis-UCA (172). Interestingly, 
injection of IL-12 and IL-18 prevents the UV-induced suppression of CHS by induction of 
the nucleotide excision repair system (173, 174). These results confirm that DNA damage is 
essential in the UVB-induced suppression of CHS. In these studies on the effect of IL-12 on 
UV-induced immunosuppression no attention was given to IL-12 subunits, i.e. whether these 
IL-12 actions are truly specific to IL-12 or are contributed to the IL-12p40 subunit which is 
shared with IL-23. 
Furthermore, supernatant of irradiated keratinocytes can also inhibit CHS in recipient 
mice (175). Keratinocytes upregulate receptor activator of NF-κB ligand (RANKL) upon 
UVB irradiation. Transgenic mice with overexpressed RANKL in basal keratinocytes have 
increased numbers of regulatory T cells, whereas overexpression of RANKL suppresses CHS, 
indicating an involvement of RANKL in UVB induced systemic immunosuppression (176). 
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The CHS response is also suppressed by UVB in humans (117). A single exposure to 
4 MED or repetitive daily exposures to 0.75 to 2 MED for four consecutive days suppressed 
the induction of CHS in humans when the antigen was applied locally to the site of irradiation. 
A single dose of 4 MED also inhibited the systemic induction of immunity (177). 
The murine CHS model shows that UVB radiation inhibits antigen-specific adaptive 
immune responses, of which the effectors are Th1 and Th17 cells. These T-cell subsets are 
also critical in the pathogenesis of psoriasis, although the antigen specificity is unknown. 
The function of regulatory T cells is defective in psoriasis, although their numbers do not 
differ from that of normal controls (178). It is possible that induction of regulatory T cells 
plays a role in the effectiveness of UVB therapy in psoriasis, although this effect was not 
demonstrated in in vivo studies. Serum levels of IL-10 do not change during phototherapy 
(179), but PBMC isolated after phototherapy produce more IL-10 upon in vitro stimulation 
than PBMC from untreated patients (180). Migration of Langerhans cells is defective in 
psoriasis (43), and it was not investigated whether UVB phototherapy affects this property.
In conclusion, suppressive effects of UVB on adaptive immunity might partly account 
for the efficacy of UVB treatment in psoriasis, but it was never formally shown in patients 
undergoing phototherapy. As in psoriasis innate immunity might be more important than 
adaptive immunity, UVB effects on the CHS response would not give sufficient explanation 
for the efficacy of this treatment in psoriasis. In addition, NB-UVB did not suppress the CHS 
response in mice (136), whereas it is highly efficacious in psoriasis, which would argue for 
distinct mechanisms in the immunosuppressive and anti-psoriatic effects of UVB.
Mode of action of (NB-)UVB in psoriasis
Primary molecular targets of UVB phototherapy in psoriasis
From the primary UVB target molecules that were discussed above, the involvement of 
urocanic acid (181) and DNA damage (182, 183) was studied during the phototherapy of 
psoriasis. Furthermore, expression of cytoprotective enzymes was assessed (184). The most 
important conclusions of these studies are discussed below.
The epidermal cis-UCA concentration was found to be increased by heliotherapy of 
psoriasis, from a mean initial value of 0.2 nmol/cm2 to a mean final value of 2.9 nmol/cm2. 
Clinical response of psoriasis to heliotherapy, however, seemed to be independent of UCA 
isomer levels (181).
The amount of DNA mutations during phototherapy was assessed in order to evaluate 
its carcinogenic potential and compare it with that of BB-UVB (182, 183). NB-UVB 
induced equal amount of DNA photoproducts as BB-UVB at equally erythemogen doses, 
indicating that NB-UVB is not more carcinogenic than BB-UVB (182). The amount of CPD 
increased in the psoriatic skin during the first three treatment sessions, but not hereafter. 
Clinical improvement is usually only noticable after several weeks of treatment (183). 
Expression of many drug metabolizing and cytoprotective enzymes that play a role in 
the cellular defense against reactive oxygen species is constitutively higher in psoriatic 
plaques. The role of this high scavenger enzyme expression in psoriatic lesions is unknown. 
Interestingly, in non-lesional skin of psoriatic patients scavenger enzyme expression is reduced 
compared to the skin of healthy subjects, and is increased by UV radiation (184).
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Local effects of UVB in psoriatic skin
Locally, NB-UVB phototherapy reverses several pathologic alterations in psoriasis. 
Keratinocyte proliferation decreases (185, 186). The number of T lymphocytes in the 
epidermis and dermis decreases, very probably due to apoptosis (187, 188) (Figure 5). 
The decrease in epidermal T cells correlated well with the clinical improvement, which was 
not true for the change in dermal T cell numbers (185). In addition, decrease in epidermal 
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Figure 5. Local effects of UVB in psoriatic plaques. 
UVB-induced alterations are marked with dark coloring. Upon UVB phototherapy the number of T lymphocytes 
decreases in the epidermis and the dermis due to apoptosis. UVB-induced increased expression of FasL on 
keratinocytes contributes to the apoptosis of intraepidermal T lymphocytes. T lymphocytes that remain in the lesion 
produce less IFN-γ. Neutrophil granulocytes are the source of enhanced IL-4 production upon UVB irradiation. 
Keratinocyte proliferation decreases during UVB phototherapy, as well as the expression of adhesion molecules and 
other activation markers by keratinocytes.
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T cell numbers also correlated with long-lasting remission after treatment (186). Interestingly, 
early relaps was seen in this study in all patients with remaining keratin 16 staining at the end 
of NB-UVB treatment (186). Epidermal and dermal T cell numbers were significantly more 
reduced by NB-UVB than by BB-UVB (187). It was shown in vitro that T lymphocytes are 
10-fold more sensitive to the cytotoxic effects of UVB than keratinocytes, which explains 
their depletion from the epidermis upon UVB phototherapy (185). In addition, whereas 
hyperplastic keratinocytes in untreated psoriatic plaques do not express CD95L/FasL on their 
plasma membrane, after NB-UVB treatment there is strong and diffuse keratinocyte CD95L/
FasL expression that coincided in a temporal fashion with depletion of intraepidermal T cells, 
indicating a role for FasL in epidermal T cell apoptosis (189). 
T cells that remain in the lesions after 4 weeks of NB-UVB treatment produce less IFN-γ 
and IL-12 and more IL-4 (188, 190, 191) (Figure 5). Already one single dose of broadband 
UVB radiation resulted in decreased IFN-γ production and increased IL-4 production in 
psoriatic skin, and interestingly, neutrophils were found to be the source of the increased IL-4 
production (192). 
The number of Langerhans cells is decreased after NB-UVB phototherapy in non-lesional 
psoriatic skin (193). It is not known whether this is the case in the lesion as well.
Systemic effects of UVB in psoriasis
Cellular effects
Expression of adhesion molecules on the surface of circulating cells decreases during NB-
UVB phototherapy. On the surface of PBMC of psoriatic patients, the skin homing cutaneous 
lymphocyte-associated antigen (CLA) decreased gradually during NB-UVB phototherapy, 
parallel with the PASI reduction (194). The same was observed for very late antigen (VLA)-
4α, but not for ICAM-1 on PBMC. Accordingly, binding of psoriatic PBMC to psoriatic 
plaque tissue was completely inhibited after 14 days of daily NB-UVB treatment (195). 
This inhibition also correlated with decrease in ICAM-1 and E-selectin expression in the 
plaque tissue after NB-UVB treatment, demonstrating that UVB effects in the skin are also 
important for the reduced skin homing of circulating cells.
Cytokine secretion of in vitro stimulated PBMC isolated from psoriatic patients before 
and during UVB phototherapy was also investigated by several groups. In an early study, 
IL-2 production by peripheral blood lymphocytes upon stimulation with phytohaemagglutinin 
(PHA) and phorbol myristate acetate (PMA) was slightly decreased in patients with psoriasis 
as compared to healthy volunteers (196). In lymphocytes isolated after UVB phototherapy 
(15 UV treatments), IL-2 synthesis could not be induced by addition of PHA+PMA. In addition, 
T helper cell activity of CD4+ lymphocytes of psoriatic patients at the end of phototherapy was 
decreased as compared to that of cells from healthy controls, as measured by graft versus host 
response induced by these cells (196). 
When PBMC of psoriatic patients, isolated before NB-UVB therapy and weekly hereafter 
for two weeks, were stimulated with superantigen in vitro, reduced production of IL-1β, IL-2, 
IL-5 and IL-6 and increased production of IL-10 was detected (180). 
Furthermore, NB-UVB treatment (as well as treatment with PUVA and BB-UVB) resulted 
in reduced cytotoxic activity of circulating NK cells (197), whereas the number of circulating 
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NK cells remained unchanged (198). In contrast, local coal tar treatment did not affect the 
cytotoxic activity of NK cells (197).
Effects on soluble factors
IL-1α level is elevated 4 h after UVB radiation of psoriatic patients, but this effect is 
gone after 24 h (199). Serum IL-6 level is shown to be an early marker of clinical response 
to UVB phototherapy (200). Interestingly, serum levels of immunosuppressive IL-10 and 
proinflammatory TNF-α did not change during phototherapy (179), whereas serum soluble 
TNF-R1 levels decreased (201). 
After phototherapy, vitamin D levels were dramatically increased by UVB (but not by 
PUVA) in psoriatic patients as well as in controls (202). Serum vitamin D levels in psoriasis 
patients increased less with NB-UVB than with broadband UVB phototherapy (203). 
This difference between BB-UVB and NB-UVB on vitamin D synthesis would indicate that 
vitamin D synthesis does not correlate with the clinical efficacy, as NB-UVB is at least as 
effective to treat psoriasis as BB-UVB.
In conclusion, psoriatic plaques differ from normal skin in their content of chromophores 
for UVB and in scavenging enzymes for ROS. Initiating molecular events of UVB-efficacy in 
psoriasis are not well defined. Depletion of epidermal lymphocytes, and decrease in adhesion 
molecules on PBMC correlated with the clinical improvement, confirming a critical role for 
T lymphocytes in psoriasis. UVB-induced expression of FasL on keratinocytes plays a role 
in this epidermal T cell apoptosis (Figure 5). In addition, cytokine expression of skin resident 
and circulating cells is altered upon UVB phototherapy. 
GENOME-wIDE ExPRESSION STUDIES 
Genome-wide expression studies in psoriasis
Several genome-wide expression studies have been published on the expression profile 
of lesional psoriatic skin. Some of them compared lesional skin with non-lesional skin 
(204-211), others compare psoriatic lesional skin with other inflammatory skin disorders 
(74, 212-215), and yet another group of studies followed patients receiving different treatments 
for psoriasis and compared gene expression profiles at different time points during treatment 
(87, 103, 216-218). These studies described the genomic signature of psoriasis lesions, helping 
thereby the better understanding of the molecular pathophysiology of the disease (Figure 6). 
Studies comparing lesional psoriatic skin with non-lesional skin and normal skin confirmed 
increased proliferation, altered epidermal differentiation and barrier function, and an activated 
immune response in psoriatic skin, and provided new insights into the pathogenesis, such as a 
large contribution of CD11c+ myeloid dendritic cells, as well as an activation of interferon- and 
Wnt-signaling pathways (204-209). A study with basic importance for all other investigations 
showed that the psoriasis transcriptome does not depend on body site location, and correlates 
well with disease severity (210). 
The psoriatic transcriptome was compared to cell-specific gene expression profiles to 
identify the contribution of different cellular subsets to the pathogenesis. With this approach 
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a surprisingly large contribution of myeloid DC to the psoriatic transcriptome was found 
(212, 219). Interestingly, gene expression profiling of IL-1α-stimulated keratinocytes identified 
a set of psoriasis genes, among them mainly antimicrobial peptides and other components of 
the epidermal barrier, emphasizing anomalies of innate immunity in psoriasis (220, 221).
Comparison of gene expression profiles of psoriasis and atopic dermatitis was performed 
by several research groups (74, 212-215). Advantage of this approach is that molecules that 
are secondary to the chronic inflammatory and hyperproliferative state will not be found, but 
only genes that are truly pathogenic (214). A major difference between psoriasis and atopic 
dermatitis is the high expression of antimicrobial peptides in psoriasis (214). Dermal myeloid 
DC produce different inflammatory mediators in psoriasis and atopic dermatitis, TNF-α and 
iNOS being dominant inflammatory mediators in psoriasis (212). Chemokine expression 
Figure 6. Scheme of the vicious circle of chronic psoriatic skin inflammation. 
Modified from Kulski et al. (207). The activated epidermis produces chemokines, cytokines and angiogenic factors. 
In the dermis, pDC produce IFN-α, which triggers an adaptive immune response. Inflammatory myeloid DC activate 
T cells to produce proinflammatory cytokines, e.g. IL-22 and IFN-γ, which in turn stimulate the regenerative phenotype 
of epidermal keratinocytes. Neutrophils are attracted to the epidermis by keratinocyte-derived chemokines, and are 
themselves a source of chemoattractant molecules.
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also differentiates psoriasis from atopic dermatitis. Chemokines with high expression in 
psoriasis are CCL4, CCL20, CXCL2, CXCL8 and the chemokine receptor CXCR2 74). 
This comparative approach applied for lichen planus, atopic dermatitis and psoriasis also 
identified the type I IFN signature as being specific to psoriasis (215).
Psoriasis was also compared with squamous cell carcinoma using the microarray 
technology (222). Hereby a set of common upregulated genes was identified, including, 
surprisingly, molecules with immunoregulatory roles, such as IFI27, IL8RB, MX1, OAS1, 
OASL and STAT1 (222).
Genome-wide expression analysis gave new information on affected molecular 
pathways of established effective therapies, constructing thereby genomic signatures of 
successful treatment of psoriasis to guide development of new therapies. Cyclosporin A 
modulated the expression of Th1 and Th17 pathway genes, and reduced the expression of the 
DC-products TNF-α and iNOS in lesional psoriatic skin (87). Phototherapy (NB-UVB 
and Dead Sea treatment) suppressed S100A proteins, TNF-α and NF-kB target genes, and 
induced the expression of the antiproliferative molecule IGFBP7 in non-lesional epidermis 
(216). In PBMC of patients, successful dithranol treatment downregulated 18 genes, amongst 
them IL-8, TNFAIP6, COX2 and desmocollin 2 (217), while experimental IL-10 treatment 
downregulated a large set of chemokines and cytokines (218). Alefacept initially stimulated 
proinflammatory genes in PBMC of the treated patients (103). Furthermore, microarray 
technology was used to investigate the validity of an experimental treatment, cyclopamine, 
an inhibitor of the hedgehog signaling pathway. Hedgehog signaling was not activated in 
psoriasis, raising hereby questions by the use of cyclopamine in psoriasis (223).
Genome-wide expression studies in UVB-treated epidermal cells
Gene expression profiling studies described the transcriptomic changes following UVB 
radiation in cultured human keratinocytes, melanocytes, and healthy human epidermis. 
The UV-response of human epidermis differed from that of keratinocytes (224). In foreskin-
derived primary human keratinocytes, three waves of changes in gene expression were 
described after irradiation with a single dose of 8 mJ/cm2 BB-UVB, in a kinetic study (225): 
within 2 hours, transcription factors (e.g. JunB, JunD, c-fos, EGR1), signal transducing and 
cytoskeletal proteins are regulated, that change the phenotype of the cells to activated, paused 
cells. C-Myc expression is suppressed, which results in decreased proliferation. In the second 
wave, between the 4th and 8th hours after irradiation, cytokines, chemokines and growth 
factors are secreted to alert the surrounding tissue to the UV damage and attract inflammatory 
cells to the skin. Later, after 16 hours differentiation-associated genes (e.g. S100A proteins, 
involucrin, SKALP/elafin and small proline-rich proteins) are regulated, enhancing the 
epidermal protective covering (225). In another study, foreskin-derived primary human 
keratinocytes were irradiated with 10 mJ/cm2 BB-UVB, and 6 h later cells were harvested 
for gene expression profiling (226). At this time point, cytochrome c genes, genes involved 
in differentiation, transcription and transport were differentially expressed as compared to 
control cells. In a third publication foreskin-derived primary keratinocytes were irradiated 
with 10, 20 or 40 mJ/cm2 BB-UVB, and gene expression changes are analysed 4 and 24 
h after irradiation (227). Here, too, induction of transcription factors, stress-response and 
proinflammatory genes were described, as well as a suppression of cell adhesion molecules 
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(in order to factilitate the migration and enhanced differentiation of the cells) and metabolism-
associated genes (227). In addition, DNA repair enzymes and extracellular matrix proteases 
were induced (227, 228). Expression of cell adhesion molecules was downregulated (227). 
In intact human epidermis, the expression profile was geared mainly towards DNA 
repair upon irradiation with a single dose of 4 MED with a BB-UVB source. In addition, 
S100A proteins, serine protease inhibitors, cell cycle regulating and apoptosis-related genes, 
cytokines, chemokines and matrix metalloproteases were induced (224). 
In primary epidermal melanocyte cultures, a single irradiation with 25 mJ/cm2 BB-UVB 
resulted in the induction of a set of p53-target genes 24 h after irradiation (229). 
In conclusion, there are a few, independent studies on expressional changes in keratinocytes, 
melanocytes or complete epidermis upon BB-UVB irradiation, which describe global gene 
expression changes, involving several transcription factors, proinflammatory molecules, 
differentiation-associated genes, DNA repair and cell cycle genes. Effects of NB-UVB on 
normal epidermal cells were not investigated. However, in 2007 Hochberg et al. compared 
the global gene expression profile before and after NB-UVB therapy or Dead Sea treatment 
in non-lesional psoriatic epidermis (216). Differentially expressed genes included S100A 
proteins, dendritic cell markers, TNF-α target genes, matrix metalloproteinases and NF-κB 
target genes. In addition, insulin-like growth factor binding protein (IGFBP)-7 was identified 
as an antiproliferative molecule with low expression in non-lesional psoriatic skin, which was 
induced by NB-UVB therapy, possibly contributing to its antipsoriatic effect.
AIMS OF THE THESIS
The aim of this thesis is to illuminate the local molecular effects of NB-UVB phototherapy 
in the epidermis in the inflamed, psoriatic environment, and to identify molecular pathways 
that are responsible for the efficacy of this treatment modality in psoriasis. 
In patients with psoriasis, global gene expression profiling was performed of epidermal 
samples acquired before, during and after NB-UVB phototherapy, in both lesional and non-
lesional skin. This microarray study was complemented by ex vivo studies using skin of healthy 
subjects (Chapter 2). Based on the results of the gene expression profiling promising NB-
UVB target molecules were selected and further investigated in vitro, ex vivo and in mice.
Our group previously described activated IFN-α signalling in psoriasis, and upregulation 
of receptors for double-stranded RNA in psoriasis lesions. This upregulation of dsRNA 
receptors was mimicked in vitro by IFN-α treatment of primary keratinocytes. We asked 
whether NB-UVB affects this aspect of innate immune activation in psoriasis, investigating 
dsRNA receptor expression and its response to NB-UVB radiation in vivo in psoriatic patients 
and in vitro in primary human keratinocytes (Chapter 3). 
Recently a novel psoriasis-like skin inflammation mouse model was described by our 
group. We used this model to validate and explore findings of the microarray study on the 
transcription factor GATA3 (Chapter 4). 
Furthermore we had the opportunity to compare the cellular effects of NB-UVB with 
those of the 585 nm pulsed dye laser in psoriasis, a treatment that selectively destructs dermal 
blood vessels, and thereby limiting the skin homing of inflammatory cells (Chapter 5). 
The conclusions of these studies are summarized in Chapter 6.
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ABSTRACT
Narrow-band ultraviolet-B (NB-UVB) phototherapy is an effective 
treatment for psoriasis. The molecular mechanisms underlying its efficacy 
are incompletely understood. We aimed to identify NB-UVB-induced 
molecular pathways that may account for the anti-inflammatory efficacy of 
the treatment.
Skin biopsies were obtained from psoriatic patients undergoing NB-UVB 
phototherapy from lesional and non-lesional skin before, during and after 
therapy. Gene expression profiling and pathway analysis was performed using 
epidermal RNA. Additionally, skin biopsies from healthy individuals were 
cultured with IL-22 and effects of UVB irradiation on the Th17 signalling 
pathway were assessed.
NB-UVB phototherapy downregulated Th17 and interferon signalling 
pathways in psoriatic epidermis. Direct inhibition of the Th17 pathway by UVB 
was confirmed in an ex vivo organ culture system by demonstrating reduced 
signal transducer and activator of transcription 3 (STAT3) phosphorylation and 
β-defensin-2 production. In addition, UVB affected well-known therapeutic 
targets in psoriasis, such as the glucocorticoid, vitamin D, peroxisome 
proliferator-activated receptor and IL-4 signalling pathways. 
In conclusion, clinical improvement of psoriasis by NB-UVB is associated 
with downregulation of Th17 and type I and II interferon signalling pathways, 
which are critical in the pathogenesis of the disease. Our data provide novel 
insights into the molecular mechanisms underlying successful NB-UVB 
therapy for psoriasis.
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UVB therapy inhibits inflammatory pathways
INTRODUCTION
Narrow-band ultraviolet-B (NB-UVB) phototherapy, referred to as NB-UVB therapy 
hereafter, is a standard and safe treatment for moderate to severe psoriasis. Its mechanism of 
action is incompletely understood and has mainly been studied in vitro or in mice. 
NB-UVB therapy has both local effects in the skin, and systemic effects. Locally, NB-
UVB therapy reverses several pathologic alterations in psoriasis: the number of epidermal 
T lymphocytes and dendritic cells (DC) decrease during phototherapy, very probably due 
to UVB-induced apoptosis (1-4). Moreover, T cells that persist in UVB-treated skin lesions 
exhibit a functional shift towards less IFN-γ and more IL-4-production (5, 6). In addition, 
keratinocyte proliferation decreases during NB-UVB therapy (4). It is not known via which 
molecular mechanisms or pathways NB-UVB achieves these cellular changes. Because most 
of the UVB radiation is absorbed by the epidermis, this is presumably the primary site of UVB 
action. 
In this study microarray technology was used to analyse kinetic changes in epidermal total 
genome expression profile induced by NB-UVB therapy, which is instrumental to identify 
novel pathways and mechanisms that are involved in its anti-inflammatory mode of action.
Microarray technology was previously used to better understand the mode of action 
of other established therapies in psoriasis such as alefacept, infliximab and cyclosporin A. 
Alefacept, an LFA3-Ig fusion protein that binds to CD2 and inhibits T cell activation, 
was found to induce leukocyte activation genes which might explain the inefficacy of this 
treatment in approximately 50% of psoriasis patients (7). Infliximab, a therapeutic antibody 
against TNF-α was shown to additionally inhibit IFN-γ-induced genes, thereby targeting a 
major pathway of the adaptive immune response in psoriasis (8). Cyclosporine A was shown 
to suppress Th1 and Th17 pathways, TNF-α and nitric oxide synthase-producing DCs in the 
skin of patients with psoriasis (9).
Transcriptomic effects of NB-UVB therapy had to date only been examined in non-lesional 
skin samples of 3 patients with psoriasis (10). We analyzed epidermal gene expression profiles 
in lesional and non-lesional skin of 10 patients with psoriasis taken before and after NB-UVB 
treatment. Additionally, in the same patients, short-term effects of NB-UVB and immediate 
targets of phototherapy were investigated in lesional and non-lesional skin 6 h after the first 
treatment session.
RESULTS
Clinical response to NB-UVB therapy
The mean PASI reduction after standard NB-UVB therapy in all patients included in 
this study was 81%. (range 58 – 100%). The mean PASI score decreased from 12.7 (range 
10.0 – 23.2) to 2.4 (range 0 – 8.4). For the microarray analysis, patient samples were pooled 
in 2 groups, as described in the Methods section. The mean PASI reduction was similar in 
these patient groups. 
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Correlation of gene expression profiles 
The degree of similarity between global gene expression profiles was assessed using the 
OmniViz package. Expression profiles of the two different pools of patient samples were 
similar to each other for all conditions, demonstrating valid duplicate measurements. 
Two clusters of samples were identified on the basis of strong similarities in their gene 
expression profiles (Figure 1). One smaller cluster was formed by lesional skin biopsies that 
were taken on the first day of NB-UVB therapy, immediately before and 6 h after irradiation. 
The strong correlation between these samples shows that NB-UVB induced relatively small 
changes in gene expression in lesional skin 6 h after irradiation. Gene expression profiles in 
lesional biopsies taken after three months of NB-UVB therapy cluster together with the non-
lesional skin biopsies taken before and after NB-UVB therapy. 
Differences between lesional and non-lesional epidermis before therapy
The gene expression profiles in untreated psoriasis lesions were compared to untreated non-
lesional skin. In lesional skin, 251 genes were upregulated and 383 genes were downregulated 
compared to non-lesional skin. There was great similarity between the gene expression 
profiles found in this study and previously reported profiles in psoriatic lesional and non-
lesional skin without NB-UVB intervention (11-18), although these studies extracted RNA 
from whole skin biopsies (epidermis and dermis together) whereas we exclusively used the 
epidermis. Genes upregulated in lesional skin included members of the interferon signaling 
pathway (e.g. IFI27, MX1, STAT1, OAS1), Th17 pathway (STAT3, β-defensin 2, CCL20, 
keratin 16, IL20R, S100A7, S100A12), other immune response genes (IL8, IL8RB, CXCR4, 
CD24), epidermal differentiation-associated genes (keratinocyte transglutaminase, SKALP/
Elafin, keratin 6, keratin 17), and various proteinases (kallikrein 6, kallikrein 13, cathepsin 
C, tissue plasminogen activator, kynunerinase). Genes higher expressed in non-lesional skin 
had functions such as cell proliferation (betacellulin, CRIP1, INSIG1), cell cycle progression 
(CCND1) and the epidermal differentiation complex (corneodesmosin, KRT15, sciellin, 
filaggrin, LCE1B). 
Genes regulated by NB-UVB phototherapy in the lesional and non-lesional epidermis
When gene expression profiles in skin samples taken before and after NB-UVB therapy 
were compared, 183 genes were downregulated and 329 genes were upregulated by NB-
UVB in lesional skin (Supplemental Tables 1 and 2). In non-lesional skin, 17 genes were 
downregulated and  1 gene upregulated after NB-UVB therapy (Supplemental Table 3). There 
was a marginal overlap between genes regulated in lesional and non-lesional skin, represented 
by 6 genes (S100A9, keratin 6, alpha-actinin, STEAP4, ets homologous factor, betacellulin).
Examination of the lists of differentially expressed genes in psoriasis lesions showed 
that NB-UVB had a strong suppressive effect on genes regulated by the Th17 and interferon 
signalling pathways and members of the epidermal differentiation complex (Table 1).
Functional annotation of the differentially expressed genes in lesional skin before vs. 
after NB-UVB therapy is shown in Supplemental Figure 1. Immune responses, response 
to virus and response to stress were suppressed by NB-UVB therapy, whereas epidermis 
development/differentiation, extracellular matrix components and negative regulators of 
biological processes were induced.
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NB-UVB downregulates the pathogenic Th17 pathway in psoriasis skin lesions
Amongst the genes that were most suppressed by NB-UVB phototherapy in lesional 
and non-lesional skin, there were many known members of the Th17 pathway (Figure 2A). 
From this group of genes, S100A9 and β-defensin 2 were selected to validate the microarray 
Figure 1. Correlation view of expression profiles of the different RNA pools. 
Red squares indicate positive pairwise correlations and blue squares indicate negative pairwise correlations. 
L: lesional samples, N: non-lesional samples; 0 h: sample taken before the first irradiation, 6 h: sample taken 6 h after 
the first irradiation, E: sample taken after completion of NB-UVB therapy; A, B: patient pools. See page 150 for a 
full-color representation of this figure.
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data at the mRNA and protein levels. Expression of S100A9 was significantly downregulated 
in lesional and non-lesional epidermis after NB-UVB phototherapy on the basis of the 
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Figure 2. NB-UVB therapy suppresses the Th17 pathway. 
A. Th17 pathway. Grey indicates gene downregulation. B. S100A9 expression measured by RT-PCR. PP: lesional, 
PN: non-lesional samples; 50%: sample taken at 50% PASI score reduction. Error bars indicate SEM, 
n=4 representative patients. C. β-defensin-2 in psoriatic skin samples during NB-UVB therapy. G-CSF: granulocyte 
colony-stimulating factor, GM-CSF: granulocyte macrophage colony-stimulating factor, SAA: serum amyloid A, CRP: 
C-reactive protein, LCN2: lipocalin 2, TIMP1: TIMP metallopeptidase inhibitor 1, MMP1: matrix metalloprotease 
1, DEFB4: β-defensin 2, SERPINB3: serine proteinase inhibitor, clade B, member 3. See page 151 for a full-color 
representation of this figure.
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microarray data. Using mRNA isolated from individual patients and quantitative RT-PCR 
we found a similar downregulation (Figure 2B). Expression of β-defensin 2, assayed by 
immunofluorescent staining, was clearly suppressed by NB-UVB phototherapy in the 
lesional skin, confirming hereby the downregulation of the Th17 pathway at the protein level 
(Figure 2C).
The Th17 cytokine IL-22 was previously shown to induce a psoriasis-like phenotype in 
reconstituted human epidermis, including induction of acanthosis, antimicrobial proteins such 
as β-defensins, and activation of STAT3 (19). We assessed the effect of NB-UVB radiation on 
these IL-22-driven functions in an ex vivo skin culture system. IL-22 stimulation increased the 
number of cells expressing phospho-STAT3, whereas this was inhibited by subsequent NB-
UVB irradiation (Figure 3A, B). Expression of β-defensin 2 in the epidermis is induced by 
IL-22 (19, 20), and this effect was drastically inhibited by NB-UVB irradiation (Figure 3C). 
Collectively, our data demonstrate that NB-UVB suppresses the Th17 pathway in psoriatic 
skin, both in vivo during NB-UVB therapy as well as in irradiated ex vivo cultured skin explants. 
NB-UVB downregulates the IFN signaling pathway in lesional psoriatic epidermis
In psoriasis lesions, NB-UVB therapy suppressed members of the IFN signalling pathway 
and many IFN-inducible molecules (Figure 4A). Interestingly, this signalling pathway was not 
affected by NB-UVB therapy in non-lesional skin. We selected the IFN-inducible cytoplasmic 
RNA receptor IFIH1/MDA5 to validate the microarray data using mRNA of individual 
Figure 3. NB-UVB inhibits epidermal STAT3 activation and β-defensin 2 production. 
A. Phosphorylated STAT3 in skin biopsies of healthy controls, treated in vitro with IL-22 +/- NB-UVB. B. Counts 
of phospho-STAT3+ nuclei in the epidermis. Error bars indicate SEM, n=4 subjects. C. β-defensin 2 mRNA 
expression in the epidermis of healthy controls. Error bars indicate SEM, n=4 subjects. See page 152 for a full-color 
representation of this figure.
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patients, including skin samples taken when the PASI scores were reduced by 50%. IFIH1/
MDA5 mRNA was suppressed in lesional skin and remained unchanged in non-lesional skin, 
confirming the microarray data (Figure 4B). Additionally, to verify the downregulation of 
the interferon signaling pathway by NB-UVB at the protein level, the expression of MxA 
protein, a well-established marker of type I IFN-signaling, was studied using immunostaining. 
The expression of MxA was markedly decreased in lesional psoriatic skin treated with NB-
UVB (Figure 4C). 
NB-UVB therapy affects the terminal epidermal differentiation
Our microarray results show that many genes that are linked to terminal epidermal 
differentiation were affected by NB-UVB therapy in both lesional and non-lesional skin 
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Figure 4. NB-UVB therapy suppresses IFN signalling pathways. 
A. IFN signalling pathways. Grey colour indicates gene downregulation. B. IFIH1/MDA5 expression measured by 
RT-PCR. PP: lesional, PN: non-lesional samples; 50%: sample taken at 50% PASI score reduction. Error bars indicate 
SEM, n=5 patients. C. MxA expression during NB-UVB therapy. IFNGR: IFN-γ receptor, IFNAR: IFN-α receptor, 
TAP1: transporter 1, ATP-binding cassette, B, IFITM1: interferon induced transmembrane protein 1, IRF1: interferon 
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factor 9. See page 153 for a full-color representation of this figure.
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(Table 1). NB-UVB also induced some selective effects in lesional versus non-lesional skin. 
For example, corneodesmosin expression in psoriasis lesions was decreased when compared 
to non-lesional skin before therapy, whereas NB-UVB therapy increased the expression in 
Table 1. IFN-signalling, Th17 pathway and epidermal differentiation are affected by NB-UVB phototherapy 
in the lesional epidermis. 
Name Symbol Fold change
Th17 pathway
S100 calcium binding protein A7 S100A7 36.5 ↓
defensin, beta 2 DEFB4 36.2 ↓
peptidase inhibitor 3, skin-derived (SKALP) SKALP 24.7 ↓
S100 calcium binding protein A9 S100A9 17.7 ↓
S100 calcium binding protein A12 S100A12 15.3 ↓
Keratin 16 KRT16 12.9 ↓
lipocalin 2 (oncogene 24p3) LCN2 11.6 ↓
serpin peptidase inhibitor, clade B (ovalbumin), member 3 SERPINB3 10.4 ↓
interleukin 8 IL8 5.0 ↓
signal transducer and activator of transcription 3 STAT3 2.5 ↓
secretory leukocyte peptidase inhibitor SLPI 1.7 ↓
interleukin 20 receptor beta IL20RB 1.9 ↓
IFN signaling
keratin 17 KRT17 9.5 ↓
interferon, alpha-inducible protein 6 IFI6 4.6 ↓
myxovirus resistance 1, interferon-inducible protein p78 (mouse) MX1 4.3 ↓
interferon-induced protein 44-like IFI44L 4.1 ↓
signal transducer and activator of transcription 1 STAT1 3.7 ↓
2’-5’-oligoadenylate synthetase 2, 69/71kDa OAS2 3.4 ↓
interferon gamma receptor 1 IFNGR 2.1 ↓
interferon induced with helicase C domain 1 (MDA5) IFIH1/MDA5 1.8 ↓
Epidermal differentiation 
keratin 6 KRT6 9.7 ↓
small proline-rich protein 2C SPRR2C 9.6 ↓
gap junction protein, beta 2, 26kDa GJB2 6.7 ↓
desmocollin 2 DSC2 5.4 ↓
keratin 15 KRT15 3.7 ↑
GATA binding protein 3 GATA3 2.9 ↑
transglutaminase K TGM1 2.4 ↓
corneodesmosin CDSN 2.1 ↑
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lesional, but not in non-lesional skin. These results were validated by RT-PCR using mRNA 
from individual patients (Figure 5A). Validation of this functional cluster at the protein level 
was done using immunostaining that clearly showed the downregulation of keratinocyte 
transglutaminase expression (downregulated 2.4-fold by NB-UVB therapy in the lesional 
epidermis in the microarray data) (Figure 5B).
NB-UVB therapy affects known therapeutic targets of psoriasis
Ingenuity Pathway Analysis software was additionally used to identify signalling pathways 
affected by NB-UVB therapy in psoriasis lesions. Interestingly, NB-UVB therapy regulated 
several pathways that are known therapeutic targets in psoriasis, such as glucocorticoid receptor 
and vitamin D receptor signalling (Table 2). Furthermore, NB-UVB therapy regulated some 
pathways that were previously identified as potential therapeutic targets in psoriasis, such as 
PPAR, IL-4 and IL-10 signalling (21-25). Pathways described as targets of UV radiation in 
normal skin and that are involved in the pathogenesis of psoriasis, such as NF-κB, MAPK, 
p53 and IGF-1 signalling were also affected by NB-UVB therapy in lesional psoriatic skin 
(Table 2). 
 
Figure 5. NB-UVB therapy suppresses epidermal differentiation. 
A. Corneodesmosin (CDSN) expression measured by RT-PCR. PP: lesional, PN: non-lesional samples; 50%: sample 
taken at 50% PASI score reduction. Error bars indicate SEM, n=5 patients. B. Transglutaminase K expression during 
NB-UVB therapy. See page 154 for a full-color representation of this figure.
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Table 2. Effect of NB-UVB phototherapy on pathways known to be therapeutic target in psoriasis, or target 
of UVB radiation.
Pathway p-value Molecules affected by NB-UVB within these pathways
Upregulated Downregulated
Therapeutic 
target in 
psoriasis
Glucocorticoid 
receptor signalling
1.1E-03 PIK3R1, PIK3C2G, HSPA2, 
BCL2, IL1R2, TGFBR2, 
TSC22D3, KAT2B, AKT3, 
NCOR2, ADRB2, UBE2I
IL8, STAT3, STAT1
VDR/RXR activation 4.2E-03 IGFBP5, NCOR2, CST6 DEFB4, SERPINB1, 
KLK6, HSD17B2
NF-κB signalling 2.3E-02 IL1R2, CSNK2A2, IL18, 
PIK3R1, PIK3C2G, AKT3, 
IL1F7
IL1F9
Induced by UV 
in normal skin
p53 signalling 2.1E-03 KAT2B, TP53INP1, PIK3R1, 
PIK3C2G, AKT3, CCND1, 
BCL2
SCO2
p38 MAPK signalling 3.5E-03 IL1R2, TGFBR2, IL18, H3F3B, 
IL1F7, EEF2K
IL1F9, STAT1
EGF signalling 5.4E-03 CSNK2A2, PIK3R1, PIK3C2G STAT3, STAT1
IGF-1 signalling 2.4E-02 CSNK2A2, PIK3R1, PIK3C2G, 
AKT3, IGFBP5, IGFBP7
Proposed as 
therapeutic 
target in 
psoriasis
LXR/RXR activation 2.5E-04 IL1R2, APOE, IL18, IL1F7, 
NCOR2
IL1F9, LDLR, CCL7
IL-10 signalling 4.2E-03 IL1R2, IL18, IL1F7 IL4R, IL1F9, STAT3
PPAR signalling 1.8E-02 IL1R2, IL18, IL1F7, NCOR2, 
PDGFC
IL1F9
IL-4 signalling 2.2E-02 PIK3R1, PIK3C2G, AKT3 IL4R, IL13RA1
Other GM-CSF signalling 1.5E-04 PIK3R1, PIK3C2G, AKT3, 
CCND1
CSF2RB, LYN, 
STAT3, STAT1
Acute phase response 
signalling
3.2E-04 PIK3R1, SOCS6, IL1F7, IL18, 
AKT3
C1S, SERPINA3, 
STAT3, C1R, IL1F9, 
SOD2, CRABP2, CFB
Interferon signalling 6.3E-04 IFIT1, OAS1, 
IFNGR1, MX1, 
STAT1
PDGF signalling 2.1E-03 CSNK2A2, PIK3R1, CAV1, 
PIK3C2G, PDGFC
STAT3, STAT1
JAK/Stat signalling 4.2E-03 PIK3R1, SOCS6, PIK3C2G, 
AKT3 
STAT3, STAT1
IL-6 signalling 7.2E-03 IL1R2, CSNK2A2, IL18, IL1F7 IL8, IL1F9, STAT3
Complement system 9.5E-03 CD59 C1R, C1S, CFB
LPS/IL-1 mediated 
inhibition of RXR 
function
1.9E-02 IL1R2, GSTA3, APOE, 
ALDH3A2, CAT, HS3ST6, 
ABCC4
ALDH1A3, PAPSS2, 
HS3ST3A1
VEGF signalling 1.9E-02 PIK3R1, PIK3C2G, AKT3, 
BCL2
HIF1A, ACTN1
Wnt/β-catenin 
signalling
2.2E-02 TGFBR2, CSNK2A2, FRZB, 
DKK3, SOX10, AKT3, CCND1
SOX9, FZD5
Xenobiotic 
metabolism signalling
3.2E-02 GSTA3, ALDH3A2, PIK3R1, 
MAF, CAT, PIK3C2G, 
HS3ST6, NCOR2 
ALDH1A3, UGT1A9, 
HS3ST3A1
Fc epsilon RI 
signalling
3.6E-02 FYN, VAV3, PIK3R1, 
PIK3C2G, AKT3
LYN
IL-2 signalling 4.3E-02 CSNK2A2, PIK3R1, PIK3C2G, 
AKT3
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The clinical starting NB-UVB dose has minor effects in lesional skin after 6 h, while in 
non-lesional skin marked gene expression changes are observed
To study the short-term effects of NB-UVB in psoriatic skin, gene expression in skin 
biopsies taken before and 6 h after the first irradiation was compared. In lesional skin only 
3 genes (CYP1B1, periostin and cryptochrome 1) were significantly (>2-fold) upregulated 6 h 
after the first irradiation. Of these genes, periostin and cryptochrome 1 were also upregulated 
in lesional skin after three months of treatment. Assessment of cryptochrome 1 expression by 
RT-PCR using individual RNA samples confirmed the microarray results (Figure 6A).
In contrast, in non-lesional skin, NB-UVB affected the expression of 272 genes more than 
2-fold, 6 h after the first irradiation, whereas none of these were affected in lesional skin. 
To investigate whether the limited response to NB-UVB in lesional epidermis was 
due to incomplete penetration of NB-UVB light into the thickened psoriatic epidermis, 
immunohistochemical staining for cyclobutane pyrimidine dimers (CPD) as marker of UV 
damage was performed on lesional and non-lesional skin samples taken before and 15 min 
after the first UV irradiation (70% MED). Robust CPD positivity was observed in almost all 
epidermal layers of the psoriatic plaque (Figure 6B, C). Thus, the relatively small number of 
genes affected by a single NB-UVB dose in lesional skin is not due to lack of penetration of 
NB-UVB in the lesional epidermis.
Figure 6. Immediate epidermal effects of NB-UVB. 
A. mRNA expression of cryptochrome 1 (CRY1) immediately before and 6 h after the first irradiation, relative to 
ABL1. Error bars indicate SEM, n=6 patients. B-C. Immunohistochemical staining for CPDs in lesional skin before 
(B) and 15 min after (C) irradiation with 70% MED. See page 155 for a full-color representation of this figure.
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DISCUSSION
Our results show that clinically effective NB-UVB therapy is associated with suppression 
of type I and type II interferon signalling and downregulation of the Th17 pathway in the 
lesional epidermis. 
IL-23 and the Th17 cytokines IL-17, IL-22 and IL-21 recently emerged as key cytokines in 
the pathogenesis of psoriasis (26). IL-23 is overproduced in psoriasis lesions by dendritic cells 
and keratinocytes, and this cytokine stimulates Th17 cells within the dermis to produce Th17 
cytokines (27-29). The prototypic Th17 cytokine IL-22 is a potent stimulator of keratinocyte 
proliferation and of the production of antimicrobial peptides, thereby representing a key 
effector in the pathogenesis of psoriasis (19, 30, 31). The Th17 pathway is also rapidly 
inhibited in psoriatic skin during treatment with Cyclosporine A and etanercept (TNF receptor – 
immunoglobulin fusion protein) (32). Cyclosporine A modulation is observed within 2 weeks 
after the start of the treatment and correlates well with the clinical improvement of the disease (9). 
The importance of the IL-17/IL-23 immunological pathway is further underlined by the 
facts that polymorphisms in genes encoding IL23R and IL12/IL23p40 are associated with 
susceptibility to psoriasis (33, 34), and that monoclonal antibodies against IL12/IL23p40 are 
highly effective in psoriasis (35). We have recently shown that psoriasis-like dermatitis in 
mice induced by the TLR7/TLR8 agonist imiquimod is critically dependent on the IL-23/
IL-17 axis (36). 
In our study, expression of Th17 pathway genes was suppressed in both lesional and 
non-lesional skin by NB-UVB therapy. Interestingly, Th17 autoinflammatory responses are 
inhibited by Vitamin D3 (37). Vitamin D3 is known to be induced by NB-UVB and we have 
found this signalling pathway to be affected by NB-UVB therapy. Inhibition of the Th17 
pathway was confirmed by demonstrating that in skin explants, NB-UVB inhibited the IL-
22-induced phosphorylation of STAT3 and the induction of β-defensin-2, already 6 h after 
irradiation. This clearly demonstrates a rapid effect of NB-UVB radiation on activation of 
the Th17 pathway. The exact mechanism of STAT3 inhibition by NB-UVB has yet to be 
determined. In primary human keratinocytes, inhibition of STAT3 activation by UVB was 
reversed by vanadate, a general inhibitor of tyrosine phosphatases, indicating the involvement 
of at least a tyrosine phosphatase in UVB-induced STAT3 inhibition (38). Interestingly, STAT3 
phosphorylation is inhibited by a reactive oxygen species (ROS)-inducer (manumycin) in 
cancer cells (39), indicating that induction of ROS might also be responsible for STAT3 
phosphorylation inhibition by NB-UVB.
Type I IFNs are produced mainly by plasmacytoid dendritic cells in autoimmune diseases 
such as systemic lupus erythematodes (40), and in response to viral infections as part of the 
innate immune response. Type I IFNs are critical in the pathogenesis of psoriasis (41-45). 
We previously showed that the type I IFN pathway is activated in psoriasis skin lesions (41). 
Furthermore, treatment of patients with pre-existing psoriasis or a familial predisposition 
for psoriasis with IFN-α can induce or exacerbate the disease (42-45). Blocking of IFN-α 
signalling in a xenograft murine model of psoriasis prevented the T cell-dependent development 
of psoriatic lesions in non-lesional skin transplanted onto immunocompromised mice (46). 
IFN-γ, a type II IFN, is mainly produced by activated Th1 cells present in psoriatic lesions 
and it has been shown to induce the regenerative psoriatic phenotype in healthy skin (47). 
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NB-UVB is known to deplete haemopoietic cells such as T lymphocytes and Langerhans 
cells from the skin (1, 48). Is conceivable that the observed inhibition of both type I and II 
IFN signalling pathways are due to depletion of lymphocytes and plasmacytoid dendritic cells 
from psoriasis lesions by NB-UVB.
Psoriatic lesions show distinctive signs of altered epidermal differentiation clinically and 
histologically (49). Importance of keratinocyte differentiation in the pathogenesis of psoriasis 
is highlighted by the fact that genetic alterations in the epidermal differentiation complex 
on chromosome 1q21 (50, 51) and around the corneodesmosin gene on chromosome 6p21 
(52) are closely associated with psoriasis. NB-UVB phototherapy modulated the expression 
of epidermal differentiation-associated genes in the psoriatic lesions towards the expression 
observed in normal skin.
A surprising finding in our study was that 6 h after the first UV-irradiation many more 
genes were differentially expressed in non-lesional skin than in lesional skin, with only 3 genes 
differentially expressed in lesional skin. This phenomenon has not been reported before since 
previous microarray studies on the genomic effects of NB-UVB in the skin used normal skin 
or cultured keratinocytes (53-56), or non-lesional skin from patients with psoriasis (10). We 
excluded the possibility of incomplete UV penetration in lesional skin by demonstrating that 
CPDs occur throughout the lesional epidermis already 15 min after a single UV irradiation.
The resistance of psoriasis lesions to UVB may be due to powerful inflammatory stimuli 
from the infiltrating immune cells, maintaining high transcription levels for many genes. 
Thus, a limitation of our in vivo kinetic study during total body NB-UVB therapy is that the 
results were obtained from psoriasis lesions exposed to 70% MED. Low starting doses during 
NB-UVB therapy are important to maintain the safety of the treatment, and the first irradiation 
(70% MED) is too low to have therapeutically relevant effects. Our results also imply that 
effects of UVB in non-inflamed skin cannot simply be extrapolated to inflamed skin. 
In this study we only used the epidermal compartment of the skin because most UVB 
radiation is absorbed there. Interactions between the epidermis and (products from) 
immunocytes in the dermis are essential for the chain of cellular and molecular events resulting 
in full blown psoriasis. 
In conclusion, our results show that clinically effective NB-UVB therapy is associated 
with downregulation of the critical Th17 and interferon signaling pathways and induction 
of ortho-differentiation in the skin. In addition several anti-inflammatory pathways, such 
as glucocorticoid, vitamin D, peroxisome proliferator-activated receptor and IL-4 signaling 
pathways are modulated by NB-UVB therapy. Our data underscore the importance of these 
pathways in the pathogenesis of psoriasis and identify them as targets of NB-UVB in the 
resolution of inflammation.
 
MATERIALS AND METHODS
Patients and treatments
Ten patients with psoriasis were recruited after informed consent (METC registration 
number 234.237/2003/210). Patients (nine men, one woman, age range 20-73) had Psoriasis 
Area and Severity Index (PASI) scores of at least 10 (Supplemental Table 4) and had not 
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received systemic therapy for at least one month or topical therapy for at least two weeks prior 
to the start of the study. Patients were treated with standard NB-UVB phototherapy until total 
clearance of psoriasis was reached, or for a maximum of three months. NB-UVB treatment 
was applied three times weekly using a Waldmann 7001 UVB cabinet equipped with Philips 
TL-01 bulbs. Starting UVB dose was 0.1-0.3 J/cm2 (depending on the skin type of the patient); 
the mean cumulative NB-UVB dose was 42.0 J/cm2 (range 30-60 J/cm2). During the course of 
UVB treatment PASI scores were evaluated every two weeks. 
Biopsy samples and RNA extraction
Three-mm biopsies were taken from psoriasis lesional and non-lesional skin before the 
start of NB-UVB therapy and after the last treatment session. To investigate the short-term 
effects of UVB radiation in psoriatic skin, biopsies were taken 6 h after the first irradiation. 
When PASI scores reached a reduction of 50% from the baseline score, additional biopsies 
from lesional and non-lesional skin were taken before and 6 h after UVB irradiation. 
For cyclobutane pyrimidine dimer (CPD) immunohistochemistry, three-mm skin biopsies 
were taken from lesional and non-lesional skin of three patients before and 15 min after the 
first treatment session of NB-UVB phototherapy. 
The epidermis was separated from the dermis after incubation in 1 mg/ml protease X 
(Sigma Aldrich, Zwijndrecht, the Netherlands) for 90 min at 37°C, and stored in RNA lysis 
buffer at –80°C until further processing. Total messenger RNA was isolated from the epidermis 
only, using GenElute Mammalian Total RNA Miniprep kit (Sigma Aldrich). RNA purity and 
integrity was verified by scanning with an Agilent 2100 Bioanalyzer using RNA 6000 Nano 
LabChip. 
Array hybridization and analysis
For hybridization on gene expression arrays, RNA samples of four individual patients 
per array (250 ng mRNA per patient) were pooled. Patients were divided into two groups 
in order to have duplicate arrays for each time point and condition (Supplemental Table 5). 
This pooling of RNA samples is a validated method in microarray studies (57, 58). The 
advantage of pooling RNA samples is that the results are less influenced by patient-specific 
variations in gene expression, and rather reflect the gene expression profile specific to the 
studied condition that is common between all patients i.e. the effect of NB-UVB. Biotinylated 
target RNA was prepared from the pooled (1 µg) total RNA, and hybridized on GeneChip 
Human Genome U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA). Array hybridization 
and scanning was performed as described previously (59). The data were read and robust 
multichip analysis (RMA) (60) was used to remove the background and normalize the data 
across arrays (61). These values were log2-transformed for further analysis, yielding numbers 
between 0 and 16. A two-way ANOVA with factors “probe” and “condition” was used for 
each probeset to calculate both average expression levels per condition (62) and a p-value for 
the difference between conditions. The resulting p-values were adjusted for multiple testing 
using Šidák step-up adjustment (63).Genes were considered differentially expressed when 
p-values were < 0.05 and the absolute fold change was greater than 2.
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Pathway analysis
The lists of genes differentially expressed in psoriasis lesions before and after 
NB-UVB therapy were subjected to Ingenuity Pathway Analysis (Ingenuity® Systems, 
www.ingenuity.com) to identify signaling pathways represented by these genes. In addition, 
functional annotation of these genes was performed using the Database for Annotation, 
Visualization, and Integrated Discovery (DAVID) (64).
Confirmation of gene expression patterns at the mRNA and protein levels
To confirm the gene expression patterns of selected genes as identified by gene expression 
microarray, RNA of individual patients was transcribed into cDNA, and RT-PCR was 
performed as described previously (65). ABL1 was used as a housekeeping control gene. 
Sequences of newly designed primers and probe numbers of the Exiqon probe library system 
(Exiqon, Vedbaek, Denmark) are listed in Table 3. 
To validate the microarray results at the protein level, immunostatinings were performed 
on biopsies from psoriasis lesions of patients. Immunostaining procedures with anti-MxA 
antibody (1:100; mouse monoclonal anti-Mx antibody, M143, Otto Haller, Freiburg, 
Germany) and anti-human keratinocyte transglutaminase (1:200; Biomedical Technologies 
Inc, Stoughton, MA) were applied as described previously (41). 
For immunofluorescent staining, cryosections were fixed for 10 min in 4% PFA in PBS. 
Before staining with anti-cyclobutane pyrimidine dimer (CPD) antibody, DNA was denatured 
using 0.07 M NaOH in 70 % ethanol, and slides were preincubated with 5% normal rabbit 
serum in PBS with 0.1% BSA. Primary antibodies used for immunofluorescent stainings 
included anti-CPD (1:4000; Kamiya Biomedical Company, Seattle, WA), anti-β-defensin 2 
(1:100; Santa Cruz Biotechnology, Santa Cruz, CA) and anti-phosphorylated STAT3 (1:50; 
Cell Signalling Technology Inc, Danvers, MA). Relevant Cy5- or TxR-conjugated antibodies 
(1:100, Abcam) were used to detect primary antibodies. All fluorescent images were made 
with an Axio Imager (Zeiss) fluorescence microscope.
Skin organ culture
Normal skin biopsies (3 mm diameter) were obtained from healthy volunteers undergoing 
breast reduction in the Department of Plastic Surgery of the Sint Franciscus Gasthuis, 
Rotterdam, the Netherlands, after informed consent. Biopsies were cultured as described 
previously (66). Recombinant human IL-22 (50 ng/ml) (R&D Systems, Abingdon, UK) was 
added to the culture medium and 16 h later biopsies were irradiated with NB-UVB using 
a small Waldmann irradiation device equipped with TL-01 UV 236-01 lamps (Waldmann 
Medizintechnik, Villingen-Schwenningen, Germany). In all experiments a single NB-UVB 
dose of 600 mJ/cm2 was used, representing a dose that is usually reached within 3 to 9 clinical 
UVB-therapy sessions (1-3 weeks of clinical treatment). The cultured biopsies were collected 
6 h after UV-irradiation. One of the 4 biopsies was snap-frozen, while the epidermis of the 
3 other biopsies was separated from the dermis and total messenger RNA was isolated as 
described above.
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Supplemental Figure 1. Top 5 GO annotation clusters as found by DAVID (Database for Annotation, 
Visualization, and Integrated Discovery) in the list of genes downregulated (a) or upregulated (b) in the lesional 
epidermis before vs. after NB-UVB therapy.
Each cluster contains multiple GO terms. Shown are the average fraction of genes assigned to the terms in the cluster 
and the geometric means of the original and Benjamini-Hochberg adjusted p-values of the terms in the cluster, 
respectively. The dashed line indicates the significance threshold (adjusted p-value = 0.05). See page 156 for a full-
color representation of this figure.
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Supplemental Table 1. Genes that are downregulated by NB-UVB phototherapy in lesional skin.
Name Symbol Fold change
Epidermal differentiation
serpin peptidase inhibitor, clade B (ovalbumin), member 4 SERPINB4 68.37
peptidase inhibitor 3, skin-derived (SKALP) PI3 23.60
keratin 16 (focal non-epidermolytic palmoplantar keratoderma) KRT16 12.94
keratin 6A / keratin 6C KRT6A /C 9.70
small proline-rich protein 2C SPRR2C 9.61
serpin peptidase inhibitor, clade B (ovalbumin), member 3 SERPINB3 7.50
gap junction protein, beta 2, 26kDa GJB2 6.66
keratin 17 KRT17 5.18
keratin 6B KRT6B 5.14
desmocollin 2 DSC2 3.46
Inflammation, IFN signaling
lactotransferrin / similar to lactotransferrin LTF 21.19
interleukin 1 family, member 9 IL1F9 5.08
interferon, alpha-inducible protein 6 IFI6 4.57
myxovirus resistance 1, interferon-inducible protein p78 (mouse) MX1 4.32
interferon-induced protein 44-like IFI44L 4.12
interferon-induced protein with tetratricopeptide repeats 3 IFIT3 3.38
interferon-induced protein 44 IFI44 3.32
interferon-induced protein with tetratricopeptide repeats 1 IFIT1 3.26
Antimicrobial
S100 calcium binding protein A7A S100A7A 36.50
defensin, beta 2 / defensin, beta 2 DEFB4 36.21
S100 calcium binding protein A12 S100A12 15.32
Proteases, protein modification
plasminogen activator, tissue PLAT 14.01
transmembrane protease, serine 11D TMPRSS11D 3.98
ISG15 ubiquitin-like modifier ISG15 3.77
kallikrein-related peptidase 6 KLK6 3.40
heparanase HPSE 3.21
Stress response
glutathione peroxidase 3 (plasma) GPX3 5.81
calcium regulated heat stable protein 1, 24kDa CARHSP1 3.62
superoxide dismutase 2, mitochondrial SOD2 3.35
Other
transcobalamin I (vitamin B12 binding protein, R binder family) TCN1 35.57
lipocalin 2 (oncogene 24p3) LCN2 11.60
aldo-keto reductase family 1, member B10 (aldose reductase) AKR1B10 8.54
Rh family, C glycoprotein RHCG 8.24
cytochrome P450 4Z2 pseudogene CYP4Z2P 5.75
hypothetical protein LOC129607 LOC129607 5.64
zinc finger CCCH-type containing 12A ZC3H12A 4.33
aldehyde dehydrogenase 1 family, member A3 ALDH1A3 4.15
cellular retinoic acid binding protein 2 CRABP2 3.77
nestin NES 3.60
hect domain and RLD 6 HERC6 3.55
fibroblast growth factor binding protein 1 FGFBP1 3.43
non-metastatic cells 7, protein expressed in NME7 3.34
ATPase, H+/K+ transporting, nongastric, alpha polypeptide ATP12A 3.27
hyaluronan synthase 3 HAS3 3.26
pancreatic lipase-related protein 3 PNLIPRP3 3.23
epithelial stromal interaction 1 (breast) EPSTI1 3.20
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Supplemental Table 2. Genes that are upregulated by NB-UVB phototherapy in lesional skin.
Name Symbol Fold change
Epidermal differentiation
serpin peptidase inhibitor, clade A, member 12 SERPINA12 6.75
keratin 77 KRT77 6.38
cystatin E/M CST6 4.24
keratin 15 KRT15 3.70
tubulin polymerization promoting protein TPPP 3.50
sciellin SCEL 3.39
laminin, beta 4 LAMB4 3.28
Cell adhesion
periostin, osteoblast specific factor POSTN 50.13
cell adhesion molecule with homology to L1CAM CHL1 3.69
Immune response
interleukin 1 family, member 7 (zeta) IL1F7 6.74
chemokine (C-C motif) ligand 27 CCL27 5.09
transforming growth factor, beta-induced, 68kDa TGFBI 3.91
wnt signaling
solute carrier family 1, member 6 SLC1A6 4.98
solute carrier family 46, member 2 SLC46A2 3.81
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog IL1F7 3.80
heat shock 70kDa protein 2 HSPA2 3.70
protocadherin 7 PCDH7 3.65
protocadherin 21 PCDH21 3.62
Notch signaling
ligand of numb-protein X 1 LNX1 4.47
mastermind-like 2 (Drosophila) MAML2 3.21
Transcription, translation
Inhibitor of DNA binding 4 ID4 8.27
eukaryotic elongation factor-2 kinase EEF2K 4.31
Apoptosis
calpain 3, (p94) CAPN3 3.34
Other
similar to AVLV472 MGC23985 9.46
microseminoprotein, beta- MSMB 8.68
chromosome 1 open reading frame 68 C1orf68 5.87
abhydrolase domain containing 12B ABHD12B 5.38
cysteine-rich protein 1 (intestinal) CRIP1 5.22
cytochrome b reductase 1 CYBRD1 5.10
betacellulin BTC 4.98
calcineurin B homologous protein 2 CHP2 4.84
syntaxin binding protein 6 (amisyn) STXBP6 4.77
asporin ASPN 4.50
proteolipid protein 1 PLP1 4.22
cytidine monophosphate-N-acetylneuraminic acid hydroxylase CMAH 4.15
integral membrane protein 2A ITM2A 4.07
insulin-like growth factor binding protein 5 IGFBP5 4.04
transmembrane protein 116 TMEM116 4.04
Hypothetical protein LOC283666 LOC283666 3.87
ribonuclease, RNase A family, 4 RNASE4 3.82
transmembrane protein 99 TMEM99 3.55
platelet derived growth factor C PDGFC 3.53
EGF-containing fibulin-like extracellular matrix protein 1 EFEMP1 3.43
protein tyrosine phosphatase, non-receptor type 21 PTPN21 3.43
heparan sulfate (glucosamine) 3-O-sulfotransferase 6 HS3ST6 3.41
carboxypeptidase E CPE 3.38
glycoprotein M6B GPM6B 3.29
dopachrome tautomerase (dopachrome delta-isomerase, tyrosine-related 
protein 2) DCT 3.27
retinoic acid induced 14 RAI14 3.27
development and differentiation enhancing factor 2 DDEF2 3.26
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Supplemental Table 3. Genes affected by NB-UVB therapy in non-lesional skin. 
Name Symbol Fold change Up/
Down
Change 
in lesional 
skin
S100 calcium binding protein A8 S100A8 24.8 Down Unchanged
S100 calcium binding protein A9 S100A9 18.1 Down 17.66 Down
S100 calcium binding protein A7 S100A7 17.6 Down Unchanged
small proline-rich protein 2B SPRR2B 10.9 Down Unchanged
keratin 6A, keratin 6C KRT6A, 
KRT6C
7.9 Down 9.7 Down
small proline-rich protein 2G SPRR2G 6.1 Down Unchanged
chitinase 3-like 2 CHI3L2 4.2 Down Unchanged
C-type lectin domain family 7, member A CLEC7A 3.0 Down Unchanged
chemokine (C-C motif) ligand 20 CCL20 2.5 Down Unchanged
S100 calcium binding protein P S100P 2.3 Down Unchanged
STEAP family member 4 STEAP4 2.1 Down 3.8 Down
actinin, alpha 1 ACTN1 2.1 Down 3.2 Down
chromosome 15 open reading frame 48 C15orf48 2.1 Down Unchanged
UDP glucuronosyltransferase 1 family, polypeptide 
A1-10 
UGT1A1-10 2.1 Down Unchanged
Ets homologous factor EHF 2.0 Down 2.0 Down
cyclin-dependent kinase inhibitor 3 (CDK2-
associated dual specificity phosphatase)
CDKN3 2.0 Down Unchanged
hypothetical protein LOC202134 LOC202134 2.0 Down Unchanged
betacellulin BTC 2.3      Up 5.0 Up
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Supplemental Table 4. Patient characteristics.
Patient nr. M/F Age PASI before PASI after ∆PASI (%)
1 M 55 13.8 1.6 88.4
2 M 33 23.2 8.4 63.8
3 M 51 10.3 0 100.0
4 M 26 10.0 0 100.0
5 M 63 10.4 1.6 84.6
6 M 52 11.4 1.5 86.8
7 M 65 13.2 5.4 59.1
8 M 74 14.3 1.0 93.0
9 M 39 10.6 0 100.0
10 F 21 10.0 4.2 58.0
Supplemental Table 5. Pooling of RNA samples. 
Condition Time point Pool A (patient numbers1) Pool B (patient numbers1)
Lesional samples Before therapy 1+2+3+4 5+6+7+8
6 h after first irradiation 1+2+3+4 5+6+7+8
After therapy 1+2+3+4 5+6+8+9
Non-lesional samples Before therapy 1+2+3+4 5+6+7+10
6 h after first irradiation 1+2+3+4 5+6+7+10
After therapy 5+6+7+10
1 Each number corresponds to one patient number as shown in Supplementary Table I.
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ABSTRACT
The mode of action of narrow-band UVB (NB-UVB) therapy in clearing 
psoriasis is incompletely understood and has been investigated only to a 
limited extent at the molecular level in patients. We previously demonstrated 
increased expression of double-stranded RNA (dsRNA) receptors in psoriasis 
lesions, resulting in enhanced sensitivity to innate triggering, thereby putatively 
contributing to the maintenance of psoriatic inflammation. 
We hypothesized that suppression of dsRNA receptor expression by NB-
UBV might add to the efficacy of this therapy. Analysis of epidermal samples of 
patients with psoriasis undergoing NB-UVB treatment demonstrated significant 
downregulation of mRNA expression of the major RIG-I-like helicase (RLH) 
family members MDA-5 and RIG-I during NB-UVB treatment, whereas the 
negative regulator LGP2 and the other activating receptors TLR3 and PKR 
were not affected. In vitro stimulation of primary human keratinocytes with 
IFN-α or IFN-γ, critical cytokines in psoriasis, resulted in upregulation of all 
activating dsRNA receptors. This induction was completely blocked by NB-
UVB irradiation, resulting in an attenuated inflammatory cytokine response to 
dsRNA (expression of IFN-β, RANTES/CCL5 and IL-6).
Thus, NB-UVB irradiation cripples the local innate inflammatory response 
induced by dsRNA. These findings suggest a new mechanism contributing to 
the clinical efficacy of NB-UVB phototherapy in psoriasis. 
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INTRODUCTION
Psoriasis, a chronic inflammatory skin disease, is nowadays considered as a genetically 
determined dysregulation of innate and adaptive immunity (1). A dysregulation of the innate 
detection and response system can lead to both the epidermal phenotype and the abnormal 
T cell function that characterize the disease (2). Examples of abnormalities in the innate 
response system in psoriasis are the increased expression of antimicrobial peptides, such as 
β-defensins and LL-37 (3) and activation of the type I interferon (IFN) system (4, 5).
We have previously shown that the cytoplasmic receptors for double-stranded RNA 
(dsRNA) retinoic acid-inducible gene-I (RIG-I), melanoma differentiation associated gene 5 
(MDA-5) and double-stranded RNA-dependent protein kinase (PKR) are upregulated in the 
epidermis of patients with psoriasis (6). These pattern recognition receptors (PRRs), together 
with Toll-like receptors (TLRs), are part of the innate detection system. Activation of these 
receptors induces the initial anti-microbial responses by upregulating antimicrobial peptides, 
inflammation and chemotaxis of leukocytes. 
DsRNA, a virus-derived molecular pattern can be recognized by the intravesicular 
transmembrane receptor TLR3, as well as by four different intracytoplasmic receptors. RIG-I 
and MDA-5 are part of the RIG-I-like helicase (RLH) family together with laboratory of 
genetics and physiology-2 (LGP2) (7). LGP2 has been suggested to function as a negative 
regulator of RIG-I/MDA-5 signaling (8). Activation of PKR, also an intracellular detector of 
viral dsRNA, leads to the inhibition of translation of the host cell, which represents a unique 
contribution to anti-viral immunity (9). 
Not only microbial components but also endogenous molecules have been shown to 
activate TLRs and other PRRs. Therefore innate antigen receptors have been implicated in the 
pathogenesis of different autoimmune diseases: in systemic lupus erythematosus, activation of 
TLR7 and TLR9 by nucleic acids from dead or dying cells is implicated, while in rheumatoid 
arthritis TLR3 is activated by RNA from necrotic cells (10, 11). Recently it was shown that in 
psoriasis, activation of TLR9 in plasmacytoid dendritic cells (pDC) by self-DNA complexed 
with the antimicrobial peptide LL37 plays a pathogenic role, by strongly inducing IFN-α 
production (12). Endogenous ligands have been described for TLR3 and RIG-I. RNA from 
necrotic cells worsens septic peritonitis and ischemic gut injury in mice, mediated via TLR3 (13). 
In addition, uptake of apoptotic material containing RNA with 5’-triphosphate groups by 
dendritic cells or macrophages leads to the engagement of RIG-I (14). 
In vitro IFN-α-treatment of primary human epidermal keratinocytes induced the 
expression of TLR3, RIG-I, MDA-5 and PKR, resulting in an increased proinflammatory 
response to dsRNA (6). Elevated IFN-α-levels in psoriasis skin might partly be responsible 
for the higher expression of dsRNA-receptors, which in turn might increase the sensitivity 
of psoriatic epidermal cells to innate triggering, thereby contributing to the vicious cycle 
of chronic inflammation. Therefore, functional blockade or downregulation of the dsRNA 
receptors would be a potential therapeutic option in psoriatic skin inflammation.
Narrow-band UVB (NB-UVB) therapy is a standard treatment for moderate to severe 
psoriasis. It is safe in terms of minimal carcinogenicity, and has high efficacy scores in a 
large proportion of patients (15-19). The mode of action of NB-UVB treatment in psoriasis 
is incompletely understood and much of current thinking is based on in vitro studies and 
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studies in mice. In general, the efficacy of NB-UVB is thought to be mediated via inhibition 
of keratinocyte proliferation, induction of apoptosis in intraepidermal bone marrow-derived 
cells (dendritic cells, (natural killer) T cells, pDCs), skewing of T cell differentiation from 
Th1 and Th17 towards the Th2 phenotype. However, it has become clear that the skin immune 
system of the mouse and the mouse genome differ more from man than previously anticipated, 
underscoring the need for studies in patients with active disease. Molecular analysis of the 
impact of NB-UVB on innate inflammatory pathways may generate more insight into the mode 
of action of NB-UVB in the pathophysiology of psoriasis and to define potential therapeutic 
target molecules.
Based on our observations on dsRNA receptor expression in psoriasis, we investigated 
whether NB-UVB treatment affects the expression and function of these molecules in 
psoriatic skin. To address this question, a dual clinical and in vitro approach was followed. 
Collectively, our data show strong inhibition of the expression and function of innate antigen 
receptors for dsRNA, both in vivo in patients with psoriasis undergoing NB-UVB therapy, as 
well as in vitro in irradiated keratinocytes. 
RESULTS
Inhibition of RIG-I and MDA-5 gene expression in patients undergoing NB-UVB 
therapy
Affymetrix gene expression arrays were used to detect differences in epidermal mRNA 
expression in patients with plaque-type psoriasis undergoing conventional NB-UVB therapy. 
The PASI scores showed an improvement from a mean of 13.3 (range 10.0 - 23.2) to a mean 
of 2.4 (range 0 and 8.4) after 12 weeks; thus, the mean PASI reduction was 84.5%. For the 
microarray analysis, patient samples were pooled in 2 groups, as described in the Materials and 
methods section and shown in Table 1. The mean PASI reduction did not differ significantly 
between these two groups. 
All five dsRNA receptors were detected on the gene expression arrays. In lesional skin, 
expression levels of RIG-I and MDA-5 were significantly reduced following NB-UVB 
treatment, with a reduction of 1.9-fold and 1.8-fold respectively (Figure 1). Expression of 
PKR was also decreased, but this change did not reach significance, whereas TLR3 and LGP2 
Table 1. Patient characteristics.
Patient nr. M/F Age PASI before PASI after ∆PASI (%) Pool nr.
1 M 55 13.8 1.6 88.4 1
2 M 33 23.2 8.4 63.8 1
3 M 51 10.3 0 100.0 1
4 M 26 10.0 0 100.0 1
5 M 63 10.4 1.6 84.6 2
6 M 52 11.4 1.5 86.8 2
7 M 65 13.2 5.4 59.1 2
8 M 74 14.3 1.0 93.0 2
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expression remained unchanged. In non-lesional skin, expression of none of these receptors 
changed significantly after NB-UVB therapy (Figure 1).
Microarray results were validated using quantitative RT-PCR on RNA samples from 
5 individual patients, including skin samples taken at a PASI reduction of 50%. ABL1 was 
used as an internal control housekeeping gene. Here, too, on average about two-fold reduction 
of MDA-5 and RIG-I expression was observed at the end of the treatment (Figure 2). 
The mean expression of MDA-5 was significantly reduced when PASI scores were at 50% of 
the baseline score (Figure 2). 
NB-UVB suppresses type I and type II IFN-induced expression of dsRNA receptors in 
primary keratinocytes
To investigate whether the in vivo observed downregulation of dsRNA receptors was 
a direct effect of NB-UVB, or only correlated with the clinical improvement of psoriasis, 
experiments were conducted using primary human keratinocytes, the primary source of 
epidermal dsRNA receptor expression (6). In order to mimic the in vivo situation in psoriasis, 
IFN-α and IFN-γ activated primary human keratinocytes were irradiated with a single dose 
of NB-UVB. IFN-α and IFN-γ are known to induce the expression of all four activating 
dsRNA receptors (6). Cells were harvested after 0, 2, 4, 8 and 24 h, and mRNA expression 
of dsRNA receptors was measured by RT-PCR. As expected, IFN-α and IFN-γ induced the 
expression of MDA-5 (maximal induction approximately 14-fold and 10-fold, respectively 
with IFN-α and IFN-γ), RIG-I (13-fold and 12-fold), TLR3 (9-fold and 5-fold), and PKR 
(4-fold and 2-fold). NB-UVB irradiation resulted in a rapid and almost complete inhibition of 
all dsRNA receptors during the first 8 h of culture. This inhibition was lost after 24 h of culture 
(Figure 3 and Figure 4). Expression of the negative regulator LGP2 was induced 5-fold by 
IFN-α and 2-fold by IFN-γ in keratinocytes. The induction of LGP2 mRNA was not affected by 
NB-UVB irradiation (Figure 3 and Figure 4). 
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Figure 1. NB-UVB inhibits mRNA expression of dsRNA receptors in psoriatic lesional epidermis. 
Lesional and non-lesional skin biopsy samples of 8 patients with psoriasis were collected before and after conventional 
NB-UVB treatment. Epidermal RNA of 4 patients was pooled for each gene expression array in order to have duplicate 
arrays for each time point, as described in the Materials and methods section. Probe sets for dsRNA receptor genes 
were selected from the array results. Bars show the mRNA expression levels of two pools (mean +/- SD). p-values 
calculated by a two-way ANOVA are indicated in the figure if < 0.05.
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NB-UVB inhibits keratinocyte activation by the dsRNA analog poly I:C
We next assessed whether the decreased expression of dsRNA receptors in irradiated 
keratinocytes would affect the functional responsiveness to dsRNA. Upon stimulation with 
polyriboinosinic-polyribocytidylic acid (poly I:C) normal keratinocytes produce a broad array 
of pro-inflammatory cytokines and chemokines, as well as adhesion molecules (20), and this 
response is boosted by pre-incubating the cells with IFN-α (6). Activation of all cytoplasmic 
dsRNA receptors in keratinocytes by poly I:C was clearly demonstrated previously (21). 
A few marker molecules of this poly I:C-induced inflammatory response in keratinocytes are 
IL-6, CCL5/RANTES, and IFN-β. All these markers are expressed at high levels in inflamed 
skin lesions of psoriasis patients. Keratinocytes were irradiated with a single dose of NB-
UVB, incubated with IFN-α or IFN-γ for 6 h and stimulated with 1 µg/ml poly I:C. Both 
type I and II IFN pre-incubation greatly enhanced the poly I:C-induced expression of IFN-β, 
RANTES and IL-6. NB-UVB-irradiation of keratinocytes resulted in a strong inhibition of the 
response to poly I:C (Figure 5 a-c). 
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Figure 2. Confirmation of the downregulation of dsRNA receptors after NB-UVB therapy using quantitative 
RT-PCR. 
Lesional skin biopsy samples of 4 patients with psoriasis were collected before and after NB-UVB treatment, and 
during treatment when PASI scores reached 50% of the baseline scores. Epidermal mRNA levels of dsRNA receptor 
genes were determined by RT-PCR, and calculated relative to ABL1 mRNA levels. Values for individual patients are 
depicted. Horizontal lines show the mean and the standard error of the mean.
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Figure 3. NB-UVB inhibits IFN-α-induced expression of dsRNA-receptors in keratinocytes. 
Primary human keratinocytes were irradiated with 600 mJ/cm2 NB-UVB, or were sham-irradiated. Immediately 
hereafter IFN-α (500 U/ml) was added to the cell culture. Cells were harvested at the time points indicated and mRNA 
expression of dsRNA receptors was quantified using RT-PCR, and calculated relative to GAPDH levels. Data are 
representative of two independent experiments with primary keratinocytes from two different donors.
100
MDA5
80
40
60
120
140
M
DA
5/
G
AP
DH
20
0
0 2 4 6 8 24
300
RIG-I
200
400
100
R
IG
-I/
G
AP
DH
0
0 2 4 6 8 24
PKR
0.4
0.2
0.3
0.5
PK
R
/G
AP
DH
0.1
0
0 2 4
time (h)6 8 24
TLR3
40
20TL
R
3/
G
AP
DH
0
100
80
60
120
0 2 4
time (h)6 8 24
LGP2
20
10
15
LG
P2
/G
AP
DH
5
0
0 2 4
time (h)6 8 24
no UV
UV
Figure 4. NB-UVB inhibits IFN-γ-induced expression of dsRNA-receptors in keratinocytes. 
Primary human keratinocytes were irradiated with 600 mJ/cm2 NB-UVB, or were sham-irradiated. Immediately 
hereafter IFN-γ (500 U/ml) was added to the cell culture. Cells were harvested at the time points indicated and mRNA 
expression of dsRNA receptors was quantified using RT-PCR, and calculated relative to GAPDH levels. Data are 
shown from two independent experiments with keratinocytes from two different donors.
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DISCUSSION
This study shows that in vivo NB-UVB treatment inhibits the expression of RIG-I 
and MDA-5 in lesional epidermis of patients with psoriasis and of all dsRNA receptors in 
keratinocytes in vitro. We have previously shown that these receptors are highly expressed 
by keratinocytes in lesional psoriatic epidermis (6). Expression of PKR and LGP2 was 
not suppressed in the patients by NB-UVB therapy. PKR is involved in the control of cell 
proliferation, differentiation and apoptosis upon virus infection (22). The persistence of PKR 
and of the negative regulator LGP2 after NB-UVB therapy suggests that immune modulation 
by UVB occurs in a selective mode, which may explain some of its reported safety.
The in vitro suppression of the proinflammatory poly I:C-response in keratinocytes by 
NB-UVB can be explained by the rapid inhibition of all activating dsRNA receptors while the 
expression of the negative regulator LGP2 remained unaffected. This may happen by direct 
short-term effect of UVB on the receptors or their signaling pathways, or by known UVB-
activated cellular processes such as DNA damage and repair, formation of reactive oxygen 
species or cis-urocanic acid. In addition, UVB radiation might interfere with the downstream 
signaling after dsRNA binding, since both UVB (23) and the dsRNA receptors TLR3 and 
PKR (21) act partly via activation of NF-κB. 
The upregulation of LGP2 by both type I and type II IFNs was not inhibited by NB-UVB. 
This effect of NB-UVB on the IFN-induced expression of LGP2 also strongly suggests that the 
inhibitory effect on other receptors is not a consequence of a general toxic effect of  UV-radiation.
In both the in vivo and the in vitro parts of our study narrow-band UVB lamps were used. 
It is known that at least 5 to 10-fold higher doses of NB-UVB are needed for the induction of 
erythema than with broad-band (BB-) UVB (24-28). NB-UVB doses required for the induction 
Figure 5. NB-UVB limits poly I:C-activation of keratinocytes pretreated with type I and type II IFNs. 
Primary human keratinocytes were irradiated with 600 mJ/cm2 NB-UVB, or sham-irradiated. Immediately hereafter 
500 U/ml IFN-α or IFN-γ was added to the cells. After incubation for 6 h these stimuli were removed and poly 
I:C (1 µg/ml) was added to the cells for 3 h. mRNA expression of RANTES/CCL5 and IFN-β was determined by 
quantitative RT-PCR, and calculated relative to GAPDH levels (a-b). IL-6 levels in the supernatants were measured 
using ELISA (c). Results of a representative experiment are shown.
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of hyperplasia, edema, sunburn cell response and Langerhans cell depletion are 5-7 times 
higher than equally effective BB-UVB doses (29). In in vitro assays, Aufiero et al studied the 
response of keratinocytes to increasing doses of NB-UVB, and found that a dose as high as 
1000 mJ/cm2 was necessary to induce apoptosis in keratinocytes, whereas in T lymphocytes a 
dose of 750 mJ/cm2 (but not one of 500 mJ/cm2) already induced apoptosis (30).
The efficacy of NB-UVB treatment has largely been attributed to its apoptotic effect on 
inflammatory epidermal T cells, and by its ability to reduce IFN-γ-dependent Th1 differentiation 
of T cells and promote Th2 differentiation (31-34). These effects on T lymphocyte skewing 
are considered a central or systemic effect of UVB (35).
The rapid suppression of dsRNA receptors by NB-UVB as demonstrated in primary 
keratinocytes, is highly suggestive for a direct effect of NB-UVB on specific dsRNA receptors. 
NB-UVB irradiation interfered with the interaction of poly I:C with these molecules, preventing 
the activation of keratinocytes as measured by IFN-β and RANTES mRNA, and IL-6 protein 
expression. These results suggest that in addition to an effect on adaptive immunity, NB-UVB 
also has a direct short-term effect on innate immunity in psoriasis. 
Decrease of dsRNA receptor expression observed in the patients might be due not only to 
direct downregulation in keratinocytes. Induction of apoptosis by NB-UVB in keratinocytes 
and other cells together with the depletion of Langerhans cells or pDC, may also play a role 
(36). Human epidermal Langerhans cells are known to express functional TLR3 (37, 38). 
MDA5, RIG-I and PKR can be expressed by neutrophils (39), a cell type predominantly 
present in Munro microabscesses in psoriatic epidermis, structures that are cleared during NB-
UVB treatment. Thus, expression of dsRNA receptors by neutrophils and/or Langerhans cells 
might contribute to the expression levels of these receptors measured in psoriatic epidermal 
RNA samples. The presence of cell types other than keratinocytes in the plaques might also 
explain the discrepancies between our in vivo and in vitro results, i.e. that whereas in primary 
human keratinocytes, the IFN-induced expression of all four activating dsRNA-receptors was 
inhibited by UV irradiation, by microarray analysis of epidermal samples only the expression 
of MDA-5 and RIG-I was significantly reduced. Interestingly, of four dsRNA receptors tested, 
these two were found to be most differentially expressed in lesional psoriatic epidermis when 
compared to healthy and non-lesional skin (6). 
The ability of UVB to inhibit IFN-γ-induced processes in keratinocytes has previously 
been demonstrated (40, 41). Our results show that UVB also suppresses the response to IFN-α 
in keratinocytes. A key mechanism involved may be inhibition of the phosphorylation of 
STAT1, a signal transduction molecule shared by type I and type II interferons. In mouse 
keratinocytes, broad-band UVB light has been shown to interfere with the phosphorylation of 
STAT1, partly by activation of a tyrosine phosphatase (40). Furthermore, interferon-dependent 
dsRNA responses have previously been shown to depend on STAT1 in human fibrosarcoma-
derived cell lines (42). 
In keratinocytes, functionality of all dsRNA receptors have been demonstrated (21). 
It will be worthwhile to investigate whether downregulation of one specific dsRNA receptor 
(e.g. via silencing with siRNA) would also be sufficient to improve the psoriatic skin pathology. 
According to our data, MDA-5 and RIG-I pathways are possible candidates to target in order 
to reduce inflammation in psoriasis, since their expression was also downregulated in in vivo 
irradiated psoriatic skin. 
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In conclusion, here we show that NB-UVB-induced improvement of skin inflammation 
in psoriasis is accompanied by a reduction in the mRNA expression of the innate cytosolic 
dsRNA receptors MDA-5 and RIG-I, but not PKR. In cultured primary keratinocytes, NB-UVB 
irradiation strongly inhibited the type I and type II IFN-induced expression of all activating 
dsRNA-receptors but not that of the negative regulator LGP2. This rapid suppression of 
dsRNA receptors and interference with poly I:C interaction with these molecules by NB-
UVB in primary keratinocytes is suggestive for a direct short-term effect on innate immunity 
in psoriasis. NB-UVB irradiation hereby breaks a positive feedback loop of epidermal 
inflammation in psoriasis. These results reveal a novel mechanism of action contributing to 
the efficacy of NB-UVB phototherapy in psoriasis.
MATERIALS AND METHODS
Patients and treatment
Eight patients with plaque type psoriasis were recruited after informed consent and prior 
approval by the Medical Ethical Committee of the Erasmus MC, University Medical Center 
(METC 234.237/2003/210). Patients (eight men, age range 26-74) with Psoriasis Activity 
and Severity Index (PASI) scores of at least 10, did not receive systemic therapy for at least 
one month or topical therapy (except for emollients) for at least two weeks prior to this study. 
Patient characteristics are depicted in Table 1. The patients were treated with standard NB-
UVB phototherapy three times weekly (increasing doses of NB-UVB) using a Waldmann 
7001 UVB cabinet equipped with Philips TL-01 bulbs, until total clearance of psoriasis or 
for a maximum of three months. Starting UVB dose was 0.1-0.3 J/cm2; the mean cumulative 
UVB dose was 45.9 (range 30-60) J/cm2. The initial NB-UVB dose was 70% of the minimal 
erythema dose (MED). PASI scores were evaluated every two weeks.
Biopsy samples, RNA extraction, array hybridization, scanning and analysis
Biopsy samples of 3 mm in diameter were taken from lesional and non-lesional skin before 
the start of NB-UVB treatment and at the end of therapy. Additional biopsies were collected 
when PASI scores reached 50% of the baseline score. The epidermis was separated from the 
dermis after incubation in 0.5 mg/ml Thermolysin (Sigma, St Louis, MO) supplemented with 
5 µg/ml Actinomycin D (Sigma) for 90 min at 37°C, and stored in RNA lysis buffer at -80°C 
until further processing. Total messenger RNA was isolated using GenElute Mammalian Total 
RNA Miniprep kit (Sigma). RNA purity and integrity was determined by scanning with an 
Agilent 2100 Bioanalyzer using RNA 6000 Nano LabChip. 
For the microarray analysis, patients were divided into 2 groups, and RNA samples from 
4 patients (250 ng mRNA per patient) were pooled, biotinylated and hybridized to each 
GeneChip Human Genome U133 Plus 2.0 array (Affymetrix, Santa Clara, CA). Two pools 
were formed from the samples taken before therapy (patients 1-4 and 5-8), as well as two 
pools from samples of the same patient groups, taken after therapy. This pooling of RNA 
samples is an accepted and validated method in microarray studies (43, 44). The advantage 
of pooling RNA samples is that the results are less influenced by patient-specific alterations 
in gene expression, and rather reflect the gene expression profile specific to the condition of 
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interest, i.e. the effect of NB-UVB in all patients. The influence of patient-specific alterations 
in gene expression was further reduced by analysis of two independent pools of RNA samples 
(biological duplicates) for each of the two conditions, “before therapy” and “after therapy”.
Array hybridization and scanning was performed as described previously (45). The data 
were read and robust multichip analysis (RMA) (46) was used to remove the background and 
normalize the data across arrays (47). These values were log2-transformed for further analysis, 
yielding numbers between 0 and 16. A two-way ANOVA with factors “probe” and “condition” 
was used for each probeset to calculate both average expression levels per condition (48) 
and a p -value for the difference between conditions. The resulting p-values were adjusted 
for multiple testing using Šidák step-up adjustment (49). For this study we looked at the 
expression levels of probesets for dsRNA receptors.
  
Quantitative RT-PCR
RNA was transcribed into cDNA, and RT-PCR was performed as described previously (50). 
Primer and FAM-labeled probe sequences for TLR3, RIG-I, MDA-5 and PKR have been 
described by Prens et al. (6). Other primer and probe sequences are listed in Table 2. 
In the microarray results a marked effect of in vivo NB-UVB treatment was observed on 
the expression levels of the housekeeping gene GAPDH. For this reason another widely used 
and accepted internal control gene, ABL1 was chosen for the validation of the results with 
RT-PCR. The expression of this gene remained stable throughout all samples.
Culture, stimulation and NB-UVB irradiation of primary keratinocytes
Primary human keratinocytes (Promocell GmbH, Heidelberg, Germany) were cultured 
in Keratinocyte Growth Medium 2 with SupplementMix (Promocell). Cells were used in 
passage 2 to 7. 
Keratinocytes were stimulated with 500 U/ml clinical grade IFN-α (IntronA IFN-α2b, 
Schering-Plough, Kenilworth, NJ), 500 U/ml clinical grade IFN-γ (Boehringer Ingelheim, 
Heidelberg, Germany), with or without the subsequent addition of 1 µg/ml poly I:C (Amersham 
Biosciences, Piscataway, NJ) as functional mimic of dsRNA.
Table 2. Sequences of primers and probes for real-time PCR.
Gene Forward primer Reverse primer Probe
LGP2 GCCTTGCAAACAGTACAACCT TCTTCAGCAAGTCCCCAAA Nr. 71 1
RANTES TGCATCTGCCTCCCCATATT AGTGGGCGGGCAATGTAG TCGGACACCACACCCTGCTGCT
IFN-β GATTCCTACAAAGAAGCAGCAAT CATCCTGTCCTTGAGGCAGTATT AGCCTCCCATTCAATTGCCACAGGA
ABL1 TGGAGATAACACTCTAAGCATAACTAAAGGT GATGTAGTTGCTTGGGACCCA
CCATTTTTGGTTTG
GGCTTCACACCATT
GAPDH TCCACTGGCGTCTTCAC GGCAGAGATGATGACCCTTTT Nr. 45 1
1 Probe from the Exiqon probe library system (Exiqon, Vedbaek, Denmark).
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Primary cell cultures were irradiated using a Waldmann irradiation device equipped with 
TL-01 UV 236-01 lamps (Waldmann Medizintechnik, Villingen-Schwenningen, Germany), 
with main emission between 310-315 nm (peak: 311 nm). In all experiments, a single UV-dose 
of 600 mJ/cm2 was used, after rinsing the cells thoroughly with PBS, leaving the cells covered 
with a thin layer of PBS to protect them from drying out. This UV dose is not apoptotic in 
human keratinocytes (51), and is higher than the starting dose of clinical NB-UVB treatment, 
during which this dose is usually reached within 1-3 weeks. Viability of keratinocytes after 
increasing doses of NB-UVB was measured by methylene blue staining (Supplemental 
Figure 1). In brief, 24 h after irradiation cell were fixed by 30 min incubation (room 
temperature) with 20% formaldehyde in 0.09% NaCl. After removal of the fixative, cells 
were incubated with 1% methylene blue (Boom BV, Meppel, the Netherlands) in 0.01 M 
H3BO3. After washing away this solution, the blue stain was extracted from the cells using a 
1:1 mixture of ice cold ethanol and 0.1 M HCl, the extract was transferred to a 96-wells plate 
and the amount of blue stain was assessed by measuring the absorbance at 650 nm using a 
Multiskan RC microplate reader (Thermo Labsystems, Finland).
At the time points indicated, total messenger RNA was extracted from the cells using 
GenElute Mammalian Total RNA Miniprep kit (Sigma). Levels of IL-6 as a prototypic 
inflammatory cytokine in the culture supernatants were determined with commercial capture 
ELISA as recommended by the manufacturer and as described elsewhere (6).
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Supplemental Figure 1. The human keratinocyte cell line HaCaT was irradiated with the indicated doses of NB-
UVB. 24 h after irradiation the viability of the cells was determined by methylene blue staining. The intensity of 
blue coloring correlates with the number of viable cells. Bars represent staining intensity. Error bars show standard 
deviation of duplicate measurements.
4
GATA3 expression is reduced in psoriasis and under conditions of 
epidermal regeneration, and is induced by narrow-band UVB
Emőke Rácz1,2, Dorota Kurek3, Marius Kant1,2, Ewout M. Baerveldt1,2,  
Edwin Florencia1,2, Sabine Mourits1,2, Dick de Ridder 4, Jon D. Laman2, 
Leslie van der Fits1,2 and Errol P. Prens1,2
1 Dept. of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands
2 Dept. of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands 
3 Dept. of Cell Biology, Erasmus University Medical Center, Rotterdam, The Netherlands
4 Information & Communication Theory Group, Faculty of Electrical Engineering, 
Mathematics and Computer Science, Delft University of Technology, Delft, The 
Netherlands
Submitted for publication
Chapter 4
86
ABSTRACT
Psoriasis is characterized by hyperproliferation of keratinocytes and by 
infiltration of Th1 and Th17 cells in the (epi)dermis. The GATA3 transcription 
factor fulfils important roles in both epidermal and T helper cell differentiation. 
Hence, we investigated the role of GATA3 in psoriatic skin inflammation. Since 
the tissue response in psoriasis is similar to that of epidermal regeneration, we 
also studied GATA3 expression under such conditions.
Psoriatic lesional skin showed decreased GATA3 expression compared to 
non-lesional skin. GATA3 expression was markedly decreased in inflamed 
skin in the imiquimod-induced psoriasis-like dermatitis mouse model. 
Tape-stripping of non-lesional skin of patients with psoriasis, a standardized 
psoriasis-inducing technique resulted in reduced GATA3 expression. 
Moreover, low GATA3 mRNA and protein expression was detected in skin 
wounds in mice. Thus, GATA3 expression is downregulated under regenerative 
and inflammatory skin conditions. GATA3 expression could be re-induced 
by successful narrow-band UVB treatment of both human psoriasis and 
imiquimod-induced dermatitis in mice. 
Based on these findings we postulate that decreased GATA3 expression 
is causatively related to keratinocyte hyperproliferation and skin barrier 
dysfunction in psoriasis. Further investigations are necessary into the 
downstream targets of GATA3 and its mode of action in regulating keratinocyte 
proliferation.
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INTRODUCTION
Psoriasis is a chronic inflammatory skin disease characterized by sharply demarcated, red, 
thick, scaly plaques. Histologically it is characterized by epidermal acanthosis, papillomatosis 
and parakeratosis, infiltrating leukocytes and in the papillary dermis a dense mononuclear 
infiltrate and dilated capillaries.
In psoriasis, altered keratinocyte differentiation is characterized by downregulation of late 
keratinocyte differentiation markers and upregulation of early differentiation markers (1), 
while the pool of proliferating keratinocytes is increased. These alterations in keratinocyte 
proliferation and differentiation lead to impairment of the skin barrier function, and this 
barrier impairment correlates with the severity of the disease (2). 
The factors controlling keratinocyte hyperproliferation and the disturbed keratinocyte 
differentiation in psoriasis remain poorly understood. Hyperproliferation in psoriasis and 
proliferation in cancers share many characteristics, such as the induction of the same oncogenes 
and transcription factors (3). In a previous study (Racz et al. submitted) we took advantage of 
one of the few effective treatments for psoriasis, narrow-band (NB)-UVB therapy, to assess 
by gene expression microarray which biological pathways are altered. One of the main factors 
emerging from this gene expression analysis was the transcription factor GATA3. 
GATA3 is a transcription factor with two zinc finger motifs that binds to a six-nucleotide 
consensus sequence (A/T)GATA(A/G) (4). In the skin, GATA3 is expressed in the epidermis 
and in the inner root sheath of the hair follicle (5) where it serves as a regulator of inner 
root cell lineage formation of the hair follicle, postnatal hair growth and maintenance (6). 
In addition, GATA3 is required for correct formation of the epidermal barrier and has a role 
in regulation of epidermal differentiation (7, 8). Antimicrobial peptides, such as β-defensins 
and S100A proteins, are upregulated in the skin of epidermis-specific GATA3 -/- mice (8). 
Recently GATA3 was proposed to regulate desquamation during epidermal differentiation, 
by activating kallikrein 1, a serine protease that is responsible for the degradation of adhesion 
molecules in corneodesmosomes (9). In addition, GATA3 is abundantly expressed in the 
developing nervous system, inner ear, the eye, skin, mammary glands, embryonic kidney and 
thymic rudiment (6, 7, 10-12). In the hematopoietic system GATA3 expression is confined to 
the T, NK and NKT cell lineages (13).
During lymphoid cell development, GATA3 is involved in decisive T cell commitment (14). 
Functional T helper cell subset differentiation to Th2 is induced by GATA3 via a Stat6-
dependent route (15-18). Polymorphisms in the Th2 cytokine genes IL-4 and IL-13 have been 
described in psoriasis (19), demonstrating that not only an excessive Th1/Th17 axis but also 
a defective Th2 axis can trigger the disease. 
We previously compared the gene expression profiles of lesional and non-lesional skin 
of patients with psoriasis (Racz et al., submitted), and found decreased GATA3 expression 
in lesional skin. Because epidermal abnormalities resembling human psoriasis occur in mice 
with an epidermis-specific deletion of GATA3-/- (7, 8), we hypothesized that downregulation 
of GATA3 was associated with the pathological changes in psoriatic skin. This prompted us to 
investigate the association between GATA3 expression and skin inflammation in psoriasis and 
in the murine imiquimod-induced psoriasis-like skin inflammation model (20).
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RESULTS
Epidermal GATA3 expression is reduced in human psoriatic lesions and in a psoriasis-
like murine skin-inflammation model
GATA3 expression was determined in situ at the protein level, using skin biopsies from 
healthy individuals, and lesional and non-lesional skin biopsies of patients with psoriasis. 
In healthy control skin GATA3 expression was present in all layers except the basal layer 
(Figure 1A). In non-lesional psoriatic skin, GATA3 expression was also visible in the basal 
layer, while in lesional psoriatic skin overall GATA3 expression was reduced being only 
slightly visible in the lower suprabasal layers (Figure 1A). The mRNA expression of GATA3 
was  downregulated in lesional psoriatic skin in a global gene expression profiling study (Racz 
et al., submitted). This finding was validated by RT-PCR using RNA samples of five patients 
with psoriasis. A 5-fold (range 3-12-fold) lower expression of GATA3 was observed in lesional 
epidermis compared to non-lesional epidermis (Figure 1B). 
Figure 1. Epidermal GATA3 expression is reduced in psoriatic lesions. 
A. GATA3 protein was present in the nuclei of differentiating layers of the epidermis in normal skin. In non-lesional 
skin expression of GATA3 was also present in the basal layer of the epidermis whereas in lesional skin GATA3 
expression was downregulated. B. Expression of GATA3 was lower in lesional skin (PP) compared to non-lesional skin 
(PN). Epidermal GATA3 mRNA expression was determined by RT-PCR using ABL1 as a housekeeping control gene. 
Bars represent mean +/- SEM (n=5 patients). C. 3 mm biopsy samples from normal human skin were cultured in the 
presence of proinflammatory cytokines for 24 h. The epidermis was separated from the dermis and GATA3 expression 
was determined by RT-PCR in epidermal RNA, using ABL1 as a housekeeping control gene. Bars represent mean +/- 
SEM (n=4 healthy donors). D. GATA3 mRNA expression in the imiquimod-induced psoriasis-like dermatitis mouse 
model. GATA3 mRNA expression was determined in imiquimod- or control cream-treated back skin of Balb/C mice. 
ABL1 was used as a housekeeping control gene. Bars indicate the mean +/- SEM (n=3 mice per group). See page 157 
for a full-color representation of this figure.
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We then assayed whether low epidermal GATA3 expression in psoriasis is a consequence of 
the presence of inflammatory cytokines derived from infiltrating immune cells that are present 
in the inflamed psoriatic skin. Human skin biopsies from healthy volunteers were cultured 
with IFN-α, a type I IFN produced mainly by plasmacytoid DC that plays an important role 
in the initiation of psoriatic plaque formation (21), IFN-γ or IL-22, prototypic Th1 and Th17 
cytokines, respectively. IFN-γ induced GATA3 expression in the epidermis, whereas IFN-α 
and IL-22 had no significant effect on GATA3 expression (Figure 1C). These data suggest that 
the reduced level of epidermal GATA3 in psoriasis is not caused by IFN-α, IFN-γ or IL-22.
Next we assessed the expression of GATA3 in a murine psoriasis-like skin inflammation 
model. Daily application of the TLR7/8 agonist imiquimod cream (trade name Aldara) on 
mouse back skin induces skin inflammation that strongly resembles human psoriasis in terms 
of phenotypic and histological appearance (20). GATA3 mRNA expression in the mouse skin 
was measured by RT-PCR on the 6th day of daily treatment with imiquimod. GATA3 mRNA 
expression was 1.7-fold lower in the imiquimod-treated mice than in mice treated with control 
cream only (Figure 1D). 
GATA3 expression in psoriasis is upregulated by effective treatment of the disease
NB-UVB phototherapy is a standard and effective treatment modality for human psoriasis. 
We evaluated whether NB-UVB treatment of patients with psoriasis or psoriasis-like skin 
inflammation in mice would restore GATA3 expression in the skin. GATA3 expression was 
measured by RT-PCR in patients with psoriasis undergoing standard NB-UVB therapy. GATA3 
mRNA expression increased gradually during the course of NB-UVB treatment, correlating 
with the clinical improvement (Figure 2A).
Interestingly, NB-UVB irradation of the mice on the 1st, 3rd and 5th day of imiquimod 
treatment resulted in less inflammation in the imiquimod-induced psoriasis-like dermatitis 
model (Figure 2B). In this model, skin inflammation as assessed by erythema, scaling and 
thickness was less pronounced after NB-UVB irradiation (Figure 2B). Accordingly, histological 
examination showed decreased epidermal thickness, improved epidermal differentiation and a 
significantly reduced number of proliferating/BrdU+ cells in imiquimod plus NB-UVB-treated 
mouse skin as compared to those treated with imiquimod alone (Figure 2C, D). In addition, 
NB-UVB treatment induced a clear reduction in markers of psoriasis disease activity in mouse 
skin, such as phosphorylated STAT3, dendritic cell and neutrophil granulocyte infiltrates and 
endothelial cells (Supplemental Figure 1). Thus, NB-UVB irradiation of imiquimod-treated 
mouse skin resulted in improvement of psoriasis-like dermatitis, as assayed by clinical, 
histological and immunohistochemical parameters. 
We next assessed whether reduction of imiquimod-induced psoriasis-like inflammation by 
NB-UVB in mice is accompanied by alterations in GATA3 expression. Therefore GATA3-
LacZ knock in mice (22) were treated with imiquimod daily, and were irradiated every other 
day with NB-UVB. In this mouse expression of the LacZ transgene is driven by the GATA3 
promoter, and thus expression of the LacZ product X-Gal depends on GATA3 promoter activity. 
On the 6th day mice were sacrificed and GATA3 expression was assayed by X-Gal staining 
of back skin. X-Gal staining was reduced in imiquimod-treated mouse skin, and was clearly 
re-induced by NB-UVB irradiation (Figure 2E).
In summary, successful treatment of psoriasis and of psoriasis-like skin inflammation 
restored the low GATA3 expression, which correlated with clinical improvement.
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Figure 2. Upregulation of GATA3 expression during NB-UVB phototherapy. 
A. GATA3 expression is upregulated during the course of NB-UVB phototherapy in patients with psoriasis. Three- 
mm biopsy samples were collected from lesional (PP) and non-lesional skin of patients with psoriasis before, during 
and after NB-UVB phototherapy. Epidermal GATA3 mRNA expression was determined with RT-PCR using ABL1 as 
a housekeeping control gene. Bars represent mean +/- SEM (n=5 patients). The broken line shows the change in the 
PASI score, relative to the baseline score. B. BALB/c mice were treated daily with imiquimod cream or control cream 
on the shaved back skin, and irradiated or sham-irradiated every other day with NB-UVB, starting on the first day of 
imiquimod treatment. Erythema, scaling, and the thickness of the back skin were scored daily on a scale from 0 to 4. 
The cumulative score (erythema plus scaling plus thickness) is shown. Symbols indicate mean score +/- SEM of three 
mice per group. C. Mice were sacrificed on day 6. Imiquimod-induced inflammation was studied on sections made 
from the back skin of the mice. Keratin 1/10 immunofluorescent staining of the back of the mice is shown. D. BrdU 
incorporation in keratinocytes in the back skin was detected by immunohistochemistry. Bars on the right represent 
the mean number of BrdU positive cells +/- SD. E. X-gal staining (blue) of heterozygous GATA3LacZ skin samples 
from mice treated with imiquimod with or without NB-UVB. X-Gal staining that in these mice correlates with 
GATA3 expression is lower in the inflamed epidermis compared to control and is induced during NB-UVB treatment. 
See page 158 for a full-color representation of this figure.
91
UVB therapy restores epidermal GATA3 in psoriasis 
GATA3 expression is reduced in the regenerating epidermis
The tissue response in psoriasis is often compared to that during epidermal 
regeneration (23). During epidermal regeneration (e.g. upon wounding) keratinocyte 
proliferation is stimulated and an inflammatory response is initiated to prevent infection 
through the injured epidermal barrier. We thus investigated whether decreased GATA3 
expression was specific to psoriatic inflammation or was also seen under conditions 
of epidermal regeneration. First, the epidermal barrier was disrupted in non-lesional 
skin of patients with psoriasis by removal of the stratum corneum via repeated tape 
stripping. Before tape stripping and 5 h later skin biopsies were taken from the tape-
stripped area, the epidermis was separated from the dermis, and mRNA expression of 
epidermal GATA3 was studied. GATA3 expression in the epidermis was reduced to 
60% on average of the baseline expression in six of the seven patients (Figure 3A).
We also investigated GATA3 expression during wound healing by performing X-Gal 
staining on sections taken from the wounded back skin of a GATA3 LacZ knock in mouse. 
Whereas X-Gal staining was observed in all epidermal layers of the epidermis adjacent to the 
wounded area, only a few X-Gal positive cell nuclei were visible in the stratum granulosum 
Figure 3. GATA3 expression is reduced in the regenerating epidermis. 
A. The stratum corneum of non-lesional skin of seven psoriatic patients was removed by repeated tape stripping to 
induce regeneration. Before and 5 h after tape stripping biopsies were taken and epidermal GATA3 expression was 
determined using RT-PCR, relative to ABL1 as a housekeeping control gene. Relative expression values of individual 
patients are shown. B. GATA3 expression is downregulated in the healing wound of murine skin. X-gal staining 
(blue) of wounded skin of a heterozygous GATA3LacZ mouse shows downregulation of the LacZ transgene under 
the control of GATA3 in the highly proliferative zone of the healing wound. Arrows indicate X-Gal positive cells; 
the border between regenerating and adjacent normal skin is marked. See page 159 for a full-color representation of 
this figure.
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and straum corneum in the healing wound. The number of X-Gal positive cells increased 
gradually towards the adjacent healthy skin (Figure 3B). 
In conclusion, GATA3 expression is reduced in conditions in which the epidermis is forced 
to regenerate.
Comparison of expression profiles in psoriasis and in epidermal GATA3-deficient mice
We then investigated which cellular processes are affected by low GATA3 expression 
in the psoriatic epidermis. For this we compared gene expression profiles obtained from 
hair follicles of epidermis-specific GATA3-/- mice (7) with those from lesional epidermis of 
patients with psoriasis. A total of 5922 genes were differentially expressed in the hair follicle 
of epidermis-specific GATA3-/- mice when compared to wild type mice (p<0.05, ≥1.2-fold 
up- or downregulated (7)). In human lesional psoriatic epidermis, which is characterized 
by low GATA3 expression, 2412 genes were differentially expressed when compared to 
non-lesional epidermis (p<0.05, ≥1.2-fold up- or downregulated) (Racz et al., submitted). 
Genes were identified that were upregulated in both GATA3 -/- mouse skin and in lesional 
Table 1. Genes differentially expressed in both psoriasis and GATA3 -/- mice.
Symbol Cell differentiation Fold 
change 
human
Fold 
change 
mouse
Up/
down
SOD2 SUPEROXIDE DISMUTASE 2, MITOCHONDRIAL 6.0 1.2 U
ALDH1A3 ALDEHYDE DEHYDROGENASE 1 FAMILY, MEMBER A3 3.9 1.5 U
TXNDC5 THIOREDOXIN DOMAIN CONTAINING 5 2.5 1.3 U
EHF ETS HOMOLOGOUS FACTOR 2.3 1.3 U
CTSB CATHEPSIN B 2.1 1.3 U
S100A6 S100 CALCIUM BINDING PROTEIN A6 (CALCYCLIN) 1.8 1.4 U
SGK1 SERUM/GLUCOCORTICOID REGULATED KINASE 1.8 2.4 U
EIF2B2 EUKARYOTIC TRANSLATION INITIATION FACTOR 2B, 
SUBUNIT 2 BETA
1.7 1.7 U
DICER1 DICER1, RIBONUCLEASE TYPE III 1.6 1.6 U
POLB POLYMERASE (DNA DIRECTED), BETA 1.6 1.4 U
PHB PROHIBITIN 1.6 1.4 U
BOK BCL2-RELATED OVARIAN KILLER 1.4 1.5 U
TXNL1 THIOREDOXIN-LIKE 1 1.3 1.3 U
CHL1 CELL ADHESION MOLECULE WITH HOMOLOGY TO 
L1CAM
4.5 2.0 D
TNFAIP3 TUMOR NECROSIS FACTOR, ALPHA-INDUCED PROTEIN 3 2.6 1.3 D
TNFRSF19 TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, 
MEMBER 19
2.3 1.4 D
FAS FAS (TNF RECEPTOR SUPERFAMILY, MEMBER 6) 2.0 1.5 D
DLG5 DISCS, LARGE HOMOLOG 5 1.9 1.6 D
FOXO1 FORKHEAD BOX O1A 1.9 1.6 D
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Table 1. Genes differentially expressed in both psoriasis and GATA3 -/- mice (continued).
Symbol Cell differentiation Fold 
change 
human
Fold 
change 
mouse
Up/
down
MYST3 MYST HISTONE ACETYLTRANSFERASE 3 1.9 1.5 D
TNFRSF25 TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, 
MEMBER 25
1.9 1.2 D
RYBP RING1 AND YY1 BINDING PROTEIN 1.8 1.5 D
SPRY1 SPROUTY HOMOLOG 1, ANTAGONIST OF FGF SIGNALING 1.8 1.5 D
MIB1 MINDBOMB HOMOLOG 1 1.7 1.4 D
PDCD6IP PROGRAMMED CELL DEATH 6 INTERACTING PROTEIN 1.6 1.4 D
UBE2B UBIQUITIN-CONJUGATING ENZYME E2B 1.6 1.5 D
JAG2 JAGGED 2 1.5 1.5 D
DHCR24 24-DEHYDROCHOLESTEROL REDUCTASE 1.2 2.1 D
Cell cycle
KLK10 KALLIKREIN 10 2.3 2.0 U
S100A6 S100 CALCIUM BINDING PROTEIN A6 (CALCYCLIN) 1.8 1.4 U
GSPT1 G1 TO S PHASE TRANSITION 1 1.7 1.4 U
PHB PROHIBITIN 1.6 1.4 U
AURKAIP1 AURORA KINASE A INTERACTING PROTEIN 1 1.5 1.4 U
PA2G4 PROLIFERATION-ASSOCIATED 2G4 1.5 1.3 U
MCC MUTATED IN COLORECTAL CANCERS 3.0 1.5 D
WEE1 WEE1 HOMOLOG 2.5 1.5 D
KAT2B K(LYSINE) ACETYLTRANSFERASE 2B 2.2 1.7 D
FOXN3 FORKHEAD BOX N3 2.1 1.5 D
MAP2 MICROTUBULE/ASSOCIATED PROTEIN 2 2.1 1.6 D
DLG5 DISCS, LARGE HOMOLOG 5 1.9 1.6 D
BUB3 BUB3 BUDDING UNINHIBITED BY BENZIMIDAZOLES 3 
HOMOLOG
1.6 1.6 D
JAG2 JAGGED 2 1.5 1.5 D
WNK1 WNK LYSINE DEFICIENT PROTEIN KINASE 1 1.5 2.3 D
DHCR24 24-DEHYDROCHOLESTEROL REDUCTASE 1.2 2.2 D
CCNI CYCLIN I 1.2 1.4 D
Apoptosis
SOD2 SUPEROXIDE DISMUTASE 2, MITOCHONDRIAL 6.0 1.2 U
ALDH1A3 ALDEHYDE DEHYDROGENASE 1 FAMILY, MEMBER A3 3.9 1.5 U
TXNDC5 THIOREDOXIN DOMAIN CONTAINING 5 2.5 1.3 U
CTSB CATHEPSIN B 2.1 1.3 U
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Table 1. Genes differentially expressed in both psoriasis and GATA3 -/- mice (continued).
Symbol Cell differentiation Fold 
change 
human
Fold 
change 
mouse
Up/
down
SGK1 SERUM/GLUCOCORTICOID REGULATED KINASE 1.8 2.4 U
POLB POLYMERASE (DNA DIRECTED), BETA 1.6 1.4 U
PHB PROHIBITIN 1.6 1.4 U
BOK BCL2-RELATED OVARIAN KILLER 1.4 1.5 U
TXNL1 THIOREDOXIN-LIKE 1 1.3 1.3 U
TNFAIP3 TUMOR NECROSIS FACTOR, ALPHA-INDUCED PROTEIN 3 2.6 1.3 D
TNFRSF19 TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, 
MEMBER 19
2.3 1.4 D
FAS FAS (TNF RECEPTOR SUPERFAMILY, MEMBER 6) 2.0 1.5 D
DLG5 DISCS, LARGE HOMOLOG 5 (DROSOPHILA) 1.9 1.6 D
FOXO1 FORKHEAD BOX O1A 1.9 1.6 D
TNFRSF25 TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, 
MEMBER 25
1.9 1.2 D
RYBP RING1 AND YY1 BINDING PROTEIN 1.8 1.5 D
PDCD6IP PROGRAMMED CELL DEATH 6 INTERACTING PROTEIN 1.6 1.4 D
DHCR24 24-DEHYDROCHOLESTEROL REDUCTASE 1.2 2.2 D
Transcription regulation
EHF ETS HOMOLOGOUS FACTOR 2.3 1.3 U
SUB1 SUB1 HOMOLOG 1.8 1.4 U
ASCC3 ACTIVATING SIGNAL COINTEGRATOR 1 COMPLEX 3 1.5 1.4 U
PA2G4 PROLIFERATION-ASSOCIATED 2G4 1.5 1.3 U
FOXP1 FORKHEAD BOX P1 1.4 1.4 U
PHB2 PROHIBITIN 2 1.3 1.4 U
TSC22D1 TSC22 DOMAIN FAMILY, MEMBER 1 3.0 1.7 D
HLF HEPATIC LEUKEMIA FACTOR 2.3 1.5 D
NFIB NUCLEAR FACTOR I/B 2.3 1.4 D
KAT2B K(LYSINE) ACETYLTRANSFERASE 2B 2.2 1.7 D
FOXN3 FORKHEAD BOX N3 2.1 1.5 D
FOXO1 FORKHEAD BOX O1A 1.9 1.6 D
MYST3 MYST HISTONE ACETYLTRANSFERASE 3 1.9 1.5 D
SMARCA2 SWI/SNF RELATED, MATRIX ASSOCIATED, ACTIN 
DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, 
MEMBER 2 1.9 1.6 D
ZNF329 ZINC FINGER PROTEIN 329 1.9 1.4 D
RYBP RING1 AND YY1 BINDING PROTEIN 1.8 1.5 D
TCF12 TRANSCRIPTION FACTOR 12 1.8 1.3 D
95
UVB therapy restores epidermal GATA3 in psoriasis 
psoriatic skin (77 genes), or were downregulated in both (97 genes) (Table 1). This list of 
genes was subjected to gene annotation using the DAVID Gene Annotation Tool. Low GATA3 
expression in both human psoriatic and GATA3 -/- murine epidermis coincided with the altered 
expression of genes involved in cell differentiation, cell proliferation and apoptosis (Table 1). 
In addition, the expression of several transcription factors was regulated in coordination with 
GATA3 (Table 1), e.g. FOXP1, FOXO1, FOXN3, TFAP2A, KLF13 and SNAI2, which are 
transcription factors that are involved in organ development and differentiation.
GATA3 expression in primary human keratinocytes during normal proliferation, 
induced differentiation and cell cycle arrest
To better understand the behavior of GATA3 during epidermal/keratinocyte differentiation, 
immunofluorescent staining of GATA3 was performed in undifferentiated and differentiated 
epidermal keratinocytes. Primary human keratinocytes were cultured under high Ca2+ 
conditions in order to stimulate differentiation, and then harvested after 24 h, fixed and stained 
with anti-GATA3 antibody. In differentiating keratinocytes GATA3 expression was localized 
to the nucleus, whereas in normal proliferating control keratinocytes GATA3 was randomly 
expressed in the nuclei and in the cytoplasm (Figure 4A, B, D). In addition, cell cycle arrest 
was induced in keratinocytes by TGF-β1 at both low and high Ca2+ concentrations. Primary 
keratinocytes were cultured with TGF-β1, harvested after 24 h and stained for GATA3. 
Interestingly, GATA3 expression in TGF-β1-treated cells was mostly localized to the 
cytoplasm, indicating transcriptional inactivity (Figure 4C, D). 
 
Table 1. Genes differentially expressed in both psoriasis and GATA3 -/- mice (continued).
Symbol Cell differentiation Fold 
change 
human
Fold 
change 
mouse
Up/
down
CTNND1 CATENIN DELTA 1 1.7 1.4 D
PBX3 PRE-B-CELL LEUKEMIA TRANSCRIPTION FACTOR 3 1.7 1.5 D
TFAP2A TRANSCRIPTION FACTOR AP-2 ALPHA 1.7 1.7 D
SUV420H1 SUPPRESSOR OF VARIEGATION 4-20 HOMOLOG 1 1.6 1.4 D
ZNF148 ZINC FINGER PROTEIN 148 1.6 1.3 D
KLF13 KRUPPEL-LIKE FACTOR 13 1.5 1.5 D
SSBP3 SINGLE STRANDED DNA BINDING PROTEIN 3 1.5 1.2 D
SNAI2 SNAIL HOMOLOG 2 1.5 1.2 D
SERTAD2 SERTA DOMAIN CONTAINING 2 1.4 1.4 D
Other
 DSC2 DESMOCOLLIN 2 4.0 1.9 U
 TF TRANSFERRIN 2.2 2.0 U
 LNX1 LIGAND OF NUMB-PROTEIN X 1 4.3 1.6 D
 INSIG2 INSULIN INDUCED GENE 2 2.9 1.4 D
 IGFBP5 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5 2.7 1.3 D
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In conclusion, GATA3 is transcriptionally active in differentiated keratinocytes, whereas no 
nuclear GATA3 was observed during cell cycle arrest, indicating a role for GATA3 during cell 
differentiation and proliferation.
DISCUSSION 
Here we show that the epidermal expression of the zinc finger transcription factor GATA3 
is consistently downregulated in psoriasis, in the imiquimod-induced psoriasis-like mouse 
model and under conditions of epidermal regeneration. Our finding that GATA3 expression is 
reduced in both psoriasis and epidermal regeneration confirms previously described parallels 
between these conditions.
The involvement of GATA3 in the pathophysiology of psoriasis is a novel finding. 
Although GATA3 has occasionally been reported in microarray studies of psoriasis (24-
26), its role and the modulation of its expression in skin has never been pursued in much 
detail. Polymorphisms in the GATA3 gene or genetic associations have not been reported 
to be associated with psoriasis, but, interestingly, are associated with atopic dermatitis, a 
chronic inflammatory skin disease with epidermal hyperplasia (27). Haploinsufficiency of 
the GATA3 gene causes the very rare HDR (hypoparathyroidism, sensorineural deafness and 
renal dysplasia) syndrome (28). Generalized psoriasis has been reported in a patient with the 
HDR syndrome (29). This finding and our current studies indicate that GATA3 might be an 
essential component of the pathophysiology of psoriasis as well.
Figure 4. GATA3 translocates to the nucleus in differentiating keratinocytes, whereas it stays in the cytoplasm 
during cell cycle arrest. 
Primary human epidermal keratinocytes were cultured on chamber slides. When cells reached ~75% confluency, CaCl2 
(B, D) and/or TGF-β1 (C, D) were added to the culture medium. After 24 h cells were fixed and immunofluorescent 
staining for GATA3 protein (pink) was performed. E. GATA3 positive cell nuclei were counted and are shown as a 
percentage of the total number of cell nuclei. See page 160 for a full-color representation of this figure.
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Most of our current insight into the function of GATA3 originates from T cell biology, 
whereas much less is known about GATA3 molecular function in keratinocytes. In T cells 
GATA3 determines Th2 cell differentiation and selectively activates the promoters of IL-4, 
IL-5, and IL-13 through chromatin remodelling. For the latter, GATA3 must translocate from 
the cytoplasm into the nucleus to access its target genes. 
Our initial mechanistic explanation was that downregulation of GATA3 could be caused 
by cytokines in the highly pro-inflammatory milieu in psoriasis lesions. However, GATA3 
expression was not suppressed by proinflammatory cytokines such as IFN-γ, IFN-α and 
IL-22, which are critical in the pathogenesis of psoriasis. The possibility that suppression of 
GATA3 is inducible by other specific mediators or cytokines or combinations that we did not 
test, cannot be ruled out. 
To identify the effects of decreased GATA3 expression in psoriasis, based on our microarray 
results, we first listed all genes known to be causally related to GATA3 i.e. differentially 
regulated in epidermis-specific GATA3 -/- mice. Genes from this list that were regulated in 
the same way (i.e. up or down) in lesional psoriatic skin versus healthy, non-lesional skin were 
selected. The resulting group of genes included negative regulators of inflammation, such 
as the psoriasis susceptibility gene TNFAIP3 (19, 30) and the Notch ligand jagged 2 (31), 
genes regulating epidermal differentiation, such as the transcription factor AP2-α (TFAP2A) 
(32), and the apoptosis-inducing FAS molecule. In addition, the transcription factors 
FOXN3, FOXO1 and FOXP1 were also regulated together with GATA3. These molecules 
play regulatory roles in organ development (33), metabolism (34) and cell proliferation (35), 
respectively. Parallel to the induction of GATA3, AP2-α (TFAP2A) and the anti-inflammatory 
TNFAIP3 and jagged 2 were also induced by NB-UVB therapy of psoriasis. Induction of 
these molecules might contribute to the anti-psoriatic effects of NB-UVB.
In conclusion, this study shows that the epidermal expression of the transcription factor 
GATA3 is consistently downregulated under conditions of keratinocyte hyperproliferation 
and altered differentiation such as in psoriasis, in murine psoriasis-like dermatitis and in 
wound healing. Our results indicate that further studies on the epidermal function of GATA3 
in psoriasis could provide novel insights into the pathophysiology of the disease. 
METHODS
Patients, NB-UVB treatment and biopsy samples
Seventeen patients (11 men, 6 women, age range 20-73) with psoriasis were recruited after 
informed consent (METC registration number 234.237/2003/210). All patients had a Psoriasis 
Area and Severity Index (PASI) score of at least 10, and had not received systemic therapy 
for at least one month or topical therapy for at least two weeks prior to the start of the study. 
Ten patients were treated with standard NB-UVB phototherapy until total clearance of psoriasis 
was achieved, or for a maximum of three months. From these 10 patients 3-mm biopsies were 
taken from lesional and non-lesional skin before the start of NB-UVB therapy and after the 
last treatment session. When PASI scores reached a reduction of 50% of the baseline score, 
additional biopsies from lesional and non-lesional skin were taken. NB-UVB treatment was 
applied three times a week using a Waldmann 7001 UVB cabinet equipped with Philips TL-01 
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bulbs. The initial UVB dose was 0.1-0.3 J/cm2 (depending on the skin type of the patient); the 
mean cumulative UVB dose was 42.0 J/cm2 (range 30-60 J/cm2). During the course of UVB 
treatment PASI scores were evaluated every two weeks. 
Biopsy samples were taken from the seven additional patients from non-lesional skin, 
from which the stratum corneum was removed by successive application of adhesive tape 
(tape stripping) of approximately 2 cm2. Five hours after tape stripping biopsies were taken 
from the treated area. 
Skin organ culture
Skin biopsies (3 mm diameter) were obtained, after informed consent, from healthy 
volunteers undergoing breast reduction in the Department of Plastic Surgery of the Sint 
Franciscus Gasthuis, Rotterdam, The Netherlands. Biopsies were cultured in a transwell 
system as described previously, with the dermis immersed in medium, and the epidermis 
exposed to the air interface (36). Recombinant human IFN-α (500 U/ml), IFN-γ (500 U/
ml) or IL-22 (50 ng/ml) (R&D Systems, Abingdon, UK) was added to the culture medium. 
These concentrations were previously demonstrated to yield optimal biological responses in 
this organ culture system. Biopsies were collected 24 h later. 
Keratinocyte culture
Primary human epidermal keratinocytes were obtained from healthy donors as described 
previously (37) and cultured in Dermalife medium (LifieLine Cell Technology, Walkersville, 
MD) on Lab-Tek Chamber slides. Keratinocytes from passages 3 to 4 were used. Cells were 
cultured with or without CaCl2 (final Ca
2+ concentration was 1.2 mM). In addition, TGF-β1 
was added to the cells at a concentration of 3 ng/ml.
RNA isolation
The epidermis was separated from the dermis after incubation in 1 mg/ml protease X 
(Sigma Aldrich, Zwijndrecht, The Netherlands) for 90 min at 37°C, and stored in RNA lysis 
buffer at -80°C until further processing. Total messenger RNA was isolated from the epidermis 
only, using a GenElute Mammalian Total RNA Miniprep kit (Sigma Aldrich). RNA purity and 
integrity was verified by scanning with an Agilent 2100 Bioanalyzer using RNA 6000 Nano 
LabChip. 
Array hybridization and analysis
For hybridization on gene expression arrays, RNA samples of four individual patients 
per array (250 ng mRNA per patient) were pooled. Patients were divided into two groups in 
order to have duplicate arrays for each time point and condition. Biotinylated target RNA was 
prepared from the pooled (1 µg) total RNA, and hybridized on GeneChip Human Genome 
U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA). Array hybridization and scanning was 
performed as described previously (38). The data were read and robust multichip analysis 
(RMA) (39) was used to remove the background and normalize the data across arrays (40). 
These values were log2-transformed for further analysis, yielding numbers between 0 and 16. 
A two-way ANOVA with factors “probe” and “condition” was used for each probeset to 
calculate both average expression levels per condition (41) and a p-value for the difference 
between conditions. The resulting p-values were adjusted for multiple testing using Šidák step-
up adjustment (42). Genes were considered differentially expressed when p-values were < 0.05. 
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 Gene expression analysis of isolated hair follicles of GATA3-/- mice was described 
previously (7). Functional annotation was performed using the Database for Annotation, 
Visualization, and Integrated Discovery (DAVID) (43).
Quantitative RT-PCR
RNA of individual patients was transcribed into cDNA, and RT-PCR was performed as 
described previously (44). ABL1 was used as a housekeeping control gene. The sequences 
of newly designed primers and probe numbers of the Exiqon probe library system (Exiqon, 
Vedbaek, Denmark) are listed in Table 2.
Mice and treatments
Induction of skin inflammation by daily imiquimod application in BALB/c and LacZ knock 
in GATA3 mice (22) was performed as described previously (20). Briefly, mice were treated 
daily with imiquimod on the shaved back skin for 5 days. Every other day, starting on the first 
day of the experiment, mice were irradiated with a Waldmann irradiation device equipped with 
TL-01 UV 236-01 lamps (Waldmann Medizintechnik, Villingen-Schwenningen, Germany), 
or were sham irradiated. The applied UVB dose was 70% of the minimal erythema dose 
(MED) on the first day and it was increased by 10% in each treatment. Scoring of the severity 
of skin inflammation was performed as described previously (20). On the 6th day, mice were 
sacrificed and 3 mm biopsy samples were taken from the back skin. Total RNA was isolated, 
transcribed into cDNA, and the expression of GATA3 was determined by RT-PCR, using 
ABL1 as a housekeeping control gene.
To determine the MED in BALB/c mice, animals were irradiated with increasing doses 
of NB-UVB. Ear thickness was measured with a micrometer (Mitutoyo, Veenendaal, 
The Netherlands) before UVB irradiation and 48 h later. The lowest NB-UVB dose at which 
ear thickness was significantly increased was 1680 mJ/cm2. Seventy percent of this dose (thus 
70% of the MED) was used as the starting dose in further experiments. 
Table 2. Primers and probes for RT-PCR.
Gene Forward primer Reverse primer Probe 
hGATA3 GCTTCGGATGCAAG
TCCA
GCCCCACAGTTCAC
ACACT
Nr. 8 1
mGATA3 CATTACCACCTATC
CGCCCTATG
CACACACTCCCTGCC
TTCTGT
CGAGGCCCAAGG
CACGATCCAG
hGAPDH TCCACTGGCGTCTT
CAC
GGCAGAGATGATGAC
CCTTTT
Nr. 45 1
h/mABL1 TGGAGATAACACTCT
AAGCA
TAACTAAAGGT
GATGTAGTTGCTTG
GGACCCA
CCATTTTTGGTTTGGG
CTTCACACCATT
1 Probe from the Exiqon probe library system (Exiqon, Vedbaek, Denmark).
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Prior to the irradiation experiment one of the LacZ knock in GATA3 mice was critically 
bitten and had to be sacrificed. We took advantage of this unintentional skin wounding to 
assess whether this insult and concomitant skin regeneration affected GATA3 expression. 
The wounded back skin of this mouse as well as unaffected adjacent tissue was embedded in 
Tissue-Tec embedding medium (Sakura, Zoeterwoude, The Netherlands) and snap-frozen. 
Immunohistochemistry, x-Gal staining and BrdU labelling
For immunofluorescent staining, cryosections or cells were fixed for 10 min in 4% 
paraformaldehyde (PFA) in PBS. Primary antibodies included anti-β-defensin 2 (1:100; 
Santa Cruz Biotechnology, Santa Cruz, CA), anti-GATA-3 (1:100; Santa Cruz Biotechnology, 
Santa Cruz, CA), anti-phosphorylated STAT3 (1:50; Cell Signaling Technology Inc, Danvers, 
MA) and K10 (mouse 1:50; Sigma, clone k8.60). Relevant FITC-, TxR- or HRP-conjugated 
antibodies (1:100, Abcam) were used to detect primary antibodies. All fluorescent images 
were taken with an Axio Imager (Zeiss) fluorescence microscope. Immunohistochemical 
staining procedures were applied as described previously (45). Primary antibodies were 
hamster anti-mouse CD11c (undiluted) to detect myeloid dendritic cells, rat anti-mouse GR-1 
(1:80) to identify neutrophil granulocytes, and rat anti-mouse Meca20 (undiluted) to visualize 
blood vessel endothelium. For standard histology PFA-fixed cryosections were stained with 
hematoxylin and eosin.
Mice were injected with 50 mg/kg bodyweight 5-bromo-2’-deoxyuridine (BrdU) and 
sacrificed 2 h later. Cryosections were fixed for 10 min in 4% PFA in PBS and washed three 
times for 5 min in PBS. A block/diluent was used: 1% BSA, 0.05% Tween in PBS. For BrdU 
immunohistochemistry with BrdU (mouse 1:100; DAKO, clone Bu20a), tissue samples were 
fixed in 4% PFA in PBS at 4°C overnight. Skin samples were subsequently embedded in 
paraffin and sectioned at 5 μm. After deparaffination sections were boiled in 0.01 M citrate 
buffer (pH 6.0) for 15 min prior to incubation with primary antibody. Sections were analyzed 
and photographed with an Olympus BX40 light microscope. 
For X-gal staining sections were fixed for 1 min in 0.5% glutaraldehyde, 1% PFA, washed 
in PBS and incubated in X-gal staining solution (5 mM K3Fe(CN)6, 5mM K4Fe(CN)6*3H20, 
2 mM MgCl2, 0.01% Nadeoxycholate, 0.02% NP40, 1 mg/ml bromo-chloro-indolyl-
galactopyranoside) for 5 h at room temperature. Sections were then fixed in 4% PFA for 10 
min and counterstained with neutral red. 
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Supplemental Figure 1. NB-UVB treatment affects epidermal differentiation, inflammatory infiltrate and 
vascular alterations in imiquimod-induced skin inflammation in mice. 
BALB/c mice were treated daily with imiquimod cream or control cream on the shaved back skin, and irradiated or 
sham-irradiated every other day with NB-UVB, starting on the first day of imiquimod treatment. Mice were sacrificed 
on day 6. Immunofluorescent staining for phosphorylated STAT3 (A), is shown, as well as immunohistochemical 
analysis of myeloid dendritic cells (CD11c, B), granulocytes (GR1, C), and endothelial cells (MECA-20, D). 
See page 161 for a full-color representation of this figure.
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ABSTRACT
Background and Objective: Pulsed dye laser (PDL) therapy is effective 
in clearing psoriasis plaques, but the mechanism of action is incompletely 
understood. Narrow-band UVB (NB-UVB) is an effective standard treatment 
for psoriasis, with a better defined mode of action. 
Our aim was to evaluate the cellular and molecular effects of PDL and to 
compare them with those of local NB-UVB, in order to gain further insight 
into their mechanisms of action in psoriasis.
Study design/Patients and Methods: Nineteen patients with stable plaque-
type psoriasis were treated either with PDL or NB-UVB. Lesional punch 
biopsies were obtained from all patients before treatment. Additional biopsies 
were obtained at 3h and 24h after PDL treatment in 5 of these patients. In 14 
patients additional biopsies were taken after 7 and 13 weeks of treatment.
Samples were analyzed for expression of molecules that play critical roles 
in the pathogenesis of psoriasis, including epidermal (β-defensin-2), immune 
cell-derived (tumor necrosis factor (TNF)-α) and vascular components 
(VEGFR). 
Results: Clinical high responders to PDL treatment showed decreased 
expression of VEGFR2, VEGFR3 and E-selectin within 24 h after PDL 
treatment. After 2 PDL treatments IL-23, TNF-α mRNA and E-selectin 
protein expression were significantly reduced, whereas after 4 treatments 
all epidermal markers and dermal T cell infiltrates normalized. In NB-UVB-
treated plaques, epidermal activation markers and E-selectin expression were 
significantly reduced after 13 weeks.
Conclusions: At the end of the treatment period both PDL and NB-UVB 
resulted in reduced expression of epidermal activation markers and reduced 
dermal T cell infiltrates. We show early effects of PDL on vascular endothelial 
growth factor receptors, followed by downregulation of TNF-α and IL-23p19, 
which might contribute to PDL efficacy in psoriasis.
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INTRODUCTION
The dilation and proliferation of the dermal papillary microvasculature is one of the early 
changes seen in a new psoriatic plaque (1). The increased dermal microvasculature facilitates 
the traffic of leukocytes from the circulation into the skin and therefore plays an important 
role in maintaining inflammation in psoriasis (2). Interference with leukocyte trafficking via 
selective destruction of the dilated capillaries may be an effective therapeutic intervention in 
psoriasis. Selective targeting of bloodvessels may be achieved with the flash-lamp pumped 
pulsed dye laser (PDL) (3). The PDL technique is based on the selective absorption of short 
pulses of 585 nm light by oxyhemoglobine inducing photothermolysis of capillaries, leaving 
the other nearby structures in the skin undamaged (4).
Several studies reported that psoriatic plaques were partly or completely cleared by PDL 
treatment (5-8). In a comparative study, PDL showed a significantly higher efficacy than a 
class II topically applied corticosteroid (8). PDL was also effective in clearing recalcitrant 
psoriatic plaques (9), whereas palmoplantar psoriasis responded well to treatment with PDL 
alone or in combination with topical calcipotriol or salicylic acid (10).
Narrow-band UVB (NB-UVB) therapy is a standard treatment modality for psoriasis. 
The mechanism of action of UVB has been investigated more thoroughly than that of PDL. 
It is known that UVB targets the epidermal compartment, inhibiting the proliferation of 
keratinocytes, abrogating antigen presentation, migration of Langerhans cells (11) and inducing 
apoptosis of activated skin-homing T cells (12, 13). Prolonged exposure to UVB light and a 
high cumulative dose may result in premature ageing of the skin and lead to a higher risk of 
skin cancer. However, recent follow-up studies in patients receiving NB-UVB for psoriasis 
did not report any increase in the incidence of skin cancer as compared to controls (14, 15). 
Long-term side effects of PDL treatment have not yet been reported. 
No significant differences in clinical efficacy were demonstrated between PDL and 
NB-UVB in a single-blind, prospective, paired randomized controlled study (16), indicating 
that PDL is a valid treatment modality for psoriasis. However, to date we lack insight into 
the cellular and molecular mechanisms induced by PDL explaining its efficacy in psoriasis. 
The aim of the present study was to investigate the effects of PDL treatment on the cellular 
and molecular markers of disease activity in psoriasis using immunohistochemical and 
quantitative RT-PCR techniques and lesional biopsies taken before, during and at the end of 
the treatment and compare them with those of NB-UVB treatment.
MATERIALS AND METHODS
Patients and biopsies
After providing written informed consent (Medical Ethical Committee, Erasmus University 
Medical Center, Rotterdam, approval nr: MEC-2004-154) 19 subjects with stable plaque 
type psoriasis were enrolled in the study. Patients intolerant to light (toxic or allergic), using 
drugs with phototoxic or photo-allergic potency, younger than 18 years, were pregnant, or 
with pre-existing or manifest skin malignancy were excluded. A wash-out period of 2 weeks 
was indicated for topical drugs and of 4 weeks for photo(chemo)therapy and systemic drugs. 
Emollients were allowed. 
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In each patient the most representative psoriasis plaque was selected for a baseline 
biopsy.
In 5 patients (3 men and 2 women aged 45 to 59 years) additional 3-mm biopsies were 
taken at 3 h and 24 h after the first PDL treatment for the analysis of the short term effects. 
In 14 patients (7 men and 7 women aged 20 to 65 years) psoriasis plaques were randomly 
selected and treated either with PDL or with NB-UVB or left untreated. In these patients 3 mm 
biopsies were taken (in each patient one from a UVB-treated site and one from a PDL-treated 
site) at week 7 (after 2 treatments of PDL and 15 treatments with NB-UVB) and at week 13 
(after 4 treatments of PDL and 30 to 33 treatments of NB-UVB). The tissue samples were 
snap-frozen in Tissue-Tek OCT (Miles, Elkhart, IN, USA) and stored at -80°C until further 
processing. 
 
Treatments
PDL treatment was performed using the V Star PDL (Cynosure Inc., Chelmsford, MA), 
emitting yellow light at a wavelength of 585 nm. During treatment, the skin was air-cooled 
using a Zimmer 6 air cooler (Zimmer Elktromedizin, Neu-Ulm, Germany). PDL treatment 
parameters were: pulse duration 0.50 ms, spot diameter 7 mm, spots overlapping ± 20%, 
and fluences between 5.5 and 6.5 J/cm2. Patients were treated with PDL every 3 weeks for 
10 weeks, a total of four treatments. 
Narrow-band ultraviolet B treatment was performed using the UVB-TL01 S (wavelength 
311 nm) handheld device (Cosmedico Medizintechnik GmbH, Villingen-Schwenningen, 
Germany). Mean UV-output was 19.4 mWatt/cm2. Calibration of the devices was 
performed before the treatment with the Optometer P 9710 (Gigahertz Optik, Puchheim, 
Germany). During treatment, the aperture of the appliance (5.0 × 10.0 cm) was held against 
the skin assuring that the distance between the device and the skin was constant in each 
patient. Minimal erythema dose (MED) was determined in each patient prior to the study. 
Mean MED NB-UVB was 0.86 J/cm2 (range 0.34–1.2 J/cm2). UVB treatment (3 times per 
week) parameters were: a start dose of 70% of the MED, dose increments of 20% of the 
previous treatment until persistent erythema appeared or clearing of the lesion was achieved. 
During 11 weeks in total 30–33 treatments were given. Mean initial dose was 0.62 J/cm2 
(range 0.24–0.86 J/cm2), mean cumulative dose 84 J/cm2 (range 40–120 J/cm2).
In each patient plaques were randomly chosen, and treated with UVB, PDL or only with 
emollient. Concomitant topical treatment with salicylic acid 5% in petrolatum was permitted 
for all plaques in between the treatment sessions, to reduce reflectance of the PDL and the NB-
UVB beam by scales, but was discontinued 2 days before PDL treatment and directly before 
UVB treatment. Clinical efficacy was assessed as described previously (16).
Immunohistochemistry
Cryosections (6 µm) were cut from each punch biopsy, mounted on glass slides, fixed in 
acetone and stained for markers of psoriasis using antibodies shown in Table 1. Endogenous 
peroxidase activity was neutralized using 4-chloro-1-naphtol. After washing in phosphate 
buffered saline (PBS) containing 0.05% Tween 20 and 0.5% bovine serum albumin (BSA), 
slides were incubated with the primary antibodies (Table 1) for 1 h at room temperature. 
They were subsequently incubated with biotinylated secondary antibodies (rabbit-anti-mouse 
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IgG (Dako, 1:400) or donkey-anti-rabbit IgG (Amersham Biosciences, 1:800)) for 30 min and 
with horseradish peroxidase (HRP)-linked streptavidin (Dako, High Wycombe, UK) for 1 h 
at room temperature. Any non-specific staining was prevented by adding unlabeled (normal) 
secondary antibody and normal human AB serum. HRP activity was visualized with amino-
9-ethylcarbazole (Sigma-Aldrich, St. Louis, MO, USA) as a chromogen, resulting in a bright 
red staining. Sections were counterstained with haematoxylin and mounted in glycerin-gelatin 
(Dako). 
From each section a representative region was selected and photographed at 100x 
magnification using an AxioCam MRc5 camera (Zeiss, Goettingen, Germany). The acquired 
images were analyzed by computer-assisted image analysis using the WCIF VisionJ 
(http://rsb.info.nih.gov/ij) software. The area occupied by stained tissue was expressed as a 
fraction of the total area of interest (i.e. epidermis or dermis). For statistical analysis of the 
quantitative data, the Wilcoxon Signed Ranks test and the Kruskal-Wallis test were used for 
unpaired and paired sets of data, respectively.
RNA extraction and RT-PCR
For total RNA extraction, twenty 10 µm cryosections were cut under RNAase-free 
conditions from each biopsy sample, directly placed in RNA lysis buffer (Sigma) followed by 
mRNA extraction. RNA was transcribed into cDNA and RT-PCR was performed using newly 
designed primers and probes. ABL1 was used as a housekeeping control gene. Primer and 
probe sequences are listed in Table 2.
RESULTS
Clinical assessment
The Physician’s Global Assessment (PGA) score was used to establish clinical 
improvement. The PGA score is a 5 point scoring system, where score 0 denotes symptom-
free state, whereas scores 1-5 represent increasing severity. Definition of each score, as 
well as the clinical outcomes of the study have been reported in more detail elsewhere (16). 
The results of present study showed that the mean clinical improvement (mean reduction 
in the PGA score) at week 13 was 46% for the PDL-treated plaques and 52% for the UVB-
Table 1. Antibodies used in the study.
Antibody Target molecule Supplier Species Titer
anti-TGK Transglutaminase K Biomedical 
Technologies Inc.
Mouse 1:200
anti-CD3 CD3, a cell surface molecule on T lymphocytes Dako Rabbit 1:100
anti-vWF Von Willebrand factor, a coagulation factor 
synthesized by endothelial cells
Abcam Rabbit 1:25000
anti-E-selectin E-selectin (CD62E), an adhesion molecule on 
endothelial cells
R&D systems Inc. Mouse 1:20
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treated plaque indicating that the clinical efficacy of both treatments were comparable. 
High responders (defined as a PGA reduction > 50%) were selected in order to evaluate the 
effects of both treatments. Clinical improvement during the treatments as assessed by the 
PGA score in the total group and in the 6 high responders is shown in Figure 1.
Early effects of the pulsed dye laser
In order to elucidate the mechanism of action of PDL in psoriasis, early changes (within 
24 h) in psoriasis plaques upon PDL treatment were investigated. In biopsies taken 3 h and 
24 h after PDL-treatment no changes were observed in mRNA expression levels of markers 
of the activated epidermal psoriasis phenotype, such as β-defensin 2 (HBD2) and keratin 17 
(KRT17), tumor necrosis factor (TNF)-α, and vascular endothelial growth factor (VEGF)-A 
(data not shown). Expression of the anti-apoptotic, heat-regulated molecule Bcl2 showed no 
alteration within this time period of time (data not shown). Expression of the endothelial 
molecules E-selectin and vascular endothelial growth factor receptor (VEGFR)-2 was 
significantly reduced in the biopsies taken 3 h after PDL treatment (Figure 2 a, b). In the 
biopsies taken at 24 h, the expression of E-selectin was still reduced, whereas the expression 
of VEGFR2 returned to baseline, indicating that the reduction of VEGFR2 was transient 
(Figure 2 a, b). Interestingly, mRNA expression of the lymphatic marker VEGFR3 showed 
an alteration similar to VEGFR2 (Figure 2c). The expression of interleukin (IL)-23p19 
mRNA was significantly reduced at 3h, and still reduced although not significantly at 24 h 
(Figure 2d). 
In summary, PDL affected the mRNA expression of VEGFR2 and VEGFR3 as early 
as 3 h after treatment, whereas E-selectin expression was significantly reduced 24 h after 
treatment. The mRNA expression of IL-23p19 was also affected by PDL treatment, although 
the expression change did not reach significance at 24 h.
Table 2. Primers and probes for quantitative real-time PCR.
Forward primer Reverse primer Probe 1
KRT17 TTGAGGAGCTGCAGAACAAG AGTCATCAGCAGCCAGACG 76
HBD2 TCAGCCATGAGGGTCTTGTA GGATCGCCTATACCACCAAA 35
TNF-α CAGCCTCTTCTCCTTCCTGAT GCCAGAGGGCTGATTAGAGA 29
IL-23p19 GTTCCCCATATCCAGTGTGG TCCTTTGCAAGCAGAACTGA 76
E-selectin ACCAGCCCAGGTTGAATG GGTTGGACAAGGCTGTGC 86
VEGF-A TGCCCGCTGCTGTCTAAT TCTCCGCTCTGAGCAAGG 1
VEGFR2 GCTCAAGACAGGAAGACCAAG GGTGCCACACGCTCTAGG 27
VEGFR3 CAAGAAAGCGGCTTCAGGTA GCAGAGAAGAAAATGCTGACG 8
Bcl2 CAACACGCAGAGAATGTAAAGC GGTAGGAGCTGTGGCGACT 45
ABL1 TGGAGATAACACTCTAAGCA
TAACTAAAGGT
GATGTAGTTGCTTGGGACCCA CCATTTTTGGTT
TGGGCTTCACAC
CATT
1 Probe numbers of the Exiqon probe library system (Exiqon, Vedbaek, Denmark).
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Long-term alterations at the mRNA level
In 14 patients, selected psoriasis plaques were treated either with PDL or with local NB-UVB. 
PDL treatment was carried out every 3 weeks for 10 weeks, in total four treatments, whereas 
NB-UVB was applied three times weekly with increasing doses. The mRNA expression of 
keratinocyte-, immune cell- and endothelial cell-associated activation markers was assessed 
by quantitative RT-PCR in biopsies taken before the start, at week 7 and week 13 of therapy 
in the group of clinical responders, in order to determine the course of the molecular changes 
during the treatment. The expression of keratin 17 and β-defensin 2 decreased significantly in 
the PDL-treated samples, corresponding with the clinical improvement. In the UVB-treated 
lesions no significant alterations in keratin 17 and β-defensin 2 expression were observed in 
responders (Figure 3 a-d).
The mRNA expression of TNF-α decreased significantly in the samples treated with 
PDL but not in those treated with NB-UVB (Figure 3 e, f). Expression of IL-23p19 mRNA 
was suppressed in the PDL-treated samples at week 7 of treatment, but returned to baseline 
levels after 13 weeks, whereas in the UVB-treated samples no significant alterations in the 
expression of IL-23p19 mRNA were detected in the clinical responders (Figure 3 g, h).
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Figure 1. Clinical improvement of psoriasis lesions during PDL and local NB-UVB treatment from baseline 
to week 13. 
In each patient, stable psoriatic plaques were randomly selected and treated with PDL or local NB-UVB. Clinical 
improvement was evaluated using the Physician’s Global Assessment (PGA) score. (a)-(b) The average clinical 
improvement in the entire study group (14 patients). (c)-(d) The average clinical improvement in 6 patients with high 
clinical response. Error bars represent the standard error of the mean (SEM).
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Expression of VEGFR2 mRNA was upregulated during both treatments, indicating an 
activated angiogenesis (Figure 3 i, j). In addition, a reduced expression of the antiapoptotic 
molecule Bcl2 was observed in the biopsies after PDL treatment (data not shown).
In summary, in 6 clinical responders PDL-treatment resulted in decreased mRNA 
expression of TNF-α and IL-23p19 at 7 weeks, and reduced β-defensin 2, keratin 17 and 
Bcl2 at 13 weeks, whereas expression of the angiogenic molecule VEGFR2 was induced. 
In the NB-UVB-treated samples mRNA expressions of these markers showed great variation 
between the patients.
Immunohistochemical alterations 
Skin biopsy samples of all 14 patients were analyzed by immunohistochemistry. To follow 
epidermal alterations, expression of transglutaminase K (TGK), an early differentiation 
marker with strong expression in psoriasis, was assessed. To assess the inflammatory 
components of disease activity, T lymphocyte infiltrates (CD3) was visualized in the dermis. 
Changes in blood vessel content were followed by Von Willebrand factor (VWf) staining, 
whereas endothelial activation was assessed by E-selectin expression. 
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Figure 2. The effects of the PDL on the expression of vascular endothelial growth factor receptors, E-selectin 
and IL-23p19 in psoriatic skin. 
The expression of (a) VEGFR2, (b) VEGFR3, (c) E-selectin and (d) IL-23p19 was determined by RT-PCR in biopsies 
taken from psoriatic lesions before, 3 h and 24 h after PDL treatment in 5 patients with psoriasis. The figures depict 
expression values in individual patients relative to the baseline. At each time point, the mean +/- SEM are marked. 
p-values are shown as calculated with the Wilcoxon signed ranks test. 
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Figure 3. The effects of PDL and UVB on the expression of psoriasis markers in lesional psoriatic skin. 
mRNA expression of (a)-(b) β-defensin 2, (c)-(d) keratin 17, (e)-(f) IL-23p19, (g)-(h) TNF-α and (i)-(j) VEGFR2 
was measured by quantitative RT-PCR in punch biopsies from 6 patients. ABL1 was used as a housekeeping control 
gene. Bars show average expression levels relative to the baseline, error bars represent SEM. p-values are shown as 
calculated with the Wilcoxon signed ranks test. 
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Global improvement of the psoriatic pathology, assessed using H&E staining, was 
observed in about 50% of patients, corresponding with the clinical improvement in psoriasis. 
No significant changes were found in the PDL-treated plaques, whereas in the NB-UVB-
treated plaques TGK and E-selectin expression was significantly decreased after 13 weeks of 
treatment in the group of 14 patients (responders and non-responders) (Figure 4).
We analyzed biopsies from 6 clinical high responders (defined as a PGA reduction 
> 50%) for epidermal and dermal markers of psoriasis, in order to evaluate the effects of 
both treatments. After 14 weeks, epidermal TGK expression and dermal T cell infiltrates 
were markedly reduced by both treatments in these 6 patients (Figure 5a-d). Von Willebrand 
factor expression was significantly decreased in the UVB-treated plaques; a marked, but not 
significant decrease was also noted after PDL treatment (Figure 5 e, f). Expression of the 
endothelial activation marker E-selectin showed a significant decrease in the PDL-treated 
samples after 7 weeks, but this change did not reach significance at week 13. E-selectin 
expression showed a gradual persistent decrease in the NB-UVB-treated lesions (Figure 5 g, h). 
 DISCUSSION
This study shows that clinical improvement of psoriasis due to PDL treatment is 
accompanied by alterations in certain classic markers of psoriasis disease activity. 
The observed effects at the mRNA level were comparable in responders to the PDL- and 
the NB-UVB treatment. The relatively low clinical efficacy of NB-UVB in this study (52% 
improvement versus minimally 60% reported for total body irradiation) may be explained by 
the fact that local NB-UVB treatment was used instead of total body irradiation. It is assumed 
that total body UVB irradiation also exerts a systemic effect (17).
A hallmark of psoriatic skin is the remarkable transformation in the local microvascular 
system characterized by dilation and tortuosity of capillaries, increased permeability, 
and high endothelial venule formation which is usually observed in lymph nodes (18). 
Figure 4. Immunohistochemical staining results in the entire study group. 
Biopsies from 14 patients with psoriasis were taken before and 13 weeks after the start of the study. Immunohistochemical 
staining for epidermal transglutaminase (TGk), CD3, von Willebrand factor (VWF) and E-selectin (E-sel) was 
performed. Staining positivity was quantified using digital image analysis. CD3 positivity was quantified separately 
in the dermis (DCD3). Bars show staining positivity at 13 weeks relative to the baseline. Error bars represent the 
SEM. 
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Figure 5. Immunohistochemical staining results in clinical responders. 
Biopsy samples from 6 clinical responders, taken before the start of treatment and 7 and 13 weeks later were stained 
using antibodies against (a)-(b) transglutaminase K (TGK), (c)-(d) CD3, (e)-(f) von Willebrand factor and (g)-(h) 
E-selectin. Staining positivity was quantified using digital image analysis. Figures depict expression values of 
individual patients relative to the baseline. At each time point, the mean +/- SEM are marked. p-values are shown as 
calculated with the Wilcoxon signed ranks test. 
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Active angiogenesis in psoriatic lesions evidenced by upregulation of VEGF and VEGFR2, 
is accompanied by endothelial cell activation as observed by the upregulation of ICAM-1, 
vascular cell adhesion molecule-1 (VCAM-1) and E-selectin. During this process, vascular 
endothelial growth factor (VEGF) signaling on endothelial cells represents the major rate-
limiting step (18). VEGF acts by engaging with its tyrosine kinase receptors VEGFR1 and 
VEGFR2 in endothelial cells. Although VEGF binds to both receptors, it appears that most of 
its biological functions are mediated via VEGFR2 (18, 19).
Our observation that the early effects of the PDL involve the decreased expression of the 
endothelial molecules VEGFR2 and E-selectin corresponds with its proposed primary target. 
However, an additional early effect was also noted on VEGFR3 (FLT4), a lymph-endothelial 
marker (20). Lymphatics are expanded in psoriasis and VEGFR3 expression is increased in 
both involved and uninvolved psoriatic skin (19). Reduction of VEGFR3 expression early 
after PDL treatment may contribute to its efficacy in psoriasis. 
Interestingly, the expression of VEGFR2 was upregulated at later time points indicating 
re-activation of angiogenesis. This active angiogenesis may counteract the antipsoriatic effect 
of the PDL treatment and may explain the insufficient clinical response in some patients. 
Another possibility might be that the main source of VEGF in psoriatic lesions, the activated 
keratinocyte, is not targeted by PDL treatment. Therefore, activated lesional keratinocytes are 
less inhibited and may continue to stimulate the lesional microvasculature. The upregulation 
of VEGFR2 may explain the enhanced efficacy of PDL treatment when combined with 
calcipotriol ointment, which targets activated keratinocytes (10).
TNF-α and IL-23 are critical cytokines in the pathogenesis of psoriasis, mainly produced by 
inflammatory dendritic cells (DC) in the dermis (21), (22). Their importance is underlined by 
the fact that biologics targeting TNF-α and IL12/IL23p40 are effective in treating psoriasis (23). 
Furthermore, both cytokines are downregulated during treatment with other effective 
therapies (24). Our study shows that after 7 weeks of PDL treatment, TNF-α and IL-23 mRNA 
was downregulated in psoriatic skin, and IL-23 even within 3 h after treatment. In combination 
with the observed reduction in the number of dermal CD3+ T cells, it may indicate that the 
vascular damage induced by PDL treatment may also affect perivascular immune cells.
Markers of keratinocyte activation and of the psoriasis phenotype were only significantly 
reduced at the end of the series of PDL and NB-UVB treatment sessions. Keratin 17 expression 
is high in the psoriatic epidermis, correlating with the clinical severity (25). Keratin 17 is 
considered to be a candidate autoantigen in psoriasis (26). Human β-defensin 2 is a molecule 
with antimicrobial activity, expressed by epidermal keratinocytes under inflammatory 
conditions such as psoriasis (27). Patients with psoriasis have higher genomic copy numbers 
of the gene encoding β-defensin 2 (28) and have higher serum β-defensin 2 levels than 
healthy controls. Serum β-defensin 2 levels were shown to correlate positively with the 
disease severity (29). Since the PDL treatment does not target the epidermis primarily, it is 
conceivable that the PDL-associated decrease in the expression of epidermal keratin 17 and 
β-defensin 2 is secondary to the dermal blood vessel damage and to the subsequent reduction 
in the inflammatory infiltrate and their mediators.
Our finding that PDL treatment is effective in approximately 50% (a subgroup) of patients 
has also been reported by others (30). In our study, the group of PDL-responders could not be 
distinguished from the non-responders in terms of specific baseline expression patterns (data 
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not shown) or immunohistochemical alterations induced by the treatment. Further studies are 
essential for identifying the prognostic markers of PDL-responsiveness in psoriasis.
In conclusion, PDL and local NB-UVB treatment are clinically equally effective in stable 
plaque-type psoriasis. At the end of the treatment period both treatments resulted in reduced 
expression of epidermal markers of keratinocyte activation as well as reduction of dermal 
T cell infiltrates. This indicates that alterations in the expression of markers of psoriasis 
activity do not clearly disclose the clinical treatment modality used and may just reflect clinical 
improvement of the disease. Furthermore we observed early effects of the PDL treatment 
on vascular endothelial growth factor receptors, followed by downregulation of TNF-α and 
IL-23p19. These are previously unrecognized factors for the efficacy of PDL treatment in 
psoriasis. 
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GENERAL DISCUSSION
Narrow-band UVB (NB-UVB) therapy is a standard treatment for moderate to severe 
psoriasis. It is safe in terms of limited carcinogenicity, and achieves high efficacy scores in a 
large proportion of patients (1-5). The mode of action of NB-UVB in psoriasis is incompletely 
understood and much of current knowledge is based on in vitro studies and studies in mice. In 
general, the efficacy of NB-UVB is thought to be mediated via: 1) inhibition of keratinocyte 
proliferation, 2) induction of apoptosis in intraepidermal bone marrow-derived cells (dendritic 
cells, (natural killer) T cells, pDCs), 3) skewing of T cell differentiation from Th1 and Th17 
towards the Th2 phenotype. However, it has become clear that the skin immune system of 
the mouse and the mouse genome differ more from man than previously anticipated (6), 
underscoring the need for studies in patients with active disease. Molecular analysis of the 
impact of NB-UVB on (innate) inflammatory pathways may generate more insight into the 
mode of action of NB-UVB in modifying the pathophysiology of psoriasis and to define 
potential therapeutic target molecules.
In this thesis global transcriptomic effects of NB-UVB therapy in psoriasis are analyzed. 
In our studies we focused on the epidermal compartment, as most UVB radiation is absorbed 
there. In general, the following conclusions were drawn: 
1)  epidermal Th17 and interferon signalling pathways are suppressed by NB-UVB; 
2)  NB-UVB downregulates innate cytosolic RNA receptors in psoriasis; and 
3)  epidermal GATA3 expression is induced by NB-UVB, and might be the basis of the
  antiproliferative effects of UVB (see also Box 1). 
In addition, we demonstrated that UVB-effects in non-lesional skin cannot simply 
be extrapolated to the mode of action in active lesions, which emphasizes the need for in 
vivo studies in lesional psoriatic skin. In order to clarify the involvement of Th17 pathway 
components such as the double-stranded RNA receptors melanoma differentiation-associated 
gene (MDA) 5, retinoic acid-inducible gene (RIG)-I, the transcription factor GATA3 in 
the therapeutic effectiveness of NB-UVB, in vitro, ex vivo and murine experiments were 
performed. All these molecules are known to be expressed by epidermal keratinocytes 
(7-9), and our epidermal samples, both lesional and non-lesional, are composed of 95% 
keratinocytes. Therefore, while investigating the roles of these molecules in psoriasis, we 
decided to study only epidermal cells in vivo and keratinocytes in vitro. However, since other 
cell types are also present in the epidermis, changes in expression within these cells (e.g. 
Langerhans cells, melanocytes, Merkel cells), or the UVB-induced change in the cellular 
composition of the epidermis (e.g. depletion of T lymphocytes, myeloid dendritic cells (DC) 
and neutrophilic granulocytes) probably also contributed to the gene expression changes we 
observed. However, the DC/Langerhans cell markers CD1a, CD1c and CD207/Langerin and 
the T cell markers CD3, CD4 and CD8 were not differentially expressed between samples 
taken before and after UV-therapy. We did detect an induction of genes involved in melanin 
synthesis, such as tyrosinase and melan-A, indicating melanocyte activation. We concluded 
that our expression data mainly represented gene expression profiles of cells other than DC, 
Langerhans cells or T lymphocytes. However, when evaluating the function of STAT3, MDA5 
or GATA3 in psoriasis, roles of these molecules in inflammatory cells and melanocytes should 
also be considered. Below, the results on the molecular targets of NB-UVB therapy in psoriasis 
are summarized and discussed in view of the future prospects of this field of research.
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The Th17 pathway as potential therapeutic target in psoriasis
Th17 cells are induced primarily by DC-derived IL-23, via the IL-23 receptor on their 
surface, made up of two subunits, IL-23R and IL-12Rβ1 (10). In the presence of IL-23, Th17 
cells produce Th17 cytokines, including IL-17A, IL-17F, IL-6, TNF-α, IL-21 and IL-22. Th17 
pro-inflammatory cytokines stimulate keratinocyte proliferation as well as drive inflammatory 
cell activation, migration and action, especially that of neutrophil granulocytes, in the skin. 
Thus they contribute to the formation of psoriatic lesions and lead to the persistent, low-grade 
inflammation characteristic of psoriasis. Many actions of the Th17 cytokines IL-21, IL-22 and 
IL-6 are mediated by the transcription factor STAT3.
We have found that NB-UVB therapy downregulated several components of the Th17 
pathway, such as STAT3 and its transcriptional targets (e.g. β-defensin 2, keratin 16, 
IL-20R, S100A7, S100A9) in the psoriatic epidermis (Figure 1). Direct inhibition of STAT3 
phosphorylation was shown in an ex vivo skin organ culture system where the number of IL-
22-induced phosphorylated STAT3-positive cell nuclei was reduced by subsequent NB-UVB 
treatment, as early as 6 h after irradiation. In addition, IL-22-induced expression of β-defensin 
2 mRNA was inhibited by NB-UVB. 
Other anti-psoriatic therapies also affect the Th17 pathway, which emphasizes the 
importance of this pathway in the resolution of psoriatic inflammation. The Th17 pathway 
Box 1. Main conclusions
• Clearance of psoriasis by NB-UVB therapy is associated with suppression of type 
I and type II interferon signalling and downregulation of the Th17 pathway in the 
lesional epidermis. NB-UVB inhibits the phosphorylation of STAT3, resulting in 
reduced expression of its transcriptional targets, for example the antimicrobial 
peptide β-defensin 2.
• NB-UVB treatment downregulates the expression of the activating dsRNA receptors 
RIG-I and MDA-5 in lesional epidermis of patients with psoriasis. Activation of 
these innate antigen receptors by virus- or host cell-derived dsRNA induces the 
production of type I interferons, which in turn activate adaptive immune responses. 
Thus, inhibition of these molecules by NB-UVB contribute to the anti-inflammatory 
effects of the treatment.
• NB-UVB therapy induces the expression of the transcription factor GATA3 in 
psoriasis. GATA3 in the epidermis induces the expression of anti-inflammatory 
and proapoptotic molecules, and regulators of epidermal differentiation. These 
GATA3 targets might be involved in the improvement of psoriatic inflammation by  
NB-UVB. We also provide evidence that proinflammatory mediators that are 
critical in the pathogenesis of psoriasis do not suppress or regulate epidermal 
GATA3 expression.
• The pulsed dye laser (PDL) is an effective therapeutic option for recalcitrant 
psoriasis. We show early effects of PDL on the expression of E-selectin and vascular 
endothelial growth factor receptors, followed by downregulation of TNF-α and  
IL-23p19. NB-UVB and PDL treatments were found to induce quite similar 
expression changes after 14 weeks of treatment.
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is modulated in the psoriatic skin during treatment with Cyclosporine A, a standard effective 
therapy for psoriasis (11). This modulation was observed already 2 weeks after the start of 
treatment and correlated well with the clinical improvement of the disease (11). Etanercept 
(TNF receptor – immunoglobulin fusion protein), another effective treatment modality in 
psoriasis, also had early inhibitory effects on Th17 cells (12). 
Direct inhibition of this pathway is achieved by the novel anti IL-12/IL-23 p40 therapies, 
such as the recently approved ustekinumab and ABT-874. These drugs seem to clear psoriasis 
very effectively and their clinical effect lasts much longer than the half-life of the drugs (13-15).
Even more specific inhibition of this pathway could be achieved by inhibition of IL-22 or 
IL-17. IL-17 targeted approaches are being developed for the treatment of psoriasis and other 
autoinflammatory diseases, and have now progressed towards Phase II clinical trial testing in 
patients with psoriasis (16). IL-22 has been successfully targeted using an anti-IL-22 antibody 
and IL-22-small interfering RNA in animal and in vitro models of lung cancer where its 
expression is also increased (17). These approaches might find their way to into the clinic for 
the treatment of psoriasis. 
In addition, selective inhibition of STAT3 phosphorylation is another way of targeting 
the Th17 pathway. Constitutive STAT3 activation has been linked to cancer initiation, 
proliferation, promotion of angiogenesis and inhibition of apoptosis. STAT3 is involved in 
Beta-defensin 2
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Figure 1. NB-UVB inhibits the phosphorylation of STAT3.
IL-22, a cytokine secreted by Th17 cells, induces the phosphorylation of STAT3. Phosphorylated STAT3 translocates 
to the nucleus and induces the transcription of genes involved in the depicted functions. NB-UVB inhibits the 
phosphorylation of STAT3, which leads to decreased expression of the STAT3 target genes.
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the induction and survival of cancer cells. Several strategies have been pursued to inhibit the 
STAT3 pathway as a therapeutic approach in treating cancers. Small molecules such as LLL-3 
(18), STA-21 (19), Stattic (20) and DNA decoys (21) bind to STAT3, abrogating its ability 
to bind to its response elements on DNA. STAT3 DNA decoys were successfully applied 
in experimental models of squamous cell carcinoma in combination with EGFR and BCL2 
antagonists (22). In summary, several strategies have been developed for the inhibition of 
STAT3 phosphorylation and activation, although it has yet to be demonstrated that inhibition 
of STAT3 phosphorylation is sufficient to clinically improve psoriasis. 
All above mentioned agents require extensive testing in in vitro and in murine models 
of psoriatic inflammation, before their efficacy and safety can be evaluated in patients with 
psoriasis.
Involvement of MDA5 and RIG-I in the anti-inflammatory effect of NB-UVB 
Retinoic acid inducible gene (RIG)-I and melanoma differentiation-associated gene 
(MDA) 5 bind virus- or host cell-derived double-stranded (ds)RNA with or without a 
5’ triphosphate end. Upon activation these cytosolic receptors stimulate the production 
of type I interferons, via activation of the transcription factor IRF3 (8). Type I interferons 
play essential roles in the initiation of psoriatic inflammation (23). Furthermore, type I IFN 
signalling is activated in psoriatic plaques (24). We postulated previously that dsRNA receptors 
play a role in the maintenance of chronic inflammation in psoriasis. We have shown that NB-
UVB treatment downregulates the expression of RIG-I and MDA-5 in lesional epidermis of 
patients with psoriasis (Figure 2). A rapid effect of NB-UVB on dsRNA receptor expression 
was demonstrated in cultured primary keratinocytes. NB-UVB irradiation suppressed the type 
I and type II IFN-induced expression of all activating dsRNA-receptors as early as 2 hours 
after irradiation, whereas expression of the negative regulator LGP2 remained unaffected. 
The proinflammatory response induced by dsRNA in keratinocytes was reduced by NB-UVB-
irradiation. NB-UVB irradiation, in such a manner, interrupts the positive feedback loop of 
epidermal inflammation in psoriasis (Figure 2). 
The exact mechanism of this suppressive effect requires further investigation. Broadband 
UVB inhibits IFN-γ-induced STAT1 phosphorylation in mouse keratinocytes (25). It would 
be worthwhile investigating whether inhibition of STAT1 phosphorylation also occurs 
in primary human keratinocytes upon NB-UVB radiation, and whether the expression of 
activating dsRNA receptors depends on STAT1 phosphorylation in these cells. Alternatively, 
NB-UVB might directly affect these receptors in the cytoplasm, or again through formation of 
ROS. Effect of NB-UVB on cytosolic innate RNA receptors was not demonstrated previously. 
The inhibitory effect we describe might contribute to the worsening or reactivation of herpes 
simplex virus (HSV) infection upon UVB exposure, as RIG-I-like helicases are involved in 
the immune response to HSV (26). In addition, many questions on the role of these receptors 
in the pathophysiology of psoriasis and their usefulness as therapeutic targets remain open. 
Further studies need to clarify whether specific inhibition or blockade of MDA5 or RIG-I 
affects psoriatic inflammation. Our imiquimod-induced skin inflammation model could be 
used to answer this question. In addition, overexpression of MDA5 and RIG-I in keratinocytes 
prior to UVB irradiation could demonstrate whether these molecules are indeed involved in 
the suppression of the inflammatory response to dsRNA by NB-UVB.
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Role of GATA3 induction in the improvement of psoriatic inflammation
The transcription factor GATA3 has regulatory roles during the formation of the epidermal 
barrier and during desquamation (27-29). In addition, GATA3 also regulates the differentiation 
of T lymphocytes, stimulating the development of Th2 cells and inhibiting the skewing 
towards the Th1 phenotype (30, 31). In addition, in breast cancer low GATA3 expression is 
associated with early metastasis and poor prognosis, whereas high GATA3 expression with 
less metastasis and better prognosis (32).
NB-UVB phototherapy upregulated the expression of GATA3 in lesional psoriatic epidermis 
(Figure 3), where GATA3 expression was lower than in non-lesional skin. Interestingly, 
GATA3 was also upregulated by Cyclosporin A treatment, correlating with the clinical 
improvement (33). We demonstrated that low epidermal expression of the transcription factor 
GATA3 is associated with altered keratinocyte proliferation and differentiation in psoriasis 
and a murine psoriasis-like skin inflammation model. We also showed that proinflammatory 
mediators that are critical in the pathogenesis of psoriasis did not suppress epidermal GATA3 
expression. This finding suggests that either low GATA3 expression is an inherent abnormality 
in the psoriatic epidermis, resulting in hyperproliferation and barrier abnormalities comparable 
to GATA3-/- mice, or it may be that other mediators are responsible for its suppression. 
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Figure 2. NB-UVB downregulates the expression of MDA-5 and RIG-I. 
Psoriatic keratinocytes are characterized by high expression of the activating cytoplasmic dsRNA receptors MDA-5 
and RIG-I, and thereby display enhanced sensitivity to virus- or host cell-derived dsRNA. Binding of these receptors 
to dsRNA results in the production of type I interferons. NB-UVB downregulates the expression of MDA-5 and RIG-I 
in the psoriatic epidermis, and limits thereby the sensitivity of these cells to dsRNA. IRF3: interferon regulatory 
factor 3
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General Discussion
Interestingly, GATA3 overexpression resulted in reduced STAT3 expression in mice (34), 
suggesting that upregulation of GATA3 by NB-UVB might be upstream of the suppression of 
STAT3-dependent events as discussed above. 
To identify the molecular effects of low GATA3 expression in psoriasis, we first constructed 
a list of genes known to be related to GATA3, i.e. differentially regulated in epidermis-specific 
GATA3-/- mice as compared to wild type mice. We then selected those genes from this list 
that were regulated in the same way (i.e. up or down) in lesional psoriatic skin (characterized 
by low GATA3 expression) versus non-lesional skin. The resulting group of genes included 
negative regulators of inflammation, such as the psoriasis susceptibility gene TNFAIP3 (35, 
36) and the Notch ligand jagged 2 (37), genes regulating epidermal differentiation, such as 
the transcription factor AP2-α (TFAP2A) (38), or the apoptosis-inducing FAS molecule. 
NB-UVB therapy induced the expression of these genes in the psoriatic epidermis, together 
with that of GATA3, which might lead to the anti-psoriatic effects of NB-UVB (Figure 3). 
In addition, the transcription factors FOXN3, FOXO1 and FOXP1 were also regulated together 
with GATA3. These molecules play regulatory roles in organ development (39), metabolism 
(40) and cell proliferation (41), respectively. 
An upstream regulator of GATA3, the p53 homolog molecule p63 (42) is induced by 
DNA damage as caused by UV radiation, Actinomycin D and other genotoxic agents (43, 44). 
Induction of p63 leads to differentiation of cancer cells (in contrast to the induction of p53 by 
the same agents, which resulted in apoptosis) (43). Although we did not detect p63 induction 
in lesional psoriatic skin by NB-UVB at the time point studied, induction of p63 expression 
Inflammation
Keratinocyte
Ortho-differentiation Apoptosis
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FASTFAP2AJAGGED 2TNFAIP3
GATA3
DNA
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Figure 3. NB-UVB induces the expression of the transcription factor GATA3. 
Expression of the transcription factor GATA3 is low in the psoriatic epidermis, potentially leading to low expression 
of anti-inflammatory and pro-apoptotic GATA3 targets. NB-UVB induces the expression of GATA3 which might 
contribute to the antipsoriatic effect of this treatment. TNFAIP3: Tumor necrosis factor, alpha-induced protein 3
TFAP2A: Transcription factor AP-2 alpha 
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might be an upstream event to the observed upregulation of GATA3 in our experimental 
systems.
The dermal vasculature as therapeutic target in psoriasis
This study shows that clinical improvement of psoriasis due to PDL treatment is accompanied 
by alterations in some classic markers of psoriasis disease activity. In responders to PDL 
and NB-UVB treatment, the treatment effects observed at the mRNA level were comparable. 
Our observation that the early effects of PDL involve reduction of the endothelial molecules 
VEGFR2 and E-selectin, corresponds with its proposed primary target (Figure 4). However, 
an additional early effect was detected on VEGFR3 (FLT4), a lymph-endothelial marker (45). 
Lymphatics are expanded in psoriasis, and VEGFR3 expression is high in both involved and 
uninvolved psoriatic skin (46). Reduction of VEGFR3 expression early after PDL treatment 
may contribute to its efficacy in psoriasis. After 2 treatment sessions with PDL, TNF-α and 
IL-23p19 mRNA expression was suppressed in the psoriatic plaques, which is probably a 
consequence of the primary PDL-effects on the dermal vasculature (Figure 4). 
Interestingly, expression of VEGFR2 was upregulated at later time points, which is 
suggestive of re-activation or recovery of angiogenesis. This active angiogenesis might 
counteract the antipsoriatic effect of PDL treatment and might account for insufficient clinical 
response in some patients. Another possibility might be that the main source of VEGF in 
psoriatic lesions, the activated keratinocyte, is not targeted by PDL treatment. Activated 
lesional keratinocytes therefore, are less inhibited and may keep stimulating the lesional 
microvasculature. The enhanced efficacy of PDL treatment when combined with calcipotriol 
ointment, which targets activated keratinocytes, may be explained by the inhibitory effects of 
calcipotriol ointment on keratinocyte-derived VEGF (47).
In conclusion, PDL and local NB-UVB treatment are clinically equally effective in chronic 
plaque psoriasis. At the end of the treatment period both treatments resulted in reduced 
expression of epidermal markers of keratinocyte activation as well as reduction of dermal 
T cell infiltrates. This indicates that alterations in the expression of markers of disease activity 
in psoriasis do not clearly disclose the clinical treatment modality used and seem to reflect 
clinical improvement of the disease. Furthermore we show early effects of the pulsed dye 
laser on vascular endothelial growth factor receptors, followed by downregulation of TNF-α 
and IL-23p19, previously unrecognized factors of PDL efficacy in psoriasis. 
Limitations
As all research, the studies described in this thesis were also limited by several factors. 
In the microarray study we were in the first place restricted in the number of skin biopsies per 
patient because of ethical reasons. Our initial experimental design was based on collecting 
10 biopsies per patient. This relatively high number of biopsies hampered the inclusion 
of patients, which therefore took a longer period than foreseen. It is difficult, in terms of 
kinetics, to determine the optimal time point to look for targets directly affected by UVB. 
During NB-UVB therapy incremental UVB doses are applied in order to maintain the safety of 
the treatment, and the first irradiation (70% MED) is too low to have therapeutically relevant 
effects. The low starting dose is probably the explanation of the limited gene expression 
effects we observed on the short term. 
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General Discussion
We have chosen to focus on the epidermis in our studies, as most of NB-UVB radiation is 
absorbed there. However, some of the radiation might reach the dermis, and as immune cells 
are more sensitive for UVB effects (48, 49), dermal effects might be therapeutically relevant. 
Furthermore, the epidermal samples we used are still composed of different types of cells. 
An elegant approach would be to study cell-specific gene expression profiles, however, as in 
this study 3 mm biopsy samples were taken, further reduction of the studied sample size by 
separation of specific cell types would have lead to insufficient RNA quantities for the gene 
expression arrays. 
For the validation of the induction of GATA3 expression by NB-UVB, the imiquimod-
induced psoriasis-like mouse model was used. In spite of the striking similarities of the 
imiquimod-induced skin inflammation in mice with human psoriasis there are also important 
differences, one being that inflammation induced by imiquimod treatment was not maintained 
chronically in this model at that time. Accordingly, NB-UVB treatment, which requires 
application for several weeks before being efficacious in humans, could only be applied three 
times in the mouse model. 
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Figure 4. The 585 nm pulsed dye laser disrupts the vicious circle of psoriatic inflammation. 
The dermal microvasculature contributes to the maintenance of chronic inflammation by high expression of 
E-selectin, a homing receptor of leukocytes, and the angiogenic VEGFR2. PDL destroys dermal blood vessels, 
resulting eventually in decreased expression of inflammatory components of psoriasis, such as TNF-α and IL-23p19. 
PSGL1: P-selectin glycoprotein ligand-1
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In the comparative study between the pulsed dye laser and the topical NB-UVB, 
limited cellular and molecular effects of NB-UVB were found, especially at mRNA level. 
However, clinical efficacy of NB-UVB in this study was also somewhat lower than would 
be expected based on published results. The lower clinical efficacy of NB-UVB in our study 
(52% improvement versus minimally 65-70% reported for total body irradiation) may be 
explained by the fact that local NB-UVB treatment was used instead of total body irradiation. 
It is assumed that total body UVB irradiation also exerts a systemic effect (50). 
Areas for future research
Gene expression profiling gives a global picture of actual mRNA levels in tissue samples at 
a certain time point. Such an approach is a great instrument to generate hypotheses on cellular 
and molecular mechanisms. Based on gene expression profiling during NB-UVB therapy 
of psoriasis and on additional experiments in vitro, ex vivo and in mice we discovered and 
subsequently hypothesized that STAT3 phosphorylation, cytosolic innate dsRNA receptors and 
GATA3 are involved in the resolution of psoriatic inflammation. Future studies are necessary 
to further unravel the exact mechanism by which UVB affects their expression and function, 
and whether these molecules are suitable therapeutic targets in psoriasis, and to establish 
whether specific targeting of any of those molecules is sufficient to improve psoriasis. 
The involvement of GATA3 in both epidermal and Th2 differentiation suggests a 
possible regulatory role for GATA3 in psoriasis, a disease characterized by disturbed 
epidermal differentiation and enhanced Th1/Th17 responses. Interestingly, polymorphisms 
in the GATA3 gene are described in atopic dermatitis, another chronic inflammatory skin 
disease with epidermal hyperplasia (51). Haploinsufficiency of the GATA3 gene causes the 
very rare HDR (hypoparathyroidism, sensorineural deafness and renal dysplasia) syndrome 
(52). Generalized psoriasis has been described in a patient with the HDR syndrome (53). 
Taken together, these data point out that it might be worthwhile to look for genetic variations 
in the GATA3 gene in patients with psoriasis. 
As in our study complete epidermis was used as a basis for gene expression profiling, 
further studies may investigate whether cells other than keratinocytes contribute to the 
described expression changes. Because of the low starting dose of standard NB-UVB 
therapy (70% MED), we could not detect direct targets of NB-UVB in our in vivo study. 
Other experimental approaches are required in order to identify these targets. Involvement 
of DNA damage in anti-inflammatory NB-UVB-effects can be studied by cell-specific 
overexpression of DNA repair photolyases (54). With this method identification of the cell 
type where DNA damage has to occur for the anti-inflammatory effect of NB-UVB would be 
possible, e.g. in the IMQ-induced skin inflammation model in mice, which we showed to be 
improved by NB-UVB. Involvement of reactive oxygen species could in turn be studied by 
application of blockers such as N-acetylcystein. 
This thesis did not address the quantitative and functional changes in epidermal sub-
populations such as Langerhans cells and regulatory T cells upon NB-UVB treatment. 
As Langerhans cells and regulatory T cells display clear abnormalities in psoriasis, and UVB 
is known to affect these cells in normal skin, it is tempting to speculate that the efficacy of 
NB-UVB therapy in psoriasis is partly due to its effect on these cells.
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General Discussion
As of the targeting of dermal microvasculature by the pulsed dye laser, we found that VEGFR2 
and VEGFR3 were downregulated at very early time points. Later on during therapy VEGFR2 
expression was induced by PDL. We speculated that this upregulation of VEGFR2 would 
probably counteract the therapeutic effect of PDL. However, this hypothesis should be tested 
in larger group of patients and also during other therapies, and correlation of the clinical 
response with VEGFR2 expression should be examined. Our finding that PDL treatment is 
effective in approximately 50% (a subgroup) of patients has also been reported by others (55). 
In our study, the group of PDL-responders could not be distinguished from the non-responders 
in terms of specific baseline expression patterns or immunohistochemical alterations induced 
by treatment. This may be addressed in future studies.
Besides psoriasis, NB-UVB phototherapy effectively clears a broad array of skin diseases 
such as atopic dermatitis, vitiligo, early-stage T cell lymphoma, chronic urticaria, lichen 
planus, polymorphic light eruption, seborrhoic dermatitis, pruritus and acquired perforating 
dermatosis (reviewed by Gambichler (56) and by Berneburg (57)). An interesting question is 
to which extent the mechanisms of NB-UVB action we identified in psoriasis are comparable 
with its effect in other skin diseases. Examination of expression changes in different target 
genes in these diseases during treatment would also extend the understanding of their 
pathophysiology.
Concluding remarks
In conclusion, gene expression profiling of psoriatic epidermal samples before, during and 
after NB-UVB therapy revealed interferon signalling and Th17 (STAT3-regulated) pathways, 
as well as the cytosolic innate RNA receptors MDA5 and RIG-I and the transcription factor 
GATA3 as target molecules of the therapy that might account for the efficacy of NB-UVB in 
Box 2. Outstanding research questions
• What is the primary target of UVB in the psoriatic epidermis? If it is DNA, in 
which cells does the UVB-induced mutated DNA result in the resolution of 
inflammation? 
• Are reactive oxygen species and cytoprotective enzymes important for the 
improvement of inflammation by NB-UVB? Does the higher expression of 
cytoprotective enzymes in lesional psoriatic skin play a role in the efficacy of  
NB-UVB?
• Are STAT3, MDA5, RIG-I and GATA3 valid therapeutic targets in psoriasis? Does 
inhibition (or, in the case of GATA3, induction) of only one of these molecules 
sufficient to limit psoriatic inflammation? 
• Do the migratory properties of Langerhans cells and the suppressive function of 
regulatory T cells change during NB-UVB therapy of psoriasis?
• Are the interferon signalling and the Th17 pathways, cytosolic RNA receptors and 
GATA3 involved in the pathophysiology of other skin diseases that can be treated 
with NB-UVB?
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psoriasis. These results at the same time indicate critical involvement of these pathways and 
molecules in the pathophysiology of psoriasis. They might be essential for the development 
and maintenance of the activated, regenerative epidermal phenotype which is characteristic 
for psoriasis. 
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Summary
SUMMARy
Psoriasis is a chronic inflammatory skin disease, characterized by elevated, red, 
scaly plaques at specific body sites. Psoriasis affects 2-3% of the Western population. 
Treatment of patients with psoriasis is often challenging as long-term use of most available 
therapies is limited by their side-effects. The aim of this thesis was to illuminate the molecular 
effects of narrow-band (NB-) UVB phototherapy, a highly effective systemic treatment 
modality in psoriasis, in order to clarify the mechanism of the resolution of psoriatic skin 
inflammation and the immune pathogenesis of the disease. In addition, by identification of 
pathways that are responsible for the effectiveness of NB-UVB we aimed for detecting novel 
potential therapeutic target molecules for the treatment of psoriasis. For this, in vivo and in 
vitro approaches were applied. 
First, patients with psoriasis undergoing standard NB-UVB phototherapy were recruited, 
and skin biopsy samples were collected before, during and after the therapy both from lesional 
and non-lesional skin. To analyze immediate effects of NB-UVB, samples were collected 
six hours after the first treatment session. To be able to correlate the results with the clinical 
severity, additional samples were collected when PASI scores reached 50% of the baseline. 
The epidermis was separated from the dermis, RNA was extracted, and gene expression 
profiling was performed. Chapter 2 describes the global results of this in vivo study. 
NB-UVB phototherapy significantly downregulated Th17 and interferon signalling pathways 
in psoriatic epidermis. IL-22, a T-cell-derived Th17 cytokine that signals via phosphorylation 
of signal transducer and activator of transcription (STAT) 3, induces the expression of 
β-defensin 2, S100A7 and S100A9, lipocalin 2 and the IL-20 receptor B. All these molecules 
were suppressed by NB-UVB therapy. We referred to this pathway as Th17 pathway because 
of this IL-22-dependent regulation. In addition, pathways that are known therapeutic targets 
in psoriasis, such as the glucocorticoid, vitamin D, peroxisome proliferator-activated receptor 
and IL-4 signalling were affected by phototherapy. The response to NB-UVB six hours after 
the first treatment session involved different, and much fewer genes in lesional skin than in 
non-lesional skin. Direct inhibition of the Th17 pathway by UVB was confirmed in an ex vivo 
organ culture system by reduced STAT3 phosphorylation and β-defensin-2 production. 
Since our group previously demonstrated high expression of innate cytosolic receptors for 
double-stranded RNA (dsRNA) in psoriatic lesions, we used the microarray data to specifically 
search for this interferon-inducible pathway. As described in Chapter 3, expression of the 
dsRNA receptors melanoma differentiation associated gene (MDA) 5 and retinoic acid-
inducible gene (RIG)-I were higher in lesional epidermis than in non-lesional samples, and 
NB-UVB therapy downregulated the expression of these two molecules in lesional skin, 
leaving the expression of the other three dsRNA receptors (TLR3, PKR and LGP2) unaffected. 
The ligand of RIG-I and MDA5 is dsRNA with or without a 5’ triphosphate end, which can 
be a byproduct of viral replication or derived from necrotic host cells. Activation of these 
receptors leads to type I interferon production. Type I interferons play essential roles in the 
initiation of psoriatic plaque formation. Furthermore, type I IFN signalling is activated in 
psoriatic plaques. In psoriasis, high epidermal expression of MDA5 and RIG-I is found in 
keratinocytes. To investigate whether downregulation of MDA5 and RIG-I by NB-UVB is 
only an epiphenomenon of resolving psoriasis or is a direct effect of UV, primary keratinocytes 
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were cultured with IFN-α or IFN-γ to upregulate dsRNA receptors (to mimic the psoriatic 
situation). Subsequent NB-UVB treatment suppressed the expression of all activating dsRNA 
receptors already within 2 hours after irradiation, and not affected the negative regulator 
LGP2. Thus, NB-UVB irradiation crippled the local innate inflammatory response induced by 
dsRNA. Since high expression of MDA5 and RIG-I possibly contributes to the maintenance 
of chronic inflammation in psoriasis, suppression of dsRNA receptor expression might play a 
role in the clinical efficacy of NB-UVB phototherapy in psoriasis. 
We detected low expression of the transcription factor GATA3 in lesional samples before 
treatment as compared to non-lesional samples, by microarray analysis. GATA3 has regulatory 
roles during the differentiation of both epidermal keratinocytes and T helper lymphocytes. 
In the skin GATA3 regulates epidermal barrier formation and desquamation. In T lymphocytes 
it stimulates the development of the T helper 2 phenotype and at the same time inhibits Th1 
differentiation. GATA3 expression was induced by NB-UVB, inversely correlating with the 
clinical improvement of psoriasis. The correlation of GATA3 expression and skin inflammation 
is further analysed in Chapter 4. The imiquimod (IMQ)-induced murine skin inflammation 
model was used. After demonstrating the beneficial effect of NB-UVB in IMQ-induced skin 
inflammation in mice, similarly to its effectiveness in human psoriasis, GATA3 expression 
was determined in the mouse skin at mRNA and protein levels. GATA3 expression was lower 
in IMQ-treated skin than in skin treated with control cream. Additional NB-UVB treatment 
induced GATA3 expression. In addition, low GATA3 expression was detected in wounded 
mouse skin, demonstrating the association of low GATA3 expression with the regenerative 
epidermal phenotype. Epidermal GATA3 expression was not suppressed by IFN-α, IFN-γ 
or IL-22 in a human ex vivo skin culture system, suggesting that low GATA3 expression in 
psoriasis is not secondary to the presence of immune cell-derived inflammatory mediators. 
Most of NB-UVB radiation is absorbed by the epidermis, which prompted us to focus on 
the epidermis in all the studies discussed above. However, psoriatic inflammation cannot be 
maintained without cells and molecules that are located in the dermis. Not only immunocytes, 
such as plasmacytoid and myeloid dendritic cells and T lymphocytes are critical for the 
formation of psoriasis plaques, but also vascular factors play a role in the inflammatory 
process. Although vascular remodelling is a hallmark of psoriasis, anti-vascular strategies 
for treating these conditions receive little attention. The pulsed dye laser (PDL) selectively 
destroys the dermal microvasculature which can result in partial or complete disappearance of 
psoriasis plaques. In Chapter 5 cellular and molecular effects of the PDL are compared with 
those of the epidermis-targeted NB-UVB. At the end of the 14-week-long treatment period 
no significant differences were detected between the cellular and molecular effects of the 
two therapies, and the clinical efficacy was also comparable. However, PDL suppressed the 
expression of the receptors for vascular endothelial growth factor 2 and 3 already three hours 
after treatment, and that of E-selectin after 24 hours. After 2 PDL treatments IL-23 and TNF-α 
mRNA and E-selectin protein expression were significantly reduced. These early effect of 
PDL might contribute to its efficacy in psoriasis. 
In conclusion, in this thesis novel mechanisms of NB-UVB action in psoriasis are revealed. 
We have shown that NB-UVB therapy affects 1) STAT3 and the Th17 pathway which in the 
epidermis is represented by antimicrobial peptides; 2) the interferon-induced innate dsRNA 
receptors MDA5 and RIG-I, and 3) the transcription factor GATA3 with involvement in 
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the proliferation and differentiation of epidermal keratinocytes. Our findings indicate that 
these molecules and pathways are critical in the pathophysiology of psoriasis and might 
represent novel therapeutic targets. Further studies need to investigate the possibilities of 
specifically modulate these molecules and to determine their usefulness as therapeutic targets 
in psoriasis.
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Psoriasis, een chronische ontsteking van de huid wordt gekenmerkt door erythemateuze 
schilferende plaques op specifieke lichaamsdelen. Twee tot drie procent van de westerse 
populatie lijdt aan psoriasis. De behandeling van psoriasispatiënten is uitdagend want 
langetermijngebruik van de meeste effectieve therapieën wordt beperkt door bijwerkingen.
Het doel van dit proefschrift was om de moleculaire effecten van smalband UVB (SB-
UVB) therapie, een zeer effectieve systemische antipsoriatische therapie, te identificeren om 
inzicht te krijgen in de mechanismen van de opklaring van psoriatische huidontsteking en 
in de immunopathogenese van psoriasis. Een verder doel was om moleculaire pathways te 
detecteren die verantwoordelijk zijn voor de verbetering van de psoriatische ontsteking en 
daardoor targets van toekomstige therapieën kunnen zijn. In vivo en in vitro methoden zijn 
toegepast.
Ten eerste zijn er huidbiopten genomen van aangedane en niet aangedane huid van 
psoriasispatiënten voor, tijdens en na SB-UVB therapie. Om de directe targets van SB-UVB 
te kunnen identificeren zijn er biopten genomen 6 uur na de eerste UVB belichting. Om 
een verband te kunnen leggen tussen de moleculaire resultaten en het klinisch effect van de 
behandeling zijn er verdere biopten verzameld enkele weken na de start van de behandeling, 
toen de PASI scores 50 % van de baseline hadden bereikt. Epidermis werd gescheiden van 
de dermis, epidermale RNA werd geïsoleerd, en de globale genexpressie werd geanalyseerd 
met behulp van microarrays. De resultaten hiervan zijn beschreven in Hoofdstuk 2. Th17 en 
interferon signalering pathways werden geremd in de psoriatische epidermis door SB-UVB. 
IL-22 is een van de zogenaamde Th17 cytokinen. IL-22 stimuleert de fosforylatie van het 
molecuul signal transducer and activator of transcription (STAT) 3, en dit leidt tot verhoogde 
expressie van o.a. β-defensine 2, S100A7, S100A9, lipocalin 2 en de IL-20 receptor B. 
Al deze moleculen werden geremd door NB-UVB fototherapie. Dit pathway werd in dit 
proefschrift Th17 pathway genoemd, vanwege de inductie hiervan door IL-22. Ook pathways 
die bekende therapeutische targets zijn in psoriasis werden beïnvloed door SB-UVB therapie, 
onder andere glucocorticoid, vitamine D, peroxisome proliferator-activated receptor en IL-4 
signalering pathways. In aangedane en niet aangedane huid van de patiënten werden volkomen 
verschillende genen beïnvloed door SB-UVB, wat het belang benadrukt van in vivo studies 
in ontstoken huid. Expressie van weinig genen veranderde 6 uur na de eerste belichting in 
aangedane huid. Een direct effect van SB-UVB op het Th17 pathway werd aangetoond in ex 
vivo gekweekte normale huidbiopten, waar SB-UVB de fosforylatie van STAT3 en de mRNA 
expressie van β-defensine 2 heeft geremd. 
Twee type I interferongeïnduceerde dubbelstrengs RNA (dsRNA) receptoren, melanoma 
differentiation-associated gene (MDA) 5 en retinoic acid-inducible gene (RIG)-I werden 
ook geremd door SB-UVB in de psoriatische epidermis. In Hoofdstuk 3 hebben wij verder 
onderzocht welke rol deze moleculen in het antipsoriatische effect van SB-UVB zouden 
kunnen spelen. MDA5 en RIG-I binden aan dsRNA die afkomstig kan zijn uit virussen of uit 
necrotische cellen van de host. Activatie van MDA5 en RIG-I leidt tot de synthese van type I 
interferonen, die belangrijk zijn in de beginfase van de ontwikkeling van psoriatische plaques. 
Type I interferon signalering is geactiveerd in aangedane psoriatische epidermis. Wij hebben 
eerder al aangetoond dat deze receptoren hoog tot expressie kwamen in psoriasis, en dat ze 
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vooral in epidermale keratinocyten werden gelokaliseerd. Om verder te onderzoeken of de 
lage dsRNA receptor expressie na SB-UVB therapie een direct effect is van UVB of alleen 
een gevolg van de verbetering van de ontsteking, hebben we kweek van primaire humane 
keratinocyten gebruikt. Expressie van dsRNA receptoren werd geïnduceerd (om de situatie in 
psoriatische huid na te bootsen) door toevoeging van IFN-α of IFN-γ. In cellen die hiernaast 
ook zijn belicht met SB-UVB ging de expressie van de activerende dsRNA receptoren 
TLR3, MDA5, RIG-I en PKR niet omhoog, maar die van de negatieve regulator LGP2 wel. 
SB-UVB heeft dus de lokale response op dsRNA verlamd. De hoge expressie van MDA5 en 
RIG-I draagt mogelijk bij aan het in stand houden van de chronische ontsteking in psoriasis, 
en de remming van dit pathway kan een rol spelen in de klinische effectiviteit van SB-UVB 
in psoriasis. 
Door middel van microarray onderzoek lage expressie van de transcriptiefactor GATA3 
werd gedetecteerd in aangedane huid van de patiënten, en expressie van deze transcriptiefactor 
werd gestimuleerd door SB-UVB therapie. GATA3 is betrokken in de differentiatie van 
zowel keratinocyten als T lymfocyten. In de huid reguleert GATA3 de vorming van de 
epidermale barriere. In T lymfocyten stimuleert GATA3 de vorming van Th2 cellen en remt 
die van Th1 cellen. In Hoofdstuk 4 is de analyse van GATA3 expressie in verschillende 
ontstekingsmodellen beschreven. Hier werd gebruik gemaakt van het imiquimod (IMQ)-
geïnduceerde huidontstekingsmodel in de muis. Eerst hebben wij aangetoond dat deze 
huidontsteking, die in veel opzichten op psoriasis lijkt, milder wordt onder invloed van SB-
UVB. In de muis, net als in de mens, was GATA3 expressie lager in ontstoken huid dan in 
niet ontstoken huid, en SB-UVB heeft de expressie omhoog gemoduleerd in ontstoken huid. 
Ook in een wond die op de muizenrug is ontstaan was GATA3 expressie lager dan in gezonde 
huid, wat bevestigt dat het regeneratieve huidfenotype, ook kenmerkend voor psoriasis, 
samengaat met lage GATA3 expressie. IFN-α, IFN-γ en IL-22 hadden geen remmende effect 
op epidermale GATA3 expressie in gekweekte normale humane huidbiopten, wat erop wijst 
dat de lage GATA3 expressie in psoriasis niet het gevolg is van de aanwezigheid van deze 
cytokinen. 
De voorgaande hoofdstukken waren vooral gericht op de epidermis, omdat SB-UVB 
grotendeels hier wordt geabsorbeerd. Dermale huidcomponenten zijn echter ook onmisbaar 
voor het in stand houden van de psoriatische huidontsteking. Cellen van het immuunsysteem 
spelen essentiële rollen in de formatie van psoriatische plaques, maar vasculaire factoren zijn 
ook betrokken in het ontstekingsproces. Hoewel vasculaire remodelling een kenmerk van 
psoriasis is, is er weinig aandacht voor therapieën die specifiek de bloedvaten beïnvloeden. 
Dermale capillairen kunnen selectief vernietigd worden met de pulsed dye laser (PDL), en dit 
kan leiden tot gedeeltelijke of complete genezing van psoriatische plaques. In Hoofdstuk 5 
zijn de cellulaire en moleculaire effecten van PDL vergeleken met die van SB-UVB, een 
“epidermale” behandeling. Na 14 weken behandeling waren er geen significante verschillen 
tussen de moleculaire effecten van de twee therapieën, dus het aangrijpingspunt van de 
behandeling was op dit tijdstip niet meer doorslaggevend voor de expressie van markers 
van psoriasis. Klinische effectiviteit van beide behandelingen waren ook vergelijkbaar. 
De bloedvatspecifieke moleculen VEGFR2 en E-selectine hadden een lage expressie binnen 
de eerste 24 uur na PDL behandeling. Na 2 behandelingen met PDL ging de expressie van 
IL-23 en TNF-α omlaag. Deze effecten dragen waarschijnlijk bij aan de effectiviteit van PDL 
in psoriasis.
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Ter conclusie: in dit proefschrift zijn nieuwe mechanismen van SB-UVB effectiviteit in 
psoriasis in kaart gebracht. 1) STAT3 en de Th17 pathway, die in de epidermis vertegenwoordigd 
wordt door antimicrobiële eiwitten; 2) de interferongeïnduceerde cytosolische dsRNA 
receptoren MDA5 en RIG-I; en 3) GATA3, een transcriptiefactor met regulerende rol in de 
proliferatie en differentiatie van de epidermis. Onze resultaten wijzen erop dat deze moleculen 
essentiële rollen spelen in de pathosfysiologie van psoriasis en potentiële therapeutische 
targets zijn. Verdere studies zijn nodig om mogelijkheden te testen voor het beïnvloeden van 
deze moleculen en hun nuttigheid als therapeutische targets in psoriasis vast te stellen.
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ABBREVIATIONS
ABL1 Abelson murine leukemia viral (v-abl) oncogene homolog 1
ANOVA analysis of variance
BB-UVB broad-band UVB
BrdU 5-bromo-2-deoxyuridine
CCND1 cyclin D1
CHS contact hypersensitivity
COX2 cyclo-oxygenase 2
CPD cyclobutane pyrimidine dimer 
CRIP1 cysteine-rich intestinal protein 1
CYP1B1 cytochrome P450, subfamily I, polypeptide 1
DC dendritic cell
dsRNA double-stranded RNA
EGF epidermal growth factor
FOX forkhead box
GR-1 granulocyte-differentiation antigen-1 (Ly-6G)
hBD2 human beta-defensin 2
HDR hypoparathyroidism, sensorineural deafness and renal dysplasia
IFIH1/MDA5 interferon induced with helicase C domain 1/ melanoma differentiation 
 associated gene 5
IFI27 interferon, alpha-inducible protein 27
IFN interferon
IGF1 insulin-like growth factor
IGFBP7 insulin-like growth factor binding protein 7
IKK1 IκB kinase 1 
IL interleukin
IMQ imiquimod
INSIG1 insulin-induced gene 1
KLF13 Kruppel-like factor 13
KRT keratin
LCE late cornified envelope
LFA3 lymphocyte function-associated antigen 3
LGP2 laboratory of genetics and physiology-2
MAPK mitogen-activated protein kinase
MDA5 melanoma differentiation associated gene 5
MED minimal erythema dose
MHC major histocompatibility complex
NB-UVB narrow-band UVB
NF-κB nuclear factor κB
NK natural killer
OAS1 2’,5’-oligoadenylate synthase 1
PASI Psoriasis Area and Severity Index
PBMC peripheral blood mononuclear cells
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pDC plasmacytoid dendritic cell
PDL pulsed dye laser
PFA paraformaldehyde 
PGA Physicians’ Global Assessment
PGE2 prostaglandin E2
PKR double-stranded RNA-dependent protein kinase
PPAR peroxisome proliferator-activated receptor
PRR pattern recognition receptor
RANKL receptor activator of NF-κB ligand
RIG-I retinoic acid-inducible gene-I
RLH RIG-I-like helicase
ROS reactive oxygen species
RT-PCR real time polymerase chain reaction
SD standard deviation
SEM standard error of the mean
SNAI2 SNAIL homolog 2 
STAT3 signal transducer and activator of transcription 3
STEAP4 six-transmembrane epithelial antigen of prostate 4
TFAP2A transcription factor AP2 alpha
TGF-β1 transforming growth factor β1
TGK keratinocyte transglutaminase
Th T helper
TLR Toll-like receptor
TNF tumor necrosis factor
TNFAIP3 tumor necrosis factor, alpha-induced protein 3
UCA urocanic acid
VEGF vascular endothelial growth factor
VEGFR vascular endothelial growth factor receptor
vWf von Willebrand factor
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2. Teaching activities
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Chapter 1: Figure 1
Figure 1. Clinical appearance of psoriatic plaques.
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Figure 1.
Figure 1. Correlation view of expression profiles of the different RNA pools. 
Red squares indicate positive pairwise correlations and blue squares indicate negative pairwise correlations. 
L: lesional samples, N: non-lesional samples; 0 h: sample taken before the first irradiation, 6 h: sample taken 6 h after 
the first irradiation, E: sample taken after completion of NB-UVB therapy; A, B: patient pools.
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Figure 2. NB-UVB therapy suppresses the Th17 pathway. 
A. Th17 pathway. Grey indicates gene downregulation. B. S100A9 expression measured by RT-PCR. PP: lesional, 
PN: non-lesional samples; 50%: sample taken at 50% PASI score reduction. Error bars indicate SEM, 
n=4 representative patients. C. β-defensin-2 in psoriatic skin samples during NB-UVB therapy. G-CSF: granulocyte 
colony-stimulating factor, GM-CSF: granulocyte macrophage colony-stimulating factor, SAA: serum amyloid A, CRP: 
C-reactive protein, LCN2: lipocalin 2, TIMP1: TIMP metallopeptidase inhibitor 1, MMP1: matrix metalloprotease 1, 
DEFB4: β-defensin 2, SERPINB3: serine proteinase inhibitor, clade B, member 3.
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Figure 3. NB-UVB inhibits epidermal STAT3 activation and β-defensin 2 production. 
A. Phosphorylated STAT3 in skin biopsies of healthy controls, treated in vitro with IL-22 +/- NB-UVB. B. Counts of 
phospho-STAT3+ nuclei in the epidermis. Error bars indicate SEM, n=4 subjects. C. β-defensin 2 mRNA expression 
in the epidermis of healthy controls. Error bars indicate SEM, n=4 subjects. 
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Figure 4. NB-UVB therapy suppresses IFN signalling pathways. 
A. IFN signalling pathways. Grey colour indicates gene downregulation. B. IFIH1/MDA5 expression measured 
by RT-PCR. PP: lesional, PN: non-lesional samples; 50%: sample taken at 50% PASI score reduction. Error bars 
indicate SEM, n=5 patients. C. MxA expression during NB-UVB therapy. IFNGR: IFN-γ receptor, IFNAR: IFN-α 
receptor, TAP1: transporter 1, ATP-binding cassette, B, IFITM1: interferon induced transmembrane protein 1, IRF1: 
interferon regulatory factor 1, PSMB8: proteasome beta 8, IFI35: interferon-induced protein 35, IRF9:interferon 
regulatory factor 9.
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Figure 5. NB-UVB therapy suppresses epidermal differentiation. 
A. Corneodesmosin (CDSN) expression measured by RT-PCR. PP: lesional, PN: non-lesional samples; 50%: sample 
taken at 50% PASI score reduction. Error bars indicate SEM, n=5 patients. B. Transglutaminase K expression during 
NB-UVB therapy. 
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Figure 6. Immediate epidermal effects of NB-UVB. 
A. mRNA expression of cryptochrome 1 (CRY1) immediately before and 6 h after the first irradiation, relative to 
ABL1. Error bars indicate SEM, n=6 patients. B-C. Immunohistochemical staining for CPDs in lesional skin before 
(B) and 15 min after (C) irradiation with 70% MED.
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Supplemental Figure 1. Top 5 GO annotation clusters as found by DAVID (Database for Annotation, 
Visualization, and Integrated Discovery) in the list of genes downregulated (a) or upregulated (b) in the lesional 
epidermis before vs. after NB-UVB therapy.
Each cluster contains multiple GO terms. Shown are the average fraction of genes assigned to the terms in the cluster 
and the geometric means of the original and Benjamini-Hochberg adjusted p-values of the terms in the cluster, 
respectively. The dashed line indicates the significance threshold (adjusted p-value = 0.05). 
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Figure 1. Epidermal GATA3 expression is reduced in psoriatic lesions. 
A. GATA3 protein was present in the nuclei of differentiating layers of the epidermis in normal skin. In non-lesional 
skin expression of GATA3 was also present in the basal layer of the epidermis whereas in lesional skin GATA3 
expression was downregulated. B. Expression of GATA3 was lower in lesional skin (PP) compared to non-lesional skin 
(PN). Epidermal GATA3 mRNA expression was determined by RT-PCR using ABL1 as a housekeeping control gene. 
Bars represent mean +/- SEM (n=5 patients). C. 3 mm biopsy samples from normal human skin were cultured in the 
presence of proinflammatory cytokines for 24 h. The epidermis was separated from the dermis and GATA3 expression 
was determined by RT-PCR in epidermal RNA, using ABL1 as a housekeeping control gene. Bars represent mean +/- 
SEM (n=4 healthy donors). D. GATA3 mRNA expression in the imiquimod-induced psoriasis-like dermatitis mouse 
model. GATA3 mRNA expression was determined in imiquimod- or control cream-treated back skin of Balb/C mice. 
ABL1 was used as a housekeeping control gene. Bars indicate the mean +/- SEM (n=3 mice per group).
Appendix
158
Chapter 4: Figure 2Figure 2
A B
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Before During After
NB-UVB phototherapy
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
1 2 3 4 5 6
days
sc
or
e 
(0
-1
2)
control
IMQ
IMQ+UV
GATA3
PASI 
score reduction
G
AT
A
3 
/ 
A
B
L1
PA
SI
 s
co
re
 /
 b
as
el
in
e 
PA
SI
 s
co
re
Control IMQ IMQ+UV
0
2
4
6
8
10
12
14
16
18
Control IMQ IMQ+UV
no
 o
f B
rd
U
(+
) n
uc
le
i/1
00
 n
uc
le
i
Control IMQ IMQ+UV
C
D
Control IMQ IMQ+UV
E
K
er
at
in
 1
/1
0
B
rd
U
X
-G
al
 (G
AT
A
3)
Figure 2. Upregulation of GATA3 expression during NB-UVB phototherapy. 
A. GATA3 expression is upregulated during the course of NB-UVB phototherapy in patients with psoriasis. Three- mm 
biopsy samples were collected from lesional (PP) and non-lesional skin of patients with psoriasis before, during and after 
NB-UVB phototherapy. Epidermal GATA3 mRNA expression was determined with RT-PCR using ABL1 as a housekeeping 
control gene. Bars represent mean +/- SEM (n=5 patients). The broken line shows the change in the PASI score, relative to 
the baseline score. B. BALB/c mice were treated daily with imiquimod cream or control cream on the shaved back skin, and 
irradiated or sham-irradiated every other day with NB-UVB, starting on the first day of imiquimod treatment. Erythema, 
scaling, and the thickness of the back skin were scored daily on a scale from 0 to 4. The cumulative score (erythema plus 
scaling plus thickness) is shown. Symbols indicate mean score +/- SEM of three mice per group. C. Mice were sacrificed 
on day 6. Imiquimod-induced inflammation was studied on sections made from the back skin of the mice. Keratin 1/10 
immunofluorescent staining of the back of the mice is shown. D. BrdU incorporation in keratinocytes in the back skin was 
detected by immunohistochemistry. Bars on the right represent the mean number of BrdU positive cells +/- SD. E. X-gal 
staining (blue) of heterozygous GATA3LacZ skin samples from mice treated with imiquimod with or without NB-UVB. 
X-Gal staining that in these mice correlates with GATA3 expression is lower in the inflamed epidermis compared to control 
and is induced during NB-UVB treatment.
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Figure 3. GATA3 expression is reduced in the regenerating epidermis. 
A. The stratum corneum of non-lesional skin of seven psoriatic patients was removed by repeated tape stripping to 
induce regeneration. Before and 5 h after tape stripping biopsies were taken and epidermal GATA3 expression was 
determined using RT-PCR, relative to ABL1 as a housekeeping control gene. Relative expression values of individual 
patients are shown. B. GATA3 expression is downregulated in the healing wound of murine skin. X-gal staining 
(blue) of wounded skin of a heterozygous GATA3LacZ mouse shows downregulation of the LacZ transgene under 
the control of GATA3 in the highly proliferative zone of the healing wound. Arrows indicate X-Gal positive cells; the 
border between regenerating and adjacent normal skin is marked.
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Figure 4. GATA3 translocates to the nucleus in differentiating keratinocytes, whereas it stays in the cytoplasm 
during cell cycle arrest. 
Primary human epidermal keratinocytes were cultured on chamber slides. When cells reached ~75% confluency, CaCl2 
(B, D) and/or TGF-β1 (C, D) were added to the culture medium. After 24 h cells were fixed and immunofluorescent 
staining for GATA3 protein (pink) was performed. E. GATA3 positive cell nuclei were counted and are shown as a 
percentage of the total number of cell nuclei.
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Supplemental Figure 1. NB-UVB treatment affects epidermal differentiation, inflammatory infiltrate and 
vascular alterations in imiquimod-induced skin inflammation in mice. 
BALB/c mice were treated daily with imiquimod cream or control cream on the shaved back skin, and irradiated or 
sham-irradiated every other day with NB-UVB, starting on the first day of imiquimod treatment. Mice were sacrificed 
on day 6. Immunofluorescent staining for phosphorylated STAT3 (A), is shown, as well as immunohistochemical 
analysis of myeloid dendritic cells (CD11c, B), granulocytes (GR1, C), and endothelial cells (MECA-20, D).

